### Comprehensive Report on Global Medication Shortages (2021–2024)

#### Introduction
Medication shortages are a growing global concern, affecting both developing and developed countries.

These shortages can have severe consequences, particularly for patients with chronic life-threatening conditions who rely on life-saving medications.

This report aims to provide a comprehensive overview of the scope of medication shortages between 2021 and 2024, the reasons behind them, and how healthcare systems have coped.

Additionally, it will address specific concerns regarding the potential impact on your parent's medications and suggest alternative solutions.

#### Scope of Medication Shortages (2021–2024)
Medication shortages have been reported globally, affecting various therapeutic areas including oncology, neurology, cardiology, and infectious diseases.

The shortages have impacted both generic and branded medications, with some of the most affected categories including:
- **Chemotherapy drugs** (e.

g.

, cisplatin, carb

### Comprehensive Report on Global Medication Shortages (2021–2024)

#### Introduction
Medication shortages are a growing global concern, affecting both developing and developed countries.

Title:

Content: Chairman of Wafd Party
Dr. Abdul Sindh Yamama
Chairman of the Board of Directors
Dr. Ayman is an accountant.
Editor-in-Chief
I'm sorry.
My grandfather, Zainuddin.
Chairman of Wafd Party
Dr. Abdul Sindh Yamama
Chairman of the Board of Directors
Dr. Ayman is an accountant.
Editor-in-Chief
I'm sorry.
My grandfather, Zainuddin.
Smuggling burns drug stability
Libya and Sudan are the main destinations.
And the profits are huge.
Deficiencies include stents, heart medications, diabetes, pressure, and tumors.
It is an undeniable fact that the Egyptian pharmaceutical market is experiencing a crisis of shortage of some vital items on which citizens depend mainly, and at all levels, which exacerbated the suffering of patients in public hospitals affiliated to the government, which receive subsidized medicines at low prices, so that the so-called alternative class becomes a citizen ’ s refuge, to get the necessary dose of medicine, to alleviate his health suffering or save his life.
At a time when it is assumed that more than 90% of medicines are manufactured in Egypt, citizens' complaints about the lack of many medicines and medical supplies in the markets and hospitals are escalating to the extent that deputies submitted a number of requests for briefing through the deputies, stressing that the crisis lies in the raw material itself and imported in dollars.
And the pressure.
Thyroid and sugar.
The main reasons lie in the importation of 95% of raw materials in addition to the presence of “smuggling brokers ” whose mission is to smuggle Egyptian medicine to neighboring conflict countries, especially Libya and Sudan, in order to sell it abroad at exorbitant prices, and to reap huge profits, according to some pharmacists and specialists. In addition to Sudan ’ s import of Egyptian medicine in hard currency, especially with the licenses of Egyptian medicine compared to others and the stopping of factories in neighboring countries because of their conflicts.
According to Ali Abdullah, head of the Egyptian Society for Pharmaceutical Studies (an NGO), the lack of medicines and their disappearance from the local market is a real crisis in case of smuggling, such as insulin, tumors, anesthesia, surgical supplies, serums and vaccines.
The shortage of hard currency in Egypt is also one of the reasons for the disappearance of medicines.
Mahfouz Ramzi, head of the Pharmaceutical Manufacturing Committee at the Cairo Pharmacists Syndicate, pointed out that there are organized gangs that smuggle medicine to countries of conflicts and wars, explaining that “most operations are conducted through land border roads, and the Egyptian Drug Authority is responsible for inspecting companies, factories and any pharmaceutical institution, to ensure that medicines produced in Egypt are in the normal sequence until they reach pharmacies. ”“ Some smuggling professionals deal with drug stores, where they buy large quantities of medicines, take advantage of discounts on them, and then smuggle them abroad to take advantage of the price difference. ”
The Executive Director of the Egyptian Center for the Right to Medicine, Mahmoud Fouad, confirmed that "the drug stores have turned into an illegal business and a back gate for drug smuggling and expired drug trade, as most of them are not licensed and sold without invoices, and are not subject to the umbrella of the Ministry of Health, in addition to the lack of health standards required to practice the profession of pharmacy, after some stores are run from apartments away from the eyes of the Ministry of the control bodies. 90% of its owners are not pharmacists. ”
“Are these stores registered with the Ministry of Health?
And are they subject to pharmaceutical inspection or from the Drug Control and Research Authority? ”, stressing that most of the small pharmacies in the villages “do not have the ability to buy medicine from distribution companies, which makes them resort to buying from stores after agreeing on specific facilities and periods for payment, ” pointing out that“ popular medicines in Egypt are the most smuggled abroad. ” From 250 pounds ($8 at the official exchange rate).
According to Dr. Ashraf Hatem, Chairman of the Health Committee in Parliament, it is a social responsibility, and priorities must be set, and all parties sitting together may help to solve the crisis, in light of the apparent shortage of a number of medical drugs, and his demand that the Drug Authority publish periodically and daily alternatives to the missing medicines in the absence of the original medicine. In addition, the pharmaceutical industry continues to operate and produce.
For all this and for the continuation of the crisis of drug shortage it was necessary to search and investigate the causes and solutions!
During the meeting of Gamal al-Laith, Chairman of the Chamber of Pharmaceutical Industry at the Federation of Industries, in the presence of Minister of Health Dr. Khaled Abdel Ghaffar, the Governor of the Central Bank, Hassan Abdullah, and others, he sent letters of reassurance to the Egyptian people about the existence of a solution to pump the needs of the market of foreign currency to end the shortage of medicines. Or psychologically for the patient.
He said: « The medicines that suffer from the shortage, some of them are sugar drugs and other drugs tumors and drugs of the glands and heart, drugs related to chronic diseases, which is now being secured, and we as factories work with a stock of raw materials enough for 4-6 months, and this stock reached only weeks, and therefore we are now in the stage of risk, and therefore the government began to move ».
He added that the health sector is supported by the provision of foreign exchange resources to provide all needs according to a plan to deal with such circumstances, stressing the importance of full coordination between the unified purchasing authority and the pharmaceutical industry room as well as pharmaceutical companies to face any problems related to the shortage of supplies, medicines and medical consumables.
As well as a detailed presentation on the commitments implemented and not implemented in the period from June 2023 to January 2024, with regard to the provision of (medicines, medical supplies, laboratory supplies, devices, raw materials and packing materials), and the Minister was briefed on the results of the mechanisms established with the Central Bank of Egypt to pay the obligations in foreign currency to meet the demands of the health care sector.
In the end, the official spokesman stressed that the shortage of drugs does not exceed 15% and the drugs directed to tumors are at the forefront of the shortcomings because of their close link to the currency and what faces the supply chains, otherwise all drugs and within them are compatible... The complaints are due in their entirety to the lack of knowledge of citizens with the trade names of medicines.
In addition to the above, a severe shortage of anesthetic drugs, dental pening drugs, nephrology and recovery drugs, which will cause a real disaster that threatens the conduct of surgical operations for patients, and thus increase the waiting lists in hospitals and the occurrence of complications for patients that may result in loss of their lives.
The head of the medicine division of the Federation of Chambers of Commerce, Ali Ouf, revealed that a request will be submitted to the Egyptian Drug Authority early next week to move the prices of 1,500 items in light of what he described as developments in the situation and rising costs.
He pointed out that « the need to raise the wages of workers in the pharmaceutical sector to compensate them for the cost of living and therefore must raise salaries so that they can live in the current conditions and the sector will bear the increase of salaries at the expense of cost and raise the minimum insurance ».
On the shortage of medicines, Amin al-Dabraki, one of the dealers in the pharmaceutical market, said that the main reason for the crisis is the lack of active substances imported by companies.
This is mainly due to the dollar crisis, in addition to the withdrawal of some financial companies from the Egyptian pharmaceutical market.
On the inability of the Ministry of Health to move the prices of medicines with the movement of the exchange rate, he said that the solutions are the intervention of the state by providing a fixed customs dollar for pharmaceutical companies, while moving the prices of medicines, in addition to starting factories to produce active substances inside Egypt.

Title:

Content: Patients complained to Putin about the shortage of 42 rare drugs
21 December 2020, 08: 02
Photo: 1Mediainvest.ru
The All-Russian Union of Patients sent an appeal to the President of the Russian Federation Vladimir Putin on behalf of 20 patient associations.
It lists 42 rare drugs intended for the treatment of chronic diseases.
The reason for the shortage is that they were included in the recommendations for the treatment of patients with coronavirus.
In this regard, there is an increased demand for them, write “New news ”.
According to Izvestia, the organization is confident that funding should be increased, production increased, and the mechanism for regulating the marginal cost of drugs from the list of vital and important drugs (VED) should be changed.
The co-chairman of the GSP, Yuliy Zhulev, said that in a number of cases the organization did not receive answers from relevant NGOs, or they indicated that there was no problem.
In the list of scarce drugs are vital, intended for the treatment of oncology and cystic fibrosis, for patients with multiple sclerosis, rheumatic diseases, primary immunodeficiency and others.
The GSP noted that problems with the availability of drugs have worsened since September 2020.
Zhulev said that this is due to the fact that the distribution of drugs is also carried out on those who are sick with coronavirus.
First of all, it concerns antibiotics.

Title:

Content: Posted Today, 09: 47
Published Today, 09: 47
Modified Today, 09: 49
Updated Today, 09: 49
Serbia faces shortage of 34 drugs
19 June 2023, 09: 47
Serbian Minister of Health Danica Grujicic reported a shortage of 34 drugs in the country, writes Pravda.Ru.
She stressed that although this problem can be partially solved by using analogues, there are cases when replacement is not possible.
In particular, Grujicic noted that they received information about the termination of supplies of the drug “Madopara ”, which is necessary for the treatment of Parkinson ’ s disease.
The Minister stressed that the solution to this problem can be found through cooperation with the Russian Federation.
They are considering purchasing medicines from Russia, where they are available at a lower cost.

Title:

Content: 19: 53 GMT09 November 2021
LIVE
The world.
Copy the link
0 01
Follow us via
The World Health Organization (WHO) warned on Tuesday of the risk of a worldwide injection shortage of up to 2 billion units by next year, threatening to disrupt vaccination efforts.
The shortfall is mainly due to COVID-19 vaccination campaigns, where billions of injections are used more than usual around the world, which has negatively affected the world ’ s supply of this essential tool.
The World Health Organization ’ s senior adviser on securing access to medicines and health products, Lisa Hedman, said that as the supply of doses of the coronavirus vaccine increases, the supply of injections must be kept up.
"We are raising real concern that there may be a shortage of immunization syringes, which in turn will lead to serious problems, such as slowing down vaccination efforts."
And she went on to say:
"Depending on how the vaccine is absorbed, the deficit could range from 1 billion to 2 billion injections."
More than 7.25 billion doses of the coronavirus vaccine have been given to the global population, nearly double the number of routine vaccinations given annually and double the number of injections required, according to an AFP tally.
See also:
World Health Organization: The pace of coronavirus transmission in Europe is very worrying
WHO approves emergency use of India ’ s Covaxine anti-coronavirus vaccine
WHO resolves controversy over combined coronavirus and flu vaccines
Keywords:
Coronavirus, WHO

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
Report: Lack of Obesity Drugs and Weight Loss Causes Inconvenience
Patients who are prescribed highly effective anti-obesity drugs are concerned about the increasing difficulty in obtaining them amid the long-term shortage caused by the high demand for drugs, according to a report published recently by the American website Axios.
Ethan Lazarus, a Denver-based certified bariatric physician, said: “They ’ ve been out of stock everywhere for about a month, and it ’ s gone from being easy to locate to being very difficult.
Lazarus and other doctors who spoke with Axios said almost all of their patients in recent weeks had difficulty finding their prescribed dose.
Patients are increasingly contacting pharmacies to keep track of their prescriptions and, in many cases, have to switch doses or medications altogether.
For some patients, one of the most disturbing aspects is how quickly persistent thoughts about food return.
Christine Rehn Fielding, director of the New York University Langone Weight Management Program, said that “food noise ” disappears in people who eat GLP products,“ and feel very free. ”
At the same time, doctors said some patients are also having more difficulty convincing insurers to re-allow coverage of their prescriptions after several tighter rules at the beginning of the year to curb spending on expensive drugs.
Experts say that stopping taking medications, even for a week or two, can be annoying.
Patients begin with lower doses before gradually increasing them to higher doses, a process that usually takes months.
- Ah!

Title:

Content: NEWS
NEWS
Putin said about the shortage of some drugs in pharmacies
Photo: Moscow 24 / Nikita Simonov
As a result of inspections, there was a shortage of some drugs in pharmacies, as well as an increase in prices for certain drugs.
This was stated by Vladimir Putin during a meeting with the government.
However, the Russian leader stressed that there has been an increase in the production of pharmaceutical products in Russia.
“For three quarters of last year, it amounted to about 22%, and 60% in our market are already domestic medicines.
Nevertheless, the deficit was formed for some drugs, and prices have grown, ” Putin said.
Meanwhile, Roszdravnadzor did not confirm reports of a shortage of antibiotics in Russian pharmacies.
The department assured the residents of the state that the supply and release of drugs continues.
Before that, the press spread information that in Russia there are not enough antibiotics intended for the treatment of children.
Labeling operator says there is no shortage of antibiotics in Russia
More news - in the telegram channel "Moscow 24".
Subscribe!
close
Contact Us
Feedback form
Attach file
Send
close

Title:

Content: Advertisement
NEWS
The Ministry of health included iodine, aspirin and paracetamol in the list of potentially deficient drugs
Today at 19: 58
The Interdepartmental Commission of the Ministry of Health included 97 items in the list of drugs that could potentially become scarce in the Russian market.
This is reported by “Kommersant ”.
The list includes iodine, ibuprofen, acetylsalicylic acid (aspirin), lidocaine, paracetamol, fentanyl, phenobarbital (the main component of valocordine and corvalol) and other drugs.
With regard to these drugs, the Government will take measures to ensure that they are available to consumers.
According to the “Pharmaceutical Bulletin ”, the Ministry of Health issued 44 permits to accelerate the registration of drugs.
Another 80 permits for amendments under the shortened procedure, 11 permits for the circulation of drugs in foreign packaging and 7 permits for the temporary circulation of unregistered medicines in the country.
Earlier, Izvestia reported a deficiency of Tamoxifen, used in many oncological diseases, in particular breast cancer.
In turn, the Ministry of Health reported more than 470 thousand packages of the drug in civil circulation.
That ’ s about six months, they said.
Read also
Events of the week on afisha.ru
We recommend you

Title:

Content: Thursday, 14 Jumada I 1444 Hijri, corresponding to 08 December 2022 AD
A medical crisis in Kuwait.
Urgent parliamentary action
Contact – Editorial Team:
Two deputies in the Kuwaiti National Assembly submitted two requests to the Parliamentary Health Affairs Committee to study the causes of the shortage of medicines, which has become a crisis threatening the health of Kuwaitis, according to media reports.
Medications are not available for dispensing
MP Dr. Jenan Bushehri sent a letter to the National Assembly, in which she confirmed that “despite the assurances of officials in the Ministry of Health of sufficient pharmaceutical stock for the community, many medicines are not available for disposal, which makes the general health situation on the verge of collapse, ” according to“ Al-Qabas ”.
Boushehri asked the Health Affairs Committee to study the causes of the shortage of medicines in private and private health institutions and centers, and to submit its report in the next session, including the causes, results, recommendations and those responsible for the crisis.
The MP stressed that all constitutional options are available in the event of any complacency or inaction in the development of permanent solutions that preserve the health of the population of the State of Kuwait.
Also read:
18 "homosexuals" arrested in a massage and massage center in Kuwait..
They committed adultery and lured teenagers.
200 drugs not available
MP Faisal al-Kandari asked Prime Minister Sheikh Ahmed Nawaf al-Ahmad al-Sabah to form an investigation committee on the lack of medicines and irregularities in the Ministry of Health, and said: "We will wait for the results before using constitutional tools."
Al-Kandari added: “I continue to extend a helping hand to the government for the benefit of Kuwait and its people, and I have gradually used constitutional tools, waiting for the procedures to address the issue of the unavailability of more than 200 types of medicines. ”

Title:

Content: Go to main content
Live broadcast
The expert commented on the possibility of a shortage of drugs in Russia
0
Photo: Izvestia / Zurab Javakhadze
Voice-over text
Highlight the main
INCLUDING
off
In Russia there is no shortage of drugs, including imported, said in an interview with “Izvestia ” Vice-President of the Russian Union of Industrialists and Entrepreneurs (RSPP) Viktor Cherepov.
“We currently have no shortage of medicines in any of the groups, because all sanctions are applied with a reservation after the comma: there is not much, except for medicines, medical products and agricultural products.
None of the drugs fall under sanctions, all foreign companies continue to supply within the framework of concluded contracts, ” he said.
Supply disruptions were due solely to logistical problems.
“Container transportation was disrupted, trucks could not pass through the customs of Belarus, Lithuania and Finland in a timely manner.
Now drugs and substances are coming in, ” the vice-president of the RSPP emphasized.
According to the expert, in theory, Russia may lack innovative drugs that require additional registration in the country.
However, there are ways to solve this problem.
Among them, Cherepov called the government decree on the accelerated registration of such drugs, point permits for the purchase of unregistered drugs, parallel imports and the so-called compulsory licensing.
Read more in an exclusive interview with Izvestia:
“No medicine has been sanctioned, supplies continue ”
Read also
Live broadcast

Title:

Content: Nationwide Adderall shortage impacting area pharmacies in the Panhandle

Published: Oct. 19, 2022 at 5:07 PM CDT|Updated: 19 minutes ago

AMARILLO, Texas (KFDA) - The Food and Drug Administration has declared a nationwide Adderall shortage and the Panhandle is feeling the affects.

The FDA blames the shortage on manufacturing delays.

Health experts say a shortage in stimulant medications is actually not a rare occurrence.

“The amount of medication that is produced is limited and regulated by the government, so there have been other years where towards the end of the year in particular, we start to struggle with supply issues. In this case, however, while that does seem to be probably one of the contributing factors, the other issue we’re facing, at least what we’re hearing about it right now, is that the manufacturing delays have been an issue and some of that has been secondary to the labor shortages,” said Dr. Carolyn Lentsch-Parcells, pediatrician and assistant professor at Burnett School of Medicine at TCU.

Martin Tipton Pharmacy is being impacted by this shortage.

“We’re having to order from various manufacturers right now, not our normal manufactures just because we cannot get them from our normal ones,” said Mark Vogler, Martin Tipton Pharmacy.

Fortunately its patients have been able to get their needed medication, just a different brand.

Amarillo Pharmacy is also being impacted, saying the drug has been back ordered for the past two months.

The Amarillo Pharmaceutical Care Center at Texas Tech Physicians is also seeing a back order on one of the strengths of the drug.

“The drug company manufacturers short-acting and extended-release, for example. So, a pharmacist, in this situation, will work collaboratively with the patient’s provider to find an available strength and dosage to meet the patient’s needs until the original strength becomes available again,” said Amarillo Pharmaceutical Care Center at Texas Tech Physicians.

Dr. Lentsch-Parcells acknowledged this may be an uneasy time for those depending on Adderall, especially with the end of the semester and holidays approaching. She encourages you to reach out to your providers.

“There are various strategies that we will sometimes use to help our patients get the best care possible, while we are trying to ride out the shortage, so that might be changing dosage or using dosage forms that are available to replace their typical medication,” said Dr. Lentsch-Parcells

She emphasizes not to make any changes to your medications without speaking to your providers first.

Pharmacy chains, like CVS and Walgreens, both confirm they are seeing intermittent supply issues with the generic form of the drug.

Title:

Content: Lebanon..
Medication crisis is the talk of communication platforms and the army documents warehouse raids (Video)
With the continuation of the Lebanese crisis, the search for medicines has become a daily habit for thousands of Lebanese citizens, especially with the scarcity of a number of them, especially medicines for chronic diseases, and the scarcity of foreign exchange required to import these important treatments has complicated matters.
The pioneers of social media platforms in Lebanon expressed their anger and resentment at the poor conditions reached by the medical sector, in light of the stockpiling of medicines by some monopolists for the purpose of selling them at high prices without taking into account the health conditions of patients.
One of the activists tweeted: “Every pharmacist is motivated by the owners of drug cartels monopolized by being afraid of his interests and participating with them or benefiting from them and afraid to play the role. ”
Another asked, “Why are you silent, people of Lebanon, and what are you silent about your state of suffering while your leaders have medicine, food, fuel, electricity and they have worked as slaves. ”
The head of the parliamentary health committee Issam Araji tweeted, “The apparent process of forming the government Talaat Tabkha Bahs, your place is Roh.
A major interruption in medicines and medical supplies and on the market dollar price, and patients are unable to pay the imaginary costs of hospitalization and the war of stations and bread.
Immigrants at the airport.
And outrageous prices.
“A described lack of responsibility aimed at destroying the country and its regime. ”
Since 2020, the features of a shortage of medicines in the local market began due to the lack of the dollar necessary for imports, as was the case with wheat and fuel of all kinds.
Recently, the Lebanese Armed Forces raided warehouses where large quantities of medicines were stored for sale at the black market price.
The Lebanese army posted videos on Twitter documenting its raid.
Last month, Lebanese Health Minister Hamad Hassan announced the seizure of tons of medicines hidden in warehouses in the center and south of the country, at a time when Beirut is suffering from a severe shortage of medicines.
Hassan ordered the sale of existing medicines to citizens and pharmacies, especially infant formula and necessary medicines, in the presence of the pharmaceutical inspection body of the Ministry of Public Health.
In the context, a UN official, on Saturday, expressed surprise at the “indifference ” of Lebanese officials to the situation of the people in the country, who are suffering from difficult living conditions.
This came according to the Special Representative of the Secretary-General of the United Nations in Lebanon, Joanna Frontska, during her meeting with Maronite Patriarch Mar Bishara Boutros Al-Rai in the summer patriarchal edifice in the town of Diman (North), according to the official Lebanese News Agency.
Frontska said she was "surprised by the indifference of officials to the situation of the people who are suffering due to the difficult living situation."
The agency quoted the sponsor as praising "the initiatives undertaken by the United Nations towards Lebanon," expressing hope "for more support so that the Lebanese citizen can withstand the crises he is experiencing."
After the meeting, Frontska said in a statement to reporters that "Lebanon needs urgent solutions, especially the formation of a government," stressing that the United Nations "will continue to support Lebanon," according to the same source.
Due to political differences, Lebanese officials have been unable to form a new government for more than a year to end the economic collapse and succeed the current caretaker government, which resigned six days after a catastrophic explosion at the Beirut port on August 4, 2020.
Since late 2019, Lebanon has been suffering a severe economic crisis that has led to a financial collapse, the loss of fuel, medicines and other basic goods, as well as a record rise in poverty and unemployment.
Source: Al Jazeera Mubasher + Social Media + Agencies
About this story
More News
Most Read

Title:

Content: Israel faced an acute shortage of various drugs: the Association of pharmacists announced the details
Pharmacists said that the problem is not properly solved by state bodies, in particular the Ministry of Health.
The Association of Pharmacists has warned of an acute shortage of drugs, including Ritalin, drugs used to treat heart and blood vessel problems, and drugs to treat skin diseases.
Pharmacists wrote about it in a letter sent to Health Minister Nietzan Horowitz and his office ’ s CEO, Nachman Ashe, on Monday.
There is a shortage of medicines in Israel.
In the past two years, and in particular in the last few months, the phenomenon of shortages has intensified, ” said David Pepo, chairman of the Association of Pharmacists.
“The shortage is understandable for a number of reasons: COVID-19, the war in Ukraine, the global employment crisis and the economic crisis, ” Pepo explained.
“To this should be added the serious disruptions taking place in the distribution systems of medicines in Israel, which are due to staff shortages, malfunctions, high distribution costs and many other explanations of all sorts, ” Pepo said.
Earlier, Cursor wrote that in supermarkets in the coming days, a shortage of chicken and turkey is expected.
Recall that scientists have named a substance that reduces the risk of suicide.
In addition, the Minister of culture Healy Tropper said whether to cooperate with Netanyahu.
Read the latest news from Israel and the world on the Kursor channel in Telegram.
Author of the material:
TAGS:

Title:

Content: Newswise — OAK BROOK, Ill. (May 19, 2022) – Recent disruptions in a pharmaceutical supply chain have impacted the global availability of GE Healthcare Omnipaque™ iohexol iodinated contrast media (ICM) for radiologic examinations. A new Special Report published in the journal Radiology provides consensus recommendations for dealing with the shortage of ICM in the near term and discusses long-term issues and potential solutions to supply chain problems.

“We are facing issues similar to those we faced in the early days of the COVID-19 pandemic, caused by a limited supply of an important pharmaceutical, critical to our ability to care for our patients,” said Thomas M. Grist, M.D., chair of the Department of Radiology at the University of Wisconsin School of Medicine and Public Health in Madison and lead author of the Radiology Special Report. “One important difference, however, is that our hospitals and health systems are more adept at establishing incident command centers to implement rapid responses to the challenges we face and communicating those changes to our patients and referring physicians.”

Iohexol is a common agent used in a multitude of CT and X-ray exams. The iohexol shortage has created a national challenge to radiology’s collective ability to provide health care to patients needing these exams and will have short- and potentially long-term impact on quality medical care.

Although four companies supply ICM to the U.S., other manufacturers are unable to rapidly scale up ICM production to meet the demand created by the reduction in iohexol.

The shortage traces its origins to the recent COVID-19-related shutdown of a manufacturing facility in Shanghai, China. In an April 19 letter to consumers, GE Healthcare announced it would be limiting orders of iohexol. The facility has since reopened with production output currently at 50% and expected to increase. GE Healthcare has also expanded production capacity at its manufacturing site in Cork, Ireland.

“It is too easy for us to take for granted the readily available supply of something that is so important to our patients and our radiologic practices until it’s gone,” Dr. Grist said. “We need to commit to changing the supply chain so that a single event in a faraway country does not put us in this predicament again. We owe it to our patients who trust us with their lives and well-being every day of the year.”

The shortage has already had an effect on patient care. Across the U.S., hospitals dependent on iohexol are postponing treatment-monitoring imaging for cancer patients, as they attempt to preserve the contrast material for the most urgent cases.

The Special Report offers strategies for mitigating the impact of the shortage. Short-term strategies include establishing an incident command center to direct and monitor ICM usage, delaying elective contrast-enhanced CT exams, converting exams to non-contrast when possible, reducing contrast dose, and substituting other types of exams, such as MRI, ultrasound or non-contrast PET-CT.

Strategies for the coming months include contrast repackaging, multi-use, and multi-access tactics, negotiation with payers on billing and reimbursement, and consistent communication with ordering providers to ensure compliance.

Long-term strategies include advocating for legislation to facilitate contrast manufacturing plants in the U.S., improving institutional inventory of contrast supplies, and supporting the vendors to expand manufacturing.

“RSNA and its journals are committed to providing critical guidance to help our members navigate challenging times,” said RSNA President, Bruce G. Haffty, M.D. “This Radiology Special Report provides helpful strategies for managing the iodinated contrast shortage and offers practical recommendations for mitigating the impact of future shortages of this type on the radiology community and our patients.”

The authors hope that the radiology and hospital communities will take this lesson as a wake-up call to adapt the radiology supply chain to prevent similar emergencies in the future.

“We need to endeavor to ensure that companies with significant market share have diverse production locations and capacity,” Dr. Grist said. “We should also look at the ancillary components for ICM administration and make certain we have adequate supplies in stock. Any and all supplies we use may be the next subject of shortages over the next few months or years.”

See also: Iodinated Contrast Shortage Challenges Radiologists.

###

Short-, Mid-, and Long-Term Strategies to Manage the Shortage of Iohexol.” Collaborating with Dr. Grist were Cheri L. Canon, M.D., Elliot K. Fishman, M.D., Maureen P. Kohi, M.D., and Mahmud Mossa-Basha, M.D.

Radiology is edited by David A. Bluemke, M.D., Ph.D., University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, and owned and published by the Radiological Society of North America, Inc. (RSNA) (https://pubs.rsna.org/journal/radiology)

RSNA is an association of radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Illinois. (RSNA.org)

For patient-friendly information on contrast materials, visit RadiologyInfo.org.

SEE ORIGINAL STUDY

Title:

Content: Experts have recorded a shortage of antibiotics in the world due to the increase in the number of infectious diseases.
On December 21, writes the Financial Times with reference to the head of the group of the World Health Organization (WHO) for the supply of medicines and ensuring access to them Lisa Hedman, reports Day.Az.
Twenty-eight of the 35 countries for which WHO collects data are deficient in penicillin-type drugs.
In the United States and Canada complained about the lack of amoxicillin.
Less is known about the situation in poor or small countries, according to Hedman.
It is noted that in addition to the difficulties experienced by pharmaceutical manufacturers in the pandemic, the current situation is complicated by high energy prices, and this leads to a decrease in profits of companies.
In addition, countries, according to Hedman, did not expect that in the first year without masks, respiratory infections would hit the population so hard.
In addition to antibiotics, pharmacists also complain about the lack of painkillers, drugs for tuberculosis and drugs for skin infections.

Title:

Content: Healthcare companies moved higher as tech companies continue to enter the space.

Facebook parent Meta Platforms has created a tool to predict the structure of hundreds of millions of proteins using artificial intelligence. Researchers say it promises to deepen scientists' understanding of biology, and perhaps speed the discovery of new drugs.

Meanwhile, a drug used to extend the lives of people with advanced prostate cancer is in short supply and will be for months, leaving some patients with no treatment option as the manufacturer works to ramp up production. The Food and Drug Administration said last week the availability of Pluvicto is limited as manufacturer Novartis struggles to meet demand. The drugmaker said the shortage stems from manufacturing and delivery issues.

Write to Amy Pessetto at amy.pessetto@dowjones.com

(END) Dow Jones Newswires

03-16-23 1727ET

Title:

Content: BETA
This is a BETA experience. You may opt-out by clicking here

More From Forbes

Edit Story

Breaking The Rules Of Healthcare: Overpaying For Drugs That Underachieve

Since this time last year, the U.S. Food and Drug Administration (FDA) has granted approvals for 42 new medications. The press releases for these drugs would lead a reasonable person to conclude that a pharmaceutical revolution is underway—that the drug industry is ushering in a brave new era of medical advances.

The truth is far less flattering. Despite enormous hype and dozens of new medications flooding the market each year, major pharmaceutical breakthroughs are exceedingly rare. The overwhelming majority of “blockbuster” drugs represent minimal (if any) improvement over existing treatments.

This is not because drug companies lack the scientific knowhow, research capabilities or dollars to deliver lifesaving medications.

Instead, drug-industry innovation has been stifled by an unwritten rule in healthcare; one that has guided nearly all pharmacological research and development (R&D) efforts of the 21st century.

The rule: Maximize drug profits by minimizing the risk of failure

In the previous century, before the term “wonder drug” was hyperbolically applied to every new FDA-approved medication on the market, drug companies almost always swung for the fences.

Consider the countless lives improved and saved by the true wonder drugs of the 20th-century.

Like insulin, discovered in 1921 to treat diabetes. Or penicillin, the infection-fighting antibiotic derived from mold in 1928. Or mechlorethamine, a 1940s weapon of chemical warfare turned cancer-fighting agent now used in chemotherapy drugs. Or the life-saving psychiatric medication chlorpromazine, now known as Thorazine, created in 1951. Or birth control (approved by the FDA in 1960), or statins that reduce heart-disease (like Lipitor, patented in 1985) or the HIV/AIDS treatment zidovudine (better known as AZT, 1987).

For each of these medications, the research and development (R&D) process was intense and time-consuming. The go-to-market costs were massive with the potential to bankrupt the underwriting drug companies involved.

But despite the expenses and risks, pharmaceutical leaders were driven then by an intrinsic desire to save lives. As George Merck put it in 1950 near the end of his 25-year run as Merck CEO: “We try never to forget that medicine is for the people. It is not for the profits. The profits follow.”

In the 1980s, that outlook shifted. Newly elected president Ronald Reagan pulled back government regulations, which sent the stock market soaring. Pharmaceutical shares skyrocketed more than 950% over the next 12 years.

By the 1990s, outsized CEO salaries and exorbitant drug prices had become the norm. The focus of the industry swung from saving lives to increasing shareholder value. Drug companies wanted to maximize prices while minimizing drug-development risks. They succeeded, and drug spending in the United States took off.

To spotlight the difference, consider that from 1960 to 1980 prescription drug sales remained fairly static as a percent of U.S. gross domestic product, consuming just 5% of all medical costs. Between 1980 and 2000, however, sales tripled. Today, prescription drug expenditures exceed $460 billion a year, accounting for 16.7% of all healthcare dollars spent.

The smoke and mirrors of drug pricing

Pharma leaders love to trumpet how expensive and time-consuming it is to bring a new drug to market. They collectively assert that ever-rising prices are needed to “cover accelerated investment in researching and developing new and better medications to protect Americans.”

That message has found a receptive audience among patients. Today, 68% of Americans believe that the cost of R&D is “a major contributing factor” to high drug prices.

The data tell a different story about where the money goes. One report found that 9 of 10 top drugmakers spend billions more on marketing than R&D. Another investigation noted that 80 cents of every $1 in prescription drug sales go to something other than R&D—be it profit, overhead, taxes, etc.

To be clear: Drug companies are not struggling to make ends meet or afford the cost of R&D. In fact, a 2019 analysis found that drugmakers could afford to lose $1 trillion in sales and still be the nation’s most profitable industry sector.

Maximizing revenue by minimizing risk

Two recent FDA approvals—Aduhelm, the first new Alzheimer’s medication in over two decades, and Trodelvy, a targeted treatment for aggressive breast cancer—demonstrate that drugmakers aren’t living up to their potential, despite the high prices and industry hype.

The companies behind Aduhelm and Trodelvy have issued a combined total of 70 press releases (34 from Biogen and 36 from Gilead) about their respective flagship drugs.

Notwithstanding the sheer quantity of promotion, neither drug will have a meaningfully positive impact on the lives of people with Alzheimer’s or breast cancer.

Look at Aduhelm. Two years before its approval, Biogen halted testing amid inconclusive and concerning results. In trials, the drug wasn’t shown to preserve intellectual function for patients. But rather than abandoning the medication or pausing to invest in additional R&D, the company filed for accelerated approval, which the FDA granted against the cautions and protests of its scientific advisory committee.

Upon approval, Aduhelm was projected to earn upward of $112 billion in annual sales with an initial price tag of $56,000 (five times greater than its estimated value)—a maximal profit projection for a drug with minimal value. This controversial drug and its accelerated pathway to approval have congress taking a closer look at the FDA. And for good reason. Since 1992, nearly half (112) of the 253 drugs given speedy approval have not been proven to extend longevity or improve quality of life.

And then there’s Trodelvy, a key drug in Gilead’s oncology portfolio. It was invented by Immunomedics, Inc., which Gilead purchased for $21 billion (one of more than 30 cancer drugs Gilead has acquired in the past five years).

Priced at over $2,200 per vial, a 21-day cycle of the new breast-cancer treatment costs $16,000 and contributed to an 11% revenue increase for Gilead in 2021 (leading to a $19 million bonus for the company’s CEO).

So, is Trodelvy worth the price? A company press release boasts a 49% reduction in the risk of death for patients who take the drug.

That figure is misleading at best. In studies, the medication extended median overall survival to 11.8 months compared to 6.9 months in the control group. The “statistically significant survival benefit” noted in the press release makes it sound as if patients taking the drug beat their cancer. In reality, they died less than five months later than patients who took standard chemotherapy.

When we zoom out and look at the 90-some new oncology drugs approved by the FDA this century, the average gain in life expectancy is a mere 73 days. Much of that time is spent in pain, dealing with debilitating side effects while being isolated from loved ones.

By following the rule of maximizing profits at minimal risk, pharmaceutical companies now routinely price and promote minimally effective drugs as if they were lifesaving medications.

Even the highly effective Covid-19 vaccines—the most celebrated innovation of the 21st century—were brought to market with minimal risk. The federal government paid for much of the underlying development costs through decades of NIH-funded research and minimized the risks to companies by fronting $18 billion as part of “Operation Warp Speed.”

Breaking the drug-industry’s unwritten rule

For drug companies, the lure of charging high prices ($2.1 million in one case) and generating huge profits (more than any other industry sector) distorts research priorities. As a result, pharmaceutical companies ignore many of the biggest areas of clinical need.

Consider antibiotics, a drug category that remains extremely under-researched and underfunded. Public health officials agree that antibiotic resistance undermines our entire modern medical system. Nationwide, drug-resistant bugs are becoming a growing threat, putting millions of lives at risk. That is, unless drug companies can discover the next generation of treatments.

But there’s a problem: Antibiotics are usually prescribed for a short 10- to 14-day course, generating only a tiny profit. Thus, identifying a new class of antibiotics is (financially) risky and nowhere as profitable as the drugs currently garnering the most interest—like cancer drugs, which can be priced at $120,000 to $150,000 a year regardless of efficacy.

Right now, more than 600 cancer drugs are being tested for clinical use. Meanwhile, there are no breakthrough antibiotics on the horizon.

For the past two decades, life expectancy in the United States has stalled. Our nation needs better, safer, more effective medications. But drug companies won’t develop them until the industry inverts its focus: not on minimizing risk but on maximizing its impact on human lives.

Americans won’t be able to afford those drugs until another rule of the drug industry is broken: the rule governing how drug companies price their newest medications. That will be the focal point of the next article in the Breaking The Rules Of Healthcare series.

Follow me on Twitter or LinkedInCheck out my website or some of my other work here

Title:

Content: Anzeige
Mehr »
Login
Dienstag, 24.08.2021 Börsentäglich über 12.000 News von 669 internationalen Medien
Heute im Fokus: Relay Medical – Das COVID-19-Nonplusultra!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
76 Leser
Artikel bewerten:
(0)

Heritage CARES Says Engaged Aftercare for Substance Use Treatment Is a Critical Predictor of Long-Term Success

COPPELL, TX / ACCESSWIRE / August 24, 2021 / Recovery from substance use disorders (SUD) isn't easy. Within the first year of recovery, The Journal of American Medical Association (JAMA) estimates that between 40% and 60% of individuals who receive treatment will experience a relapse.

Heritage CARES, the leading virtual support program designed to help individuals struggling with stress, substance use, and/or suicidal ideation, believes individuals in recovery who receive the proper aftercare treatment don't have to experience relapse. Active, engaged aftercare treatment, such as that provided by the Heritage CARES program, is one of the biggest factors in SUD treatment success and reduced rates of relapse and re-admission.

CARES is an acronym for Comprehensive Addiction Recovery Education and Support. The virtual program from Heritage provides participants and their families convenient access to support from licensed health care professionals on any mobile device at any time, significantly increasing the potential for long-term recovery success for patients who have been through SUD treatment programs.

According to drugabuse.gov, "Unfortunately, when relapse occurs, many deem treatment a failure. This is not the case: successful treatment for addiction typically requires continual evaluation and modification as appropriate, similar to the approach taken for other chronic diseases."

The Heritage CARES model was involved in a 2020 study conducted by Clemson University, Prisma Health, University of South Carolina School of Medicine and FAVOR-Greenville. The study found that "SUD is a chronic, relapse-prone disease, and the most critical factor for predicting improvement at 5 years post-discharge is ongoing engagement (Weisner et al., 2003)." Over a 6-month post-discharge period, 84% of the participants stayed on track with a recovery coach vs. 34% of the participants who received a traditional standard of care without a coach.

Heritage CARES EVP and Executive Director Rich Jones, MA, MBA, LCAS, SAP, echoes the vital importance of an engaged aftercare program. "In reality, SUD treatment is short-term and acute in nature, but recovery is a process-not an event," says Jones. "The event of SUD treatment is merely the start of the process, and aftercare programs are a vital part of SUD recovery. Statistics show that continued engagement is the key to staying in recovery, and with insurance reimbursement getting tighter and moving toward a value-based foundation, insurers will scrutinize outcomes like never before."

Aftercare coaching and a guitar

Just as the name suggests, an individual enters an aftercare program following their initial treatment discharge. An effective program generalizes and sustains the progress made while in treatment. Aftercare programs keep the momentum going. Where needed, program professionals will step in to help the individual in recovery get back on track. Good aftercare comes in all shapes and sizes. The best programs find a way to work with ambivalence and resistance.

Heritage CARES' aftercare program helps patients maintain a positive recovery journey after they complete their inpatient treatment. Before leaving a facility, care managers connect patients with specially trained Assertive Community Engagement (ACE) Peer Coaches who remain involved throughout the individual's recovery journey. Assigned peer coaches use youturn, the most extensive online, on-demand video recovery library available. Youturn includes a collection of personal SUD journeys that help motivate and engage program participants-think Netflix for recovery.

ACE Coaches encourage recovery by helping those in the SUD recovery program to develop new behaviors, increase family support and take personal accountability through proactive outreach and education. Each Heritage CARES peer coach has successfully completed the treatment program themselves, so they know with precision what the individual is going through. Heritage CARES coaches emotionally connect with participants and are available as long as the individual in recovery needs their support.

"A favorite story of mine involves a Heritage CARES ACE coach who was working with someone who didn't want to be involved in the program at all," says Jones. "But our coach hung in there, keeping the conversations going, looking for a way to connect. During one session, he noticed a guitar in the background and asked about it. The participant admitted he always wanted to learn to play but never got around to it. The coach, who played the guitar, offered lessons during their sessions and, just like that, the door for engagement and trust opened."

Why is aftercare treatment necessary?

While some may question the need for aftercare, Jones says it is a vital part of the recovery process. "By the time someone enters a treatment program," he explains, "that person is pretty much at rock bottom with no structure in his life. Then that person immediately comes into a very structured environment with rules and processes in place. Following their completion of a treatment program, patients are typically discharged without any form of professional support. It's no wonder that the relapse rate is so high. But with aftercare treatment programs like Heritage CARES, individuals have access to a team of professionals providing evidence-based programs. Aftercare programs are a game-changer."

The average length of stay in inpatient rehab is up to 30 days. The average length of time in an intensive outpatient program is 8 to 12 weeks. There are longer treatment models and programs that involve care for up to a year, but they are typically very expensive, and most people do not have the time to check out for recovery for an entire year. Aftercare programs are in place to continue treatment programs while the individuals move back into their jobs, families and communities.

"Heritage CARES believes that peer support and long-term recovery coaching are the most critical pieces in the aftercare treatment puzzle," says Jones. "If the person in recovery has a consistent presence in his or her life, the recovery process is much more likely to advance in a healthy direction. Our aftercare program provides someone to gently redirect the person back onto the recovery pathway rather than leaving the patient alone to wade through challenges or wait for things to unravel completely. That simple addition to the continuum is likely to make a huge difference in people's lives."

Heritage CARES partners with leading inpatient facilities across the country. To learn more about Heritage CARES, visit https://heritagehealthsolutions.com/heritage-cares-for-addiction-support/.

About Heritage CARES

Heritage CARES (Comprehensive Addiction Recovery Education and Support) is a comprehensive program that provides support tools for substance use disorders (SUD), stress management and suicide prevention and intervention to participants and their immediate family members. The platform also includes tools for wellness and mental health as well as anxiety issues and is available for use 24 hours a day, seven days a week. There are three components to the program: peer coaching, education and care management. Heritage CARES is available for companies, rehabilitation centers and first responders. For more information on Heritage CARES, visit Heritage CARES.

MEDIA CONTACTS:

Karen Carrera, TrizCom PR on behalf of Heritage CARES
Email: heritagecarespr@trizcom.com
Cell/Text: 972-207-1935

Jo Trizila, TrizCom PR on behalf of Heritage CARES
Email: heritagecarespr@trizcom.com
Office: 972-247-1369
Cell/Text: 214-232-0078

SOURCE: Heritage CARES

View source version on accesswire.com:
https://www.accesswire.com/660992/Heritage-CARES-Says-Engaged-Aftercare-for-Substance-Use-Treatment-Is-a-Critical-Predictor-of-Long-Term-Success

Kostenloser Wertpapierhandel auf Smartbroker.de
© 2021 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

Title:

Content: NEWS
NEWS
Roszdravnadzor warned about temporary delays in the supply of medicines to pharmacies
Roszdravnadzor informed about the high probability of temporary delays in the supply of medicines to Russian pharmacies.
According to the ministry, this is due to high demand among buyers and logistical difficulties from both suppliers and manufacturers.
However, the situation began to use fraudsters.
They began to offer to buy drugs with home delivery, making an advance payment in advance.
Experts have warned that such drugs may be fake.
Details – on the air of the TV channel Moscow 24.
close
Contact Us
Feedback form
Attach file
Send
close

Title:

Content: The Ministry of Health told what they did to prevent a shortage of drugs
The head of the Ministry held a meeting with representatives of pharmaceutical companies
The head of the Ministry of health Mikhail Murashko said that the government has made decisions that will help to avoid a shortage of drugs.
He said this at a meeting with representatives of pharmaceutical companies, which took place on April 18.
In particular, an advance of 240 billion rubles was made within the framework of compulsory medical insurance, which is up to 80% of all expenses of medical organizations for drug provision, - the Minister of Health said. - This allows pharmaceutical manufacturers to clearly plan the production and supply of drugs.
Today, thanks to the labeling system, we see the movement of medicines, their remains in each region and the introduction into civilian circulation in real time.
This allows us to determine with high accuracy the positions at which subsequently reduced availability is possible, and to take the necessary measures in advance.
Murashko also noted that in the near future, the possibility of using data on the pharmaceutical substance previously included in the registration certificate of other drugs during the registration of a medicinal product will be worked out without the need for additional examinations.
This will simplify the registration process.
• LIKE0
• LAUGHT1
• SURPRISION0
• RIGHT0
• FURNITURE0
Did you see the typo?
Select a fragment and press Ctrl + Enter
� � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � �
� � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � �

Title:

Content: Ireland has been suffering a paracetamol shortage as cases of Covid-19 and the winter flu in the country soared over the festive and new year period.

The revelation was made by Health Minister Stephen Donnelly after his department received notification of a supply issue from the Health Products Regulatory Authority.

It is understood the shortage impacted some prescription paracetamol products.

Read More:Irish people complain of ‘worst ever’ winter bug sweeping country that feels like Covid but isn’t

Two suppliers affected have stated that resupply will be sometime in January 2023.

However, there are other prescription paracetamol suppliers with some stock available on the shelves.

Paracetamol is one of the medicines used most often in Ireland and especially for the flu, aches and pain.

But Mr Donnelly pointed out that there are multiple forms of the drug with different strengths and brands available from various sources.

He said: "In the event that there are some supply issues for individual medicines, alternative options such as alternative strengths and brands, generic medicines will usually be available to ensure continuity of treatment.

"In some cases where the medicine initially prescribed for the patient is unavailable, patients may be switched to a suitable therapeutic alternative following appropriate consultation with a healthcare professional."

The Health Minister said medicine shortages have been increasingly prevalent worldwide over the past decade. The causes of such shortages are multifactorial including shortage of raw materials, manufacturing difficulties and industry consolidations.

He stated: "Medicine shortages can originate at any point in the supply chain. They can involve and impact many stakeholders in different ways as the supply models and clinical use of therapies can vary across national health systems.

"Management of medicines shortages necessitates a multi-faceted, multi stakeholder response to ensure patient safety , continuity of care and protection of public health.

"Patients or their carers who have any concerns in relation to temporary alternative products provided because of medical shortages are advised to speak with their pharmacist or other healthcare [professionals] involved in their care."

Mr Donnelly was responding to a number of written Dail questions on the shortage of medicines.

READ NEXT:

Get breaking news to your inbox by signing up to our newsletter

Title:

Content: MOSCOW, 22 Mar — PRIME.
There is no reason to talk about any shortage of drugs against the background of sanctions at present, said the chief freelance specialist clinical pharmacologist of the Ministry of Health of Russia, academician of the Russian Academy of Sciences Vladimir Petrov.
He noted that there is a high demand, but there is no reason for this, since “the production is working, the supply of drugs is, including imported ones. ”
Petrov added that distributors and manufacturers often simply did not have time to deliver the right number of packages to pharmacies, but now the situation has begun to improve.
According to Petrov, the doctor when prescribing treatment should indicate the international non-proprietary name of the drug - that is, the name of the active substance.
A pharmacist in a pharmacy will almost always find several similar drugs with the same effect and the same effectiveness.
“This is a requirement of law.
Therefore, if a specific drug with a specific trade name has disappeared in a particular pharmacy, the situation should not be called a deficit, ” he said.

Title:

Content: The Ministry of Health and Welfare yesterday announced the establishment of the "Drug Supply Notification Processing Center" and announced the situation of drug shortage for the first time today. According to the Food and Drug Administration, a total of 22 drug shortages were reported between March 25 and April 4, of which 7 were found to have no shortage, 12 were recommended to use alternative drugs, and 1 was launched for no alternative drugs.
However, first-line pharmacists have been slow to respond to the expansion of the drug shortage center, pointing out that there is still a shortage of two to three drugs per day, indicating that the new system has not changed much after the road.
As many as 12 missing drugs are recommended to be replaced by alternatives, including Yuanzhou Ginkgo Ning Tablets 40mg for terminal hemorrhagic disorders, Anxiety Disorder Tablets 30mg, Gastric ulcer Tablets 30mg, Gastrointestinal spasmodic Tablets 10mg, etc.
However, some hospital pharmacists revealed to this newspaper, the Ministry of Health and Welfare "drug supply notification processing center" was established, the immediate impact on the lack of drugs is not large, now there is an average of 2 to 3 drugs per day shortage, yesterday on the road of the lack of drug platform is just another website statistics, "the Food and Drug Administration and its re-statistics of lack of drugs, can be more active, sorting really in the production of medical Agency inquiry? ”
In addition, the back-line antibiotics produced by Merck 1 gram recently also announced that it will withdraw from the Taiwan market, many medical institutions were informed in March that they will no longer supply, due to the fact that no famous drugs are available in China, so that hospitals are worried that they will be available in 1 or 2 months.
Ertapenem Sodium is a common carbapenem antibiotic. Although it is a back-line antibiotic, it is a narrow type of product, so it is usually the first choice of back-line antibiotics. In the future, if manufacturers no longer supply it, hospitals can only use broad-effect antibiotics. Infection control has a negative impact.
Huang Jingtai describes that in the future, if you can't use Yimen treatment, the treatment of bacterial infection will lead to a "bullknife", adding the possibility of future bacterial resistance. Although there are still stocks in the hospital, it is likely to not last this year.
In addition, another antibiotic, Tainin, which is also produced by Merck, has long been withdrawn from the Taiwan market, so infection doctors are worried that they will only be used in the later stage of antibiotics in the future, forming a vicious circle.
Yang Bowen, director of the pharmaceutical division of the Food and Drug Administration, responded that Yimanzhi had notified as early as July last year that due to the decline in foreign production capacity and the increase in the cost of raw materials, the supply of controlled goods was changed, and whether Yimanzhi would withdraw from Taiwan?
Through the internal evaluation of Charmer Shadong, even if the final exit will wait half a year before the market, plus there is a domestic pharmaceutical factory can produce famous drugs, it should not cause too much impact.
# Drugs # Lack of Drugs # Antibiotics # Shortage # Food and Drug Administration

Title:

Content: Egyptian News
Mohsen Hassan for DMC: Solving the Drug Shortage Crisis in the Next Few Weeks
Ahmed Wael Omar - Cairo on Tuesday, April 30, 2024 12: 36 AM - Dr. Mohsen Hassan, director of the commercial sector in one of the pharmaceutical companies in Egypt, said that in 2019 the Egyptian Drug Authority was established, a historic leap in the Egyptian pharmaceutical industry, pointing out that there are procedures to ensure the quality, effectiveness and safety of the drug starting from the raw material where it is analyzed more than once.
Mohsen Hassan added during an interview with the program "evening dmc", on the channel dmc, that the production processes of the drug are analyzed more than analysis, and the random withdrawal of the can inside the pharmacy, and change the raw material takes the same steps as the previous one again, and the matter has a large control percentage.
Mohsen Hassan stressed that after the state provided the dollar, it is now available to buy any raw materials, and the shortage of medicine is on the way to solve in the next few weeks, pointing out that the guarantee of the quality of the Egyptian product as a medicine is compared to the "brand".
He pointed out that the pharmaceutical companies are committed to any legislation or decisions of the medical authorities, which is an important part of the medical system and we have a great role in providing high quality treatment and a suitable price for the Egyptian patient, stressing that the Egyptian medicine during the recent period is comparable to foreign medicines, and 90% of the cans sold in the Egyptian market are produced by Egyptian companies.
Advertisements
You may also read.

Title:

Content: MercoPress, en Español

Montevideo, January 7th 2023 - 10:36 UTC

Shortages forecast in Argentina due to restrictions on input imports

Friday, January 6th 2023 - 09:51 UTC
Full article 0 comments

Argentina's Chamber of Chemical Products warned that due to the restrictions on imports, some critical inputs have been arriving in the country in smaller quantities, which might result in shortages of medicines, soft drinks, and shampoo, among other items.

“There were drops of 20 to 25% in basic inputs” and predicted that “if we always consume the same and lesser quantities come in, there will be a lack of products” such as shampoo, soft drinks, and medicines, the Argentine Chamber of Chemical Products' Leandro Kolker told TN.

Kolker pointed out that the main problem was the modifications that took place during 2022 in the scheme for approving imports and pointed out that

“The scenario became more complicated as from October 17,” when the Economy Ministry established the new system [known as SIRA], which makes import requests “go through different filters of several agencies,” he added. “It is a matter of time” before shortages hit consumers.
Lino Stefanuto of the Chamber of Motor Vehicle Manufacturers said things were “complicated” for spare part manufacturers.

Import restrictions are also affecting surgeries, pet food, and livestock feed. The Argentine College of Cardiovascular Surgeons had already warned last month of a “serious and dangerous situation” due to the lack of “basic and essential supplies,” mainly from the United States and China. In this scenario, several surgeries have been rescheduled and in case of emergencies, surgeries are performed with whatever materials are available, sometimes endangering the patient's life, the organization said.

The Argentine Chamber of Animal Nutrition Companies (Caena) also said in mid-December that “the impossibility of importing micro-ingredients as a consequence of the non-approval and observation of the licenses, as well as the extended terms granted for the transfer of foreign currency abroad, began to generate stock shortages” of nutrients such as vitamins, minerals and amino acids that are not produced in the country.

(Source: TN)

Categories: Economy, Investments, Argentina.

Title:

Content: -- -- -- / -- -- --
Site Management
Central Pharmacy announces receipt of 62 drugs to treat cancer patients
The Director General of the Central Pharmacy of the Hospitals, Samir Farhat, revealed that 62 drugs were received for the treatment of cancer patients.
Farhat said on Sunday in a statement to the third radio channel that within the framework of the program of the central pharmacy, the central pharmacy received a large amount of drugs intended for the treatment of cancer patients.
“From November 1, 2022 to January 1, 2023, we received 62 cancer drugs, ” he said.
"The central pharmacy has met all the needs of hospital pharmacies across different states."
He added that the central pharmacy has all the material means to take care of all hospital requests in a timely manner.
The director of the central pharmacy pointed out that the problem of drug shortage is a global problem, due to the Asian manufacturers of the drug as well as problems related to supply, in addition to the closure witnessed by China during the COVID-19 crisis.
Add your comment
All fields are required, and your email will not be published.
Please adhere to the site policy in the comments.
Your comment has been sent for review, it will be published after approval!
COMMENTS
0.
Excuse me! Excuse me!
There is no content to show!

Title:

Content: PEI

Nitroglycerin latest medication shortage

Nitroglycerin, which is used to treat heart pain, has been difficult to come by recently, joining a long list of drugs that have faced shortfalls in the last few years.

‘This isn’t the only medication that is shorted’

Nitroglycerin, which is used to treat heart pain, has been difficult to come by recently, joining a long list of drugs that have faced shortfalls in the last few years.

"It is frustrating because this isn't the only medication that is shorted," said Sheri Koshman, a cardiac pharmacist and professor in the cardiology division at the University of Alberta.

"There's all kinds of medication that is shorted all the time, and it's always this circle that goes round and round and round."

In recent months shortages of painkillers and antibiotics have also been reported.

Nitroglycerin can be used for long-term control and quick relief of heart pain, and it is the latter type where there is a shortage. Nitroglycerin dilates arteries and veins, so someone with blockages in their heart arteries can use it to open them up a little more.

For some people, nitroglycerine is an option they keep on hand but rarely use, and they will probably be OK during this shortage, said Koshman. The drug is safe to use up to a year after its expiry date, she said.

"We're telling people who have chest pain and are having to use their nitroglycerine regularly, and are perhaps running out, that they should probably see their physician to have their chest pain control reassessed," said Koshman.

"People that are needing it, and often, they should probably be reassessed by their health-care provider anyway."

The drug is really a pain treatment, and in that way not critical, she said. The important thing when experiencing heart pain is to sit down and rest. Giving your heart a break will also ease the pain.

If it doesn't go away, said Koshman, then you should seek emergency care. You may be having a heart attack.

With files from Island Morning

now

Title:

Content: In St. Petersburg pharmacies noticed queues.
What do experts say about “stockpiling medicines ”?
Pharmacy chains faced high demand amid news of a sharp weakening of the ruble, logistical disruptions and sanctions against Russia.
5
Share
Retailers, distributors and officials unanimously recommend that citizens do not panic and do not create an artificial deficit.
Stocks will last for six months, prices will increase - no more than 25%.
Sanctions are not threatened with drugs, and if necessary, European and American drugs are ready to import substitute domestic pharma.
It is true that we will have to sacrifice the rules of patent law.
The fact that residents of St. Petersburg rushed to buy medicines, reported the participants of the pharmacy market.
So the service "Apteka.ru" warns customers that "due to the increased demand for medicines, there may be an increase in the delivery time of orders."
“There is an increased demand, including for original drugs of import production, ” Olga Lipina, director of the University Pharmacy network, told Fontanka.
Photos with queues in several pharmacies, which appeared in the media and social networks, have already forced Smolny officials to urgently calm the population.
“In our difficult time, it comes to mind that we have a deficit of some kind.
I can say that there is no shortage of medicines, ” said the head of the Committee on Industrial Policy Kirill Soloveichik.
According to him, the queues are associated “exclusively with technical failures in information systems. ”
The lack of a deficit was also stated by the commissar.
For beneficiaries, the city bought medicines for six months, and for some positions and for a year in advance.
"This applies to drugs for the treatment of oncological and oncohematological diseases, diabetes, bronchial asthma, mental diseases, other diseases, as well as medical products - test strips to determine the level of glucose in the blood," - said on the page of the Ministry of "Vkontakte" .Refusals suppliers from entering into contracts, and the supply of drugs under the contracts are carried out in a timely manner, noted in the health committee.
The Ministry stressed that the goods from the list of vital (788 items) will not rise in price precisely, since prices are controlled by the state.
Retailers and manufacturers confirm that the drugs in the warehouses will last for a long time.
According to Olga Lipina, no one was ready for increased demand, so some positions may temporarily disappear from the range of pharmacies.
“You don ’ t have time to work out all the logistics, ” she says.
Suppliers also send calming letters to networks, urging them not to make purchases over the norm.
Stocks of drugs in the warehouses of manufacturers and distributors will last from 4 to 6 months, says Nikolai Bespalov, development director of the analytical company RNC Pharma.
But if people continue to panic, semi-annual volumes can be bought much faster, he said, and “this is not a very correct strategy, the hype only aggravates the situation. ”
He also recalled that the shelf life of drugs is about 2 years and it is necessary to soberly assess your need so that later expired tablets do not have to be thrown out.
The Association of Independent Pharmacies does not expect any interruptions in supplies.
“We are doing everything possible to prevent a deficit in one or another position.
Overall, the situation is stable.
Stocks of drugs have been created both in pharmacies and at suppliers, ” said Victoria Presnyakova, director of the association.
But the situation with prices is not so favorable.
The share of imported medicines in the Russian market is 56.3% in money and 31.4% in packages, the research company DSM Group reported in a report for 2020.
In addition, foreign pharmaceutical substances are used in the production of domestic medicines.
According to Olga Lipina, the price increase is already underway.
Medicines from the list of vital added to suppliers up to 5% of the cost, original or rare drugs - up to 10%.
“The exchange rate difference has not yet been won back, ” admits the top manager.
Against the background of the weakening of the ruble, suppliers increased prices from 2 to 25%, for some positions - up to 40%.
The same growth they will show in retail, says Victoria Presnyakova.
The network “PetroApteka ”, at the points of which on the Petrograd side and noticed the queue, warns that on its website“ technical work is being carried out, as a result of which prices may be displayed incorrectly. ”
According to Nikolai Bespalov, pharmacy chains face a temporary suspension of shipments, as well as the abolition of deferred payments or shares from distributors.
“Now we are talking about the growth of prices in the range of 20-25%, ” the expert estimates.
But it ’ s not enough to cause panic, he said.
In addition to short-term risks, there are long-term risks.
The total volume of imports of finished drugs to Russia in 2021 reached 787.4 billion rubles, according to RNC Pharma.
A total of 1.82 billion were imported.
Deliveries in bulk (unpackaged products) - another 166.4 billion rubles.
According to DSM Group, the highest share of imported drugs in medicines for rare diseases, which the state purchases for beneficiaries (programs “14 nosologies ”, ONLS, RLS) - 63% in monetary terms.
Moreover, imported drugs are considered to be domestic, whose production is localized in Russia.
On the one hand, drug provision has never been subject to sanctions, says Nikolai Bespalov.
On the other hand, market participants began to experience problems with logistics.
“There are precedents when on the territory of Poland trucks that went to Russia were stopped and looted.
Logists are in an alarming state, ” says Nikolai Bespalov.
According to him, the search for bypass routes and the demand for additional financial guarantees also provokes an increase in prices.
Logistics is dead.
Everything that comes from Southeast Asia has slowed down, everything that comes from Europe is on the border of Poland and Germany, ” said Dmitry Borisov, director of Polisan.
According to him, stocks of raw materials will last for six months.
Now the company is switching to the products of Russian suppliers, as well as China and India.
The collapse of the ruble will hit the profitability of production, but so far will not affect the price, since Polisan produces drugs from the list of vital, and the adjustment for them occurs once a year.
But in Russia, there were precedents when pharmaceutical companies refused to produce drugs if the price of the drug included in the list of VED, with difficulty covered the cost of its production.
According to Nikolai Bespalov, most of the drugs that are imported can be replaced by Russian companies.
“If you sacrifice the norms of patent law, you can talk about 95-98% of the total, ” he says.
But the launch of its production and the reorientation of logistics to the Asian region will take time.
“I hope that we consider this scenario as hypothetical, ” the expert comments.
China and India already supply 75% of the substances: “These two directions and half of what comes from Europe will be easily replaced. ”
At the same time, Bespalov admits that there are “irreplaceable positions ”.
Earlier, Dmitry Borisov in an interview with Vedomosti noted that the violation of patent rights for drugs threatens to turn Russia into a “banana republic ”: without real competition, the country will produce“ century-old generics ” when the rest of the world goes forward, he explained.
The manufacturer of insulins Geropharm does not experience difficulties with the supply of substances.
“To date, the production of drugs is carried out in the usual mode, ” says General Director Peter Rodionov.
But the top manager did not rule out that “due to the current situation in the future, difficulties may arise due to rising prices, difficulties with logistics. ”
Galina Boyarkova,
"Fontanka.ru"
SHARE
JOIN NOW
The most vivid photos and videos of the day are in our groups in social networks. Join now:
Did you see the typo?
Select a fragment and press Ctrl + Enter
Comments (5)
It is time to learn how to make iodine (honey, who did not understand).
That's enough.
We'll stock up on our own.
For wealthy citizens will always be available Vietnamese balm "Star".
It helps from everything - from the interior kidney, to the skin rash with migraine.
"True, you will have to sacrifice the norms of patent law." (citation)
It's not about patent law, quality will be sacrificed, that's what's scary...
The fact that there is and will not be a deficit - there is no doubt about it.
Another thing is that due to the growth of the dollar by 40% or more, prices will eventually rise by exactly the same amount.
Therefore, buying today at a cheaper price is quite a reasonable move.
And there will really be no shortage, they will bring you at a new price as much as you want.
Our partners
Lentainform
Loading...

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
Despite the availability of the dollar...
Parliamentary action on the suffering of people with chronic diseases due to the lack of treatment
Dr. Hisham Hussein, Secretary of the Suggestions and Complaints Committee of the House of Representatives, submitted a request for a briefing to Advisor Dr. Hanafi Jebali, President of the Council, addressed to the Prime Minister and Minister of Health and Population, on the continued shortage of medicines and medical supplies, despite the availability of the dollar, and the impact of this on people with chronic diseases.
Hisham Hussein pointed out that the past few days have witnessed a great problem in the insufficiency of intensive care beds and emergency departments in hospitals, due to the frequency of critical cases, which were unable to get the necessary treatment on the scheduled dates.
Hisham Hussein explained that many people with chronic diseases such as heart, kidney, tumors, diabetes and others delayed the payment of their scheduled treatment, whether from health insurance, or treatment at the expense of the state, which caused complications that led to their need to enter hospitals in emergency departments or non-intensive care.
The MP stressed that because of the heavy pressure on hospitals, many cases were unable to get the necessary treatment, which led to many complications and portends a great problem.
The member of the House of Representatives pointed out that many have pinned their hopes on the availability of the dollar in the past period, to meet the needs of the medical sector of medicines and supplies, saying: However, it seems that more action is needed in this regard.
Hisham Hussein called on the Ministry of Health, in coordination with the concerned authorities, to take the necessary measures to provide all medicines and medical supplies for the benefit of chronic diseases, by reviewing all needs, stressing the need to facilitate procedures to obtain medicines through health insurance or treatment at the expense of the state.

Title:

Content: Chairman of Wafd Party
Dr. Abdul Sindh Yamama
Chairman of the Board of Directors
Dr. Ayman is an accountant.
Editor-in-Chief
I'm sorry.
My grandfather, Zainuddin.
Chairman of Wafd Party
Dr. Abdul Sindh Yamama
Chairman of the Board of Directors
Dr. Ayman is an accountant.
Editor-in-Chief
I'm sorry.
My grandfather, Zainuddin.
Insulin, antibiotics and pressurized drugs top the list
Massive shortage of all chronic diseases drugs in Dakahlia pharmacies
Despite the announcement of increases in the prices of medicines, there is a severe shortage in Dawiya in Dakahlia governorate, which is one of the most consuming provinces of medicines due to its high population density.
Featured Medicines
The most prominent drugs that are in shortage in Dakahlia province is a long list, foremost of which are insulin drugs for diabetics, then all low pressure drugs of all kinds, whether tablets or drops, as well as solutions and important rheumatism drugs, along with all types of antibiotics and alternatives.
Diabetic disease
Abdul Rauf Ghanem says that he has been suffering from diabetes for years and was surprised several months ago by the disappearance of insulin, which caused his bad condition, as well as his daily suffering to search for it in all pharmacies without success, pointing out that the major pharmacies also disappeared insulin, what to do and who intervenes to end our suffering.
Liver Medications
Ahmed Mohammed Sadek adds that everyone knows that there is a coming increase in the prices of medicines, so what is the justification for the disappearance of medicines from pharmacies as long as prices will be increased?
He pointed out that he is one of the liver patients and has been searching for the necessary albumin for treatment for a whole week without success, and calls for the rapid provision of drugs, especially for patients with chronic diseases until this nightmare ends soon.
Disappearing Alternatives
Mr. Ibrahim confirms that the dentist prescribed him an antibiotic to treat infections in the teeth and searched for it in all pharmacies in vain, adding that he asked the pharmacist to bring an alternative, but the alternative unfortunately was not available as well, pointing out that patients are currently living difficult days as a result of the lack of availability of vital drugs.

Title:

Content: 09: 33, 03 September 2021
In Russia, there was a shortage of a vital medicine for childhood epilepsy
In Russia, there was a shortage of a vital medicine for childhood epilepsy, – writes the newspaper RBC.
Two charitable foundations have drawn attention to the problem.
In addition, parents complain about the lack of a number of drugs, including those that do not have registration in the country.
At the same time, doctors warn that replacing one drug with any analogue or suspending its intake threatens to worsen the condition of the child.
The Ministry of Industry assured that now they are taking the necessary measures for the prompt import of the drug.
They explained the interruptions in the delay in the re-registration of this funds.
Uploading comments...
The most discussed
Popular for the week
On the air today

These shortages can have severe consequences, particularly for patients with chronic life-threatening conditions who rely on life-saving medications.

Title:

Content: Patients complained to Putin about the shortage of 42 rare drugs
21 December 2020, 08: 02
Photo: 1Mediainvest.ru
The All-Russian Union of Patients sent an appeal to the President of the Russian Federation Vladimir Putin on behalf of 20 patient associations.
It lists 42 rare drugs intended for the treatment of chronic diseases.
The reason for the shortage is that they were included in the recommendations for the treatment of patients with coronavirus.
In this regard, there is an increased demand for them, write “New news ”.
According to Izvestia, the organization is confident that funding should be increased, production increased, and the mechanism for regulating the marginal cost of drugs from the list of vital and important drugs (VED) should be changed.
The co-chairman of the GSP, Yuliy Zhulev, said that in a number of cases the organization did not receive answers from relevant NGOs, or they indicated that there was no problem.
In the list of scarce drugs are vital, intended for the treatment of oncology and cystic fibrosis, for patients with multiple sclerosis, rheumatic diseases, primary immunodeficiency and others.
The GSP noted that problems with the availability of drugs have worsened since September 2020.
Zhulev said that this is due to the fact that the distribution of drugs is also carried out on those who are sick with coronavirus.
First of all, it concerns antibiotics.

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
Report: Lack of Obesity Drugs and Weight Loss Causes Inconvenience
Patients who are prescribed highly effective anti-obesity drugs are concerned about the increasing difficulty in obtaining them amid the long-term shortage caused by the high demand for drugs, according to a report published recently by the American website Axios.
Ethan Lazarus, a Denver-based certified bariatric physician, said: “They ’ ve been out of stock everywhere for about a month, and it ’ s gone from being easy to locate to being very difficult.
Lazarus and other doctors who spoke with Axios said almost all of their patients in recent weeks had difficulty finding their prescribed dose.
Patients are increasingly contacting pharmacies to keep track of their prescriptions and, in many cases, have to switch doses or medications altogether.
For some patients, one of the most disturbing aspects is how quickly persistent thoughts about food return.
Christine Rehn Fielding, director of the New York University Langone Weight Management Program, said that “food noise ” disappears in people who eat GLP products,“ and feel very free. ”
At the same time, doctors said some patients are also having more difficulty convincing insurers to re-allow coverage of their prescriptions after several tighter rules at the beginning of the year to curb spending on expensive drugs.
Experts say that stopping taking medications, even for a week or two, can be annoying.
Patients begin with lower doses before gradually increasing them to higher doses, a process that usually takes months.
- Ah!

Title:

Content: Advertisement
NEWS
The Ministry of health included iodine, aspirin and paracetamol in the list of potentially deficient drugs
Today at 19: 58
The Interdepartmental Commission of the Ministry of Health included 97 items in the list of drugs that could potentially become scarce in the Russian market.
This is reported by “Kommersant ”.
The list includes iodine, ibuprofen, acetylsalicylic acid (aspirin), lidocaine, paracetamol, fentanyl, phenobarbital (the main component of valocordine and corvalol) and other drugs.
With regard to these drugs, the Government will take measures to ensure that they are available to consumers.
According to the “Pharmaceutical Bulletin ”, the Ministry of Health issued 44 permits to accelerate the registration of drugs.
Another 80 permits for amendments under the shortened procedure, 11 permits for the circulation of drugs in foreign packaging and 7 permits for the temporary circulation of unregistered medicines in the country.
Earlier, Izvestia reported a deficiency of Tamoxifen, used in many oncological diseases, in particular breast cancer.
In turn, the Ministry of Health reported more than 470 thousand packages of the drug in civil circulation.
That ’ s about six months, they said.
Read also
Events of the week on afisha.ru
We recommend you

Title:

Content: news _ header _ top _ 970 _ 100
news _ header _ bot _ 970 _ 100
The whole world buys raw materials for medicines in India and China: how are things on the pharmaceutical market in the Republic of Tatarstan?
Tatarstantsev continues to be concerned about the issue of drug supply, although no foreign pharmaceutical company has left the Russian market.
What measures have been taken to ensure that the residents of the republic always have the necessary drugs, and where the whole world is purchased with raw materials for medicines - said Deputy Minister of Health of the Republic of Tatarstan Farida Yarkaeva.
news _ top _ 970 _ 100
Foreign pharmaceutical companies do not leave the Russian market
Pharmaceutical companies from abroad do not leave the Russian market.
“None of the foreign drug companies have announced that they are leaving the Russian market because of sanctions, ” said Deputy Minister of Health of Tatarstan Farida Yarkaeva.
In addition, some well-known foreign, transnational pharmaceutical companies themselves have written that they will continue to supply vital drugs to Russia.
Now the main risks are related to the construction of logistics chains.
However, at the federal level, it was emphasized that pharmaceutical products were a priority.
Farida Yarkaeva added that the largest transnational companies with a wide range of drugs have factories in Russia.
“They have invested huge investments in opening plants using the latest technologies in Russia, of course, they cannot leave these plants or stop their work, ” Farida Fatykhovna said.
For beneficiaries and hospitals of Tatarstan drugs are in stock
For medical institutions of Tatarstan, there is a stock of medicines in warehouses.
This was announced at a press conference in Tatar-inform by Deputy Minister of Health of Tatarstan Farida Yarkaeva.
“To provide medical institutions, medicines are available for more than 3.5 billion rubles at our state enterprise Tattekhmedpharm, ” the speaker said.
The hospitals themselves also have a supply of drugs for a period of one to three months.
“In Tattekhmedpharm, medicines for four and a half months, ” Farida Yarkaeva added.
Now the unitary enterprise is working with suppliers to speed up deliveries to the republic.
Some of them will bring the drugs even before the deadline.
“Most of the suppliers responded and will ship the drugs as a priority, ” the deputy minister added.
For federal and republican beneficiaries, there are medicines with a reserve for a period of 3.5 to 4.5 months, deliveries are going according to plan, there are no failures.
Now drugs are purchased for the second half of 2022.
“Under the program to combat diseases of the circulatory system, drugs for some items are available for a period of three months to three years.
There are drugs, including imported ones.
We have no worries, ” Farida Yarkaeva gave an example.
Monitoring the availability of medicines and their prices is now daily
To date, monitoring of the availability of vital drugs and their prices in retail pharmacies and for hospital needs was carried out monthly.
“This work is entrusted to the territorial bodies of Roszdravnadzor and, in general, to the federal service for supervision in the field of health care.
Today, in addition to these measures, municipalities carry out daily monitoring of the availability of assortment minimum drugs in pharmacies in each municipality, ” the deputy minister said.
The list of vital medicines includes 51 international generic names for the chemical substance and more than several thousand of their trade names.
Yarkaeva noted that today, for example, there is no drug ranitidine in pharmacies, but stressed that there are its analogues on the shelves of pharmacies.
61.5% of the market is occupied by domestic medicines
Farida Fatykhovna recalled that the import substitution program has been operating in the Russian Federation for several years.
“According to the estimates of the Ministry of Industry of the Russian Federation, 61.5% of all drugs circulating on the Russian pharmaceutical market in natural terms – in packages – belong to domestic drugs, ” the speaker noted.
In monetary terms, about 30% of the market are our medicines, this is due to the fact that our drugs are cheaper, Yarkaeva explained.
In addition, more than half of the drugs on the list of vital drugs can be produced on a full cycle in Russia - from pharmaceutical substances to finished drug in consumer packaging.
Recall that the list of vital drugs is about 800 international generic names for the active substance.
The prices for the list of vital drugs from manufacturers are set by the state, at the regional level, an allowance is established for the retail and wholesale sale of these drugs.
Information about not exceeding the upper limit price, the buyer can request from the pharmacy.
It can also be found on the website of the Ministry of Health.
For other drugs and medical products, pricing is free and determined by demand.
Farida Yarkaeva noted that there should be an assortment minimum in pharmacies.
The whole world buys raw materials for medicines in India and China
“Most of the substances – active substances of drugs – are imported, ” the speaker noted.
However, Farida Yarkaeva stressed that all countries of the world, including Europe and the United States, buy these raw materials in India and China.
That is, the basis of imported and domestic medicines in the vast majority originates in these two countries.
“Just in the last two years, new plants have been opened in Bratsk, Moscow and St. Petersburg for the production of active substances of pharmaceutical substances – this is also an opportunity for our stability and national security, ” Yarkaeva said.
Distributors are obliged to comply with the terms of shipment of drugs
Farida Fatykhovna told what measures are being taken at the country level to ensure uninterrupted provision of medicines to people.
“There have been major changes in the procurement rules.
A number of measures have been taken that are aimed at liberalization – that it is possible to make changes to the essential terms of the contract during budget purchases.
This is the possibility of additional purchases from a single source, ” she said.
Another change was the introduction of a larger advance than had been envisaged before.
All measures are aimed at encouraging distributors and pharmacies to quickly import drugs into the country and sell them.
“Another block of measures concerns preferences in import substitution, especially if it concerns full-cycle production, ” the deputy minister added.
The State Duma in the third reading adopted a number of measures on the possibility of importing non-Russified packages of drugs.
This also accelerates all processes, says Farida Yarkaeva.
“Manufacturers and suppliers of medical devices were obliged to notify Roszdravnadzor at least six months before the termination of production or import into the territory of the Russian Federation, ” the speaker said.
Distributors were obliged at the legislative level, if they have drugs, to comply with the terms of shipment and ship the drugs.
This is done to ensure that suppliers do not have the opportunity for their own reasons to delay medicines.
When to wait for L-thyroxine on the shelves of pharmacies?
The drug L-thyroxine is a thyroid hormone, it is used by patients who have problems with the work of this organ.
This drug is produced by several companies.
“Yes, there was a deficit.
There was a great demand that was lagging behind the possibilities.
Roszdravnadzor held a special meeting on this topic.
And he cited data that in the first week of March, the sale of the drug in all its forms was increased from pharmacies ten times, for the second week of March - more than five times, "the Deputy Minister of Health of the Republic of Tatarstan said.
This is how high demand was created.
People bought the pills for more than a year.
However, the shelf life and storage rules are for each drug, and you should not forget about it.
Roszdravnadzor stated that 12 million packages of this drug are in civil circulation in Russia, which covers the annual need of the country.
After the introduced law on the obligation of distributors to supply the drug without holding it artificially, all questions about the availability of this drug, said Yarkaeva, should disappear by themselves.
news _ right _ column _ 1 _ 240 _ 400
news _ right _ column _ 2 _ 240 _ 400
news _ bot _ 970 _ 100

Title:

Content: Healthcare companies moved higher as tech companies continue to enter the space.

Facebook parent Meta Platforms has created a tool to predict the structure of hundreds of millions of proteins using artificial intelligence. Researchers say it promises to deepen scientists' understanding of biology, and perhaps speed the discovery of new drugs.

Meanwhile, a drug used to extend the lives of people with advanced prostate cancer is in short supply and will be for months, leaving some patients with no treatment option as the manufacturer works to ramp up production. The Food and Drug Administration said last week the availability of Pluvicto is limited as manufacturer Novartis struggles to meet demand. The drugmaker said the shortage stems from manufacturing and delivery issues.

Write to Amy Pessetto at amy.pessetto@dowjones.com

(END) Dow Jones Newswires

03-16-23 1727ET

Title:

Content: default-output-block.skip-main

The Business of Fashion

Agenda-setting intelligence, analysis and advice for the global fashion community.

The Year Ahead: Can New Production Models Help Fashion Overcome Supply Chain Woes?

As supply chains remain under pressure, garment manufacturers have an opportunity to lean into vertical integration, nearshoring and small-batch production, while seeking closer upstream and downstream collaboration, according to The State of Fashion 2023.

Key insights

  • More than half of fashion executives believe supply chain disruptions will be one of the top factors impacting growth of the global economy in 2023.
  • Nearly two-thirds of fashion executives are considering creating new manufacturing hubs dedicated to serving US and European demand.
  • Collaboration will be pivotal to addressing challenges: about 60 percent of fashion executives are considering forming strategic partnerships with their suppliers.

The fashion industry operates on an outdated manufacturing system that is ripe for disruption. With many practices remaining unchanged for more than 50 years, fashion’s supply chains are neither responsive nor sustainable enough. With brands hunting for the lowest prices, manufacturing practices have become fragmented as brands outsource more and more of their production to sprawling networks of suppliers in developing countries. The number of factories has mushroomed, along with unauthorised subcontracting.

At the same time, logistics gridlocks and macroeconomic pressures continue to weigh on global supply. The war in Ukraine forced the re-routing of trade and triggered an energy crisis, while ageing port systems across the globe are creating transport bottlenecks. Global inflation has pushed up input costs — cotton and cashmere prices have increased 45 percent and 30 percent year on year in 2021 respectively — and extreme weather is hitting developing economies like Pakistan where, alongside the tragic loss of human life, as much as 45 percent of the country’s cotton crops were wiped out by floods in August 2022. As such, more than half of fashion executives in the BoF-McKinsey State of Fashion 2023 Survey identified supply chain disruptions as one of the top risks hampering the growth of the global economy in 2023.

Meanwhile, the softening of consumer demand is causing many brands to reduce their order volumes, squeezing manufacturers’ revenues. In a 2021 McKinsey survey of apparel chief purchasing officers, 66 percent said they anticipated increased volatility in consumer demand. If these and other pressures continue, margins across apparel manufacturing are expected to shrink 10 percentage points by 2030.

Amid the diverse sources of pressure on fashion’s supply chains, the system is beginning to show signs of change. To future-proof their organisations, manufacturers are adapting to the needs of fashion brands seeking increased flexibility and shorter lead times so that they can accommodate swift changes in consumer demand and unpredictable logistical disruptions. Enabled by enhanced digitisation, they will lean into new supply chain models based around vertical integration, nearshoring and on-demand systems.

From Suppliers to Partners

To mitigate risks and increase control along supply chains, some manufacturers are joining forces with producers from different specialities. For example, US textile manufacturer Mount Vernon Mills acquired a yarn spinning and weaving facility from Wade Manufacturing Company, also US-based, in a bid to gain more flexibility over its production. In Asia, Sri Lanka-based manufacturer MAS Holdings in August 2022 acquired the assets of Bam Knitting, one of the country’s fabric producing and finishing operations.

Vertical integration can help cut costs, improve margins and prevent delays across production. Similarly, consolidation of players across the supply chain has added to the deal-making. In Italy, Gruppo Florence was formed in 2020 to create a production network comprising more than a dozen small and medium-sized luxury specialists, from hat makers to jersey makers. Such deals are expected to continue in 2023.

Investments and partnerships can also foster industry innovation by connecting brands and manufacturers with innovative fabric and yarn suppliers to help bring new textiles to market. For example, athleticwear brand Lululemon’s anti-odour Silverescent fabric is the result of a partnership with materials company Noble Biomaterials. This can also enable new materials to scale. Fashion group Inditex announced in May 2022 that it had agreed to buy 30 percent of Infinited Fiber Company’s production of its textile waste fibre each year for three years, facilitating Infinited’s plans to set up its first large-capacity factory.

Several brands have prioritised sustainability-related innovation, using partnerships with fibre producers to bring recycled or circular materials to market. H&M partnered with another Swedish company — textile recycling innovator Renewcell — in 2020 to incorporate more recycled fibres into its products. Similarly, US brand The North Face works with Finnish sustainable textile material company Spinnova to source its circular fibre made from wood and waste. To scale these materials, manufacturers will need to modernise their operations in tandem and in partnership with brands.

In the luxury segment, where labour can be more skills-based than in other segments, brands have secured access to craftmanship through manufacturer acquisitions. For example, Italian sneaker brand Golden Goose announced in October 2022 that it would acquire its main supplier of seven years, Italian Fashion Team, and LVMH-owned Fendi said it has taken a majority stake in Italian knitwear maker Maglificio Matisse. Since 2015, Chanel has acquired eight manufacturers, including Italian knitwear supplier Paima. While providing the French luxury label with greater certainty in terms of supply of materials, the acquisition strategy also grants Chanel greater access to innovation.

Closer to Home

Another shifting dynamic in fashion’s supply chains involves nearshoring. By moving manufacturing closer to consumer markets, brands can increase their speed to market while reducing the cost of transport and duties and mitigating various risks, including those related to inventory.

In 2020, MAS Holdings opened a manufacturing facility in Kenya so that the business could take advantage of the preferential trade agreements (AGOA) in place with the key consumer markets of the brands it serves; the facility manufactures apparel for PVH Corp., which owns brands such as Tommy Hilfiger and Calvin Klein. Meanwhile, South Korea’s Sae-A Group has opened two spinning mills in Costa Rica, the most recent in 2022, citing the political and social stability of the region as its appeal.

Many fashion players are expected to continue to produce garments in historically low-labour cost manufacturing countries such as Bangladesh and Pakistan, but nearshoring will remain on executive radars. In the BoF-McKinsey State of Fashion 2023 Survey, 65 percent of fashion executives said they were considering nearshoring to address supply chain challenges.

These shifts are creating new manufacturing hubs dedicated to serving US and European demand. In McKinsey’s annual survey of chief purchasing officers, over 75 percent of North American respondents said they expected to increase the share of sourcing from Central America, while more than 35 percent expected to increase the share from Mexico. In Europe, Turkey is emerging as the preferred closer-to-home hub, with 85 percent of Western European respondents expecting to increase their supply from the country, followed by Eastern Europe and Northern Africa.

Spanish brand Mango has said it will move some production in China and Vietnam to Turkey, Morocco and Portugal, while US footwear brand Steve Madden moved half of its production from Vietnam to Brazil and Mexico in 2021. In Brazil, footwear exports jumped 32 percent year on year in 2021. Similarly, the value of denim imports to the US from Mexico increased 50.58 percent in the first eight months of 2021, compared to the same period the prior year.

Sourcing from closer-to-home locations can create environmental benefits, too, for instance by reducing greenhouse gas emissions and energy use, as well as unlocking access to more sustainable materials and improving water stewardship. With more than 70 percent of the industry’s greenhouse gas emissions generated from upstream activities, some manufacturers are aiming to decarbonise manufacturing and leverage their improved sustainability credentials to differentiate themselves from the competition.

Nearshoring can be challenging to get right, however. Because raw materials suppliers are located close to traditional production regions, moving production nearer to home for many Western brands can make it difficult to source materials. For speciality manufacturers, like dyers and fabric makers, a location’s lack of technical skills can also be a concern. Manufacturers will need to rethink their processes to make nearshoring successful; simply moving operations will not be effective.

While rare, some fashion brands are investing in moving some production to their domestic markets. Boston-based sportswear label New Balance opened its fifth manufacturing facility in the US in 2022 and has promoted “Made in USA” collections.

The uncertain economic environment may prompt brands and manufacturers to postpone or downsize nearshoring strategies in the short term, given that manufacturing hubs in Asia are expected to remain significantly cheaper than other locations. It should be noted that nearshoring can also threaten economic prosperity and job creation in traditional manufacturing hubs, which would be negatively impacted if their manufacturing activity were to diminish. Brands should understand the full scale of its decisions and work with manufacturers to pursue nearshoring with good governance and ethics top of mind.

Building Responsiveness

Regardless of how suppliers diversify production capabilities or global footprints, increased digitisation will enable them to support the changing needs of brands. In a 2021 McKinsey survey, apparel chief purchasing officers cited capacity planning, virtual sampling and supply chain transparency among the key areas for digital investments in the next five years.

In pre-production, digital platforms are helping brands source fabrics and create digital samples, saving time and money and reducing waste. In post-production, digital looks are facilitating quality control and improving the flow of information between suppliers and brands.

While these innovations are modernising discrete parts of the value chain, linking them together in a digitally integrated journey remains a challenge. However, new platforms are emerging that digitally connect key parts of the production process. In China, Alibaba manages a manufacturing platform that connects shopping demand on sites Taobao and TMall with production information. Consumer insights are gleaned from its website, where AI algorithms and cloud technologies provide real-time analytics that manufacturers can use to streamline production and optimise inventories. Similarly, fast-fashion player Shein designs and manufactures products in small batches using a trend-prediction model and monitors performance in real time to adjust production up or down accordingly.

Some fashion brands are looking for suppliers that can accommodate small-batch production. The requires manufacturers to invest in capabilities like 3D sampling, automated sewing and knitting, 3D and digital printing, direct-to-fabric and direct-to-garment printing, as well as automated post-production logistics to finalise orders.

In terms of the adoption of automation, the fashion industry lags other sectors, such as electronics and auto-making. However, suppliers that make a case for investing in automation will be able to differentiate themselves from competitors by facilitating faster and smaller-batch production. More than 50 percent of chief purchasing officers said they expect automation to become a major driver for sourcing decisions by 2025.

In the year ahead, both brands and suppliers should prepare to work more collaboratively than they have in the past, moving away from transactional relationships to deeper partnerships that enable both parties to benefit from innovations and mitigate risks. About 60 percent of fashion executives in the BoF-McKinsey survey said they considered forming strategic partnerships with suppliers to mitigate supply chain disruptions. Collaboration can come in many forms, from co-financing and capability sharing to rewards and other incentive systems.

While manufacturers are likely to be cost-conscious in 2023, developing capabilities for nearshoring, small-batch production and digital production processes will help them establish a competitive advantage and will make them less reliant on price as a bargaining chip in building relationships with brands.

This article first appeared in The State of Fashion 2023, an in-depth report on the global fashion industry, co-published by BoF and McKinsey & Company.

Further Reading

The seventh annual State of Fashion report by The Business of Fashion and McKinsey & Company reveals the industry is heading for a global slowdown in 2023 as macroeconomic tensions and slumping consumer confidence chip away at 2022′s gains. Download the full report to understand the 10 themes that will define the industry and the opportunities for growth in the year ahead.

© 2021 The Business of Fashion. All rights reserved. For more information read our Terms & Conditions

The Business of Fashion

Agenda-setting intelligence, analysis and advice for the global fashion community.
CONNECT WITH US ON
© 2022 The Business of Fashion. All rights reserved. For more information read our Terms & Conditions and Privacy policy.

Title:

Content: Global Smart Medical Devices Market to Reach $60.1 Billion by 2030

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.

New York, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Smart Medical Devices Industry" - https://www.reportlinker.com/p06032911/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Smart Medical Devices Market to Reach $60.1 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Smart Medical Devices estimated at US$24.7 Billion in the year 2022, is projected to reach a revised size of US$60.1 Billion by 2030, growing at aCAGR of 11.8% over the period 2022-2030. Diagnostics & Monitoring Devices, one of the segments analyzed in the report, is projected to record 11.4% CAGR and reach US$40 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Therapeutic Devices segment is readjusted to a revised 12.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $7.4 Billion, While China is Forecast to Grow at 11% CAGR

The Smart Medical Devices market in the U.S. is estimated at US$7.4 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$10.2 Billion by the year 2030 trailing a CAGR of 11% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.3% and 9.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.4% CAGR.

Select Competitors (Total 33 Featured)
- Abbott Laboratories
- Apple Inc.
- Dexcom, Inc.
- Everist Genomics
- F.Hoffmann-La Roche Ltd.
- Fitbit, Inc.
- Johnson & Johnson
- Medtronic plc.
- NeuroMetrix, Inc.
- Omron Corporation
- Philips Electronics
- Samsung Electronics Co., Ltd
- Sonova
- Sotera Wireless
- Vital Connect
- Zephyr Technology Corporation

Read the full report: https://www.reportlinker.com/p06032911/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Smart Medical Devices - Global Key Competitors Percentage
Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for Smart
Medical Devices by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 2: World 8-Year Perspective for Smart Medical Devices by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2023 & 2030

Table 3: World Recent Past, Current & Future Analysis for
Diagnostics & Monitoring Devices by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR

Table 4: World 8-Year Perspective for Diagnostics & Monitoring
Devices by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2023 & 2030

Table 5: World Recent Past, Current & Future Analysis for
Therapeutic Devices by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 6: World 8-Year Perspective for Therapeutic Devices by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2023 & 2030

Table 7: World Recent Past, Current & Future Analysis for
Online by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 8: World 8-Year Perspective for Online by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2023 & 2030

Table 9: World Recent Past, Current & Future Analysis for
Pharmacies by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2022 through
2030 and % CAGR

Table 10: World 8-Year Perspective for Pharmacies by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2023 & 2030

Table 11: World Recent Past, Current & Future Analysis for
Other Distribution Channels by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2022 through 2030 and % CAGR

Table 12: World 8-Year Perspective for Other Distribution
Channels by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2023 & 2030

Table 13: World Smart Medical Devices Market Analysis of Annual
Sales in US$ Million for Years 2012 through 2030

III. MARKET ANALYSIS

UNITED STATES
Smart Medical Devices Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2023 (E)
Table 14: USA Recent Past, Current & Future Analysis for Smart
Medical Devices by Product - Diagnostics & Monitoring Devices
and Therapeutic Devices - Independent Analysis of Annual Sales
in US$ Million for the Years 2022 through 2030 and % CAGR

Table 15: USA 8-Year Perspective for Smart Medical Devices by
Product - Percentage Breakdown of Value Sales for Diagnostics &
Monitoring Devices and Therapeutic Devices for the Years 2023 &
2030

Table 16: USA Recent Past, Current & Future Analysis for Smart
Medical Devices by Distribution Channel - Online, Pharmacies
and Other Distribution Channels - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 17: USA 8-Year Perspective for Smart Medical Devices by
Distribution Channel - Percentage Breakdown of Value Sales for
Online, Pharmacies and Other Distribution Channels for the
Years 2023 & 2030

CANADA
Table 18: Canada Recent Past, Current & Future Analysis for
Smart Medical Devices by Product - Diagnostics & Monitoring
Devices and Therapeutic Devices - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 19: Canada 8-Year Perspective for Smart Medical Devices
by Product - Percentage Breakdown of Value Sales for
Diagnostics & Monitoring Devices and Therapeutic Devices for
the Years 2023 & 2030

Table 20: Canada Recent Past, Current & Future Analysis for
Smart Medical Devices by Distribution Channel - Online,
Pharmacies and Other Distribution Channels - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 21: Canada 8-Year Perspective for Smart Medical Devices
by Distribution Channel - Percentage Breakdown of Value Sales
for Online, Pharmacies and Other Distribution Channels for the
Years 2023 & 2030

JAPAN
Smart Medical Devices Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2023 (E)
Table 22: Japan Recent Past, Current & Future Analysis for
Smart Medical Devices by Product - Diagnostics & Monitoring
Devices and Therapeutic Devices - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 23: Japan 8-Year Perspective for Smart Medical Devices by
Product - Percentage Breakdown of Value Sales for Diagnostics &
Monitoring Devices and Therapeutic Devices for the Years 2023 &
2030

Table 24: Japan Recent Past, Current & Future Analysis for
Smart Medical Devices by Distribution Channel - Online,
Pharmacies and Other Distribution Channels - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 25: Japan 8-Year Perspective for Smart Medical Devices by
Distribution Channel - Percentage Breakdown of Value Sales for
Online, Pharmacies and Other Distribution Channels for the
Years 2023 & 2030

CHINA
Smart Medical Devices Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2023 (E)
Table 26: China Recent Past, Current & Future Analysis for
Smart Medical Devices by Product - Diagnostics & Monitoring
Devices and Therapeutic Devices - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 27: China 8-Year Perspective for Smart Medical Devices by
Product - Percentage Breakdown of Value Sales for Diagnostics &
Monitoring Devices and Therapeutic Devices for the Years 2023 &
2030

Table 28: China Recent Past, Current & Future Analysis for
Smart Medical Devices by Distribution Channel - Online,
Pharmacies and Other Distribution Channels - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 29: China 8-Year Perspective for Smart Medical Devices by
Distribution Channel - Percentage Breakdown of Value Sales for
Online, Pharmacies and Other Distribution Channels for the
Years 2023 & 2030

EUROPE
Smart Medical Devices Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2023 (E)
Table 30: Europe Recent Past, Current & Future Analysis for
Smart Medical Devices by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2022 through 2030 and %
CAGR

Table 31: Europe 8-Year Perspective for Smart Medical Devices
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2023 & 2030

Table 32: Europe Recent Past, Current & Future Analysis for
Smart Medical Devices by Product - Diagnostics & Monitoring
Devices and Therapeutic Devices - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 33: Europe 8-Year Perspective for Smart Medical Devices
by Product - Percentage Breakdown of Value Sales for
Diagnostics & Monitoring Devices and Therapeutic Devices for
the Years 2023 & 2030

Table 34: Europe Recent Past, Current & Future Analysis for
Smart Medical Devices by Distribution Channel - Online,
Pharmacies and Other Distribution Channels - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 35: Europe 8-Year Perspective for Smart Medical Devices
by Distribution Channel - Percentage Breakdown of Value Sales
for Online, Pharmacies and Other Distribution Channels for the
Years 2023 & 2030

FRANCE
Smart Medical Devices Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2023 (E)
Table 36: France Recent Past, Current & Future Analysis for
Smart Medical Devices by Product - Diagnostics & Monitoring
Devices and Therapeutic Devices - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 37: France 8-Year Perspective for Smart Medical Devices
by Product - Percentage Breakdown of Value Sales for
Diagnostics & Monitoring Devices and Therapeutic Devices for
the Years 2023 & 2030

Table 38: France Recent Past, Current & Future Analysis for
Smart Medical Devices by Distribution Channel - Online,
Pharmacies and Other Distribution Channels - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 39: France 8-Year Perspective for Smart Medical Devices
by Distribution Channel - Percentage Breakdown of Value Sales
for Online, Pharmacies and Other Distribution Channels for the
Years 2023 & 2030

GERMANY
Smart Medical Devices Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2023 (E)
Table 40: Germany Recent Past, Current & Future Analysis for
Smart Medical Devices by Product - Diagnostics & Monitoring
Devices and Therapeutic Devices - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 41: Germany 8-Year Perspective for Smart Medical Devices
by Product - Percentage Breakdown of Value Sales for
Diagnostics & Monitoring Devices and Therapeutic Devices for
the Years 2023 & 2030

Table 42: Germany Recent Past, Current & Future Analysis for
Smart Medical Devices by Distribution Channel - Online,
Pharmacies and Other Distribution Channels - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 43: Germany 8-Year Perspective for Smart Medical Devices
by Distribution Channel - Percentage Breakdown of Value Sales
for Online, Pharmacies and Other Distribution Channels for the
Years 2023 & 2030

ITALY
Table 44: Italy Recent Past, Current & Future Analysis for
Smart Medical Devices by Product - Diagnostics & Monitoring
Devices and Therapeutic Devices - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 45: Italy 8-Year Perspective for Smart Medical Devices by
Product - Percentage Breakdown of Value Sales for Diagnostics &
Monitoring Devices and Therapeutic Devices for the Years 2023 &
2030

Table 46: Italy Recent Past, Current & Future Analysis for
Smart Medical Devices by Distribution Channel - Online,
Pharmacies and Other Distribution Channels - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 47: Italy 8-Year Perspective for Smart Medical Devices by
Distribution Channel - Percentage Breakdown of Value Sales for
Online, Pharmacies and Other Distribution Channels for the
Years 2023 & 2030

UNITED KINGDOM
Smart Medical Devices Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2023 (E)
Table 48: UK Recent Past, Current & Future Analysis for Smart
Medical Devices by Product - Diagnostics & Monitoring Devices
and Therapeutic Devices - Independent Analysis of Annual Sales
in US$ Million for the Years 2022 through 2030 and % CAGR

Table 49: UK 8-Year Perspective for Smart Medical Devices by
Product - Percentage Breakdown of Value Sales for Diagnostics &
Monitoring Devices and Therapeutic Devices for the Years 2023 &
2030

Table 50: UK Recent Past, Current & Future Analysis for Smart
Medical Devices by Distribution Channel - Online, Pharmacies
and Other Distribution Channels - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 51: UK 8-Year Perspective for Smart Medical Devices by
Distribution Channel - Percentage Breakdown of Value Sales for
Online, Pharmacies and Other Distribution Channels for the
Years 2023 & 2030

REST OF EUROPE
Table 52: Rest of Europe Recent Past, Current & Future Analysis
for Smart Medical Devices by Product - Diagnostics & Monitoring
Devices and Therapeutic Devices - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 53: Rest of Europe 8-Year Perspective for Smart Medical
Devices by Product - Percentage Breakdown of Value Sales for
Diagnostics & Monitoring Devices and Therapeutic Devices for
the Years 2023 & 2030

Table 54: Rest of Europe Recent Past, Current & Future Analysis
for Smart Medical Devices by Distribution Channel - Online,
Pharmacies and Other Distribution Channels - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 55: Rest of Europe 8-Year Perspective for Smart Medical
Devices by Distribution Channel - Percentage Breakdown of Value
Sales for Online, Pharmacies and Other Distribution Channels
for the Years 2023 & 2030

ASIA-PACIFIC
Smart Medical Devices Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Asia-Pacific for 2023 (E)
Table 56: Asia-Pacific Recent Past, Current & Future Analysis
for Smart Medical Devices by Product - Diagnostics & Monitoring
Devices and Therapeutic Devices - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 57: Asia-Pacific 8-Year Perspective for Smart Medical
Devices by Product - Percentage Breakdown of Value Sales for
Diagnostics & Monitoring Devices and Therapeutic Devices for
the Years 2023 & 2030

Table 58: Asia-Pacific Recent Past, Current & Future Analysis
for Smart Medical Devices by Distribution Channel - Online,
Pharmacies and Other Distribution Channels - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 59: Asia-Pacific 8-Year Perspective for Smart Medical
Devices by Distribution Channel - Percentage Breakdown of Value
Sales for Online, Pharmacies and Other Distribution Channels
for the Years 2023 & 2030

REST OF WORLD
Table 60: Rest of World Recent Past, Current & Future Analysis
for Smart Medical Devices by Product - Diagnostics & Monitoring
Devices and Therapeutic Devices - Independent Analysis of
Annual Sales in US$ Million for the Years 2022 through 2030 and
% CAGR

Table 61: Rest of World 8-Year Perspective for Smart Medical
Devices by Product - Percentage Breakdown of Value Sales for
Diagnostics & Monitoring Devices and Therapeutic Devices for
the Years 2023 & 2030

Table 62: Rest of World Recent Past, Current & Future Analysis
for Smart Medical Devices by Distribution Channel - Online,
Pharmacies and Other Distribution Channels - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR

Table 63: Rest of World 8-Year Perspective for Smart Medical
Devices by Distribution Channel - Percentage Breakdown of Value
Sales for Online, Pharmacies and Other Distribution Channels
for the Years 2023 & 2030

IV. COMPETITION
Read the full report: https://www.reportlinker.com/p06032911/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Title:

Content: There were 1,546 press releases posted in the last 24 hours and 437,288 in the last 365 days.

General Anesthesia Drugs Market to Surpass US$6.44 Billion by 2030 Drives Due to Cancer is Becoming Prevalent | Persistence Market Research

Global demand for general anesthesia drugs rises with growing chronic disease cases. The United States grapples with shortages of key drugs like dexmedetomidine and midazolam

New York, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Market Size & Overview:

The global General Anesthesia Drugs market is poised for substantial growth, with a projected Compound Annual Growth Rate (CAGR) of 3.4%. Anticipated to rise from a value of US$5.10 billion in 2023 to US$6.44 billion by 2030, the market is driven by the increasing prevalence of chronic diseases like cancer, cardiovascular ailments, and osteoarthritis.

The General anesthesia drugs market play a pivotal role in inducing and maintaining unconsciousness, ensuring the absence of pain sensation during medical procedures, ranging from cardiac surgeries and joint replacements to cancer and gastrointestinal surgeries.

The demand for general anesthesia drugs is witnessing an upswing due to factors such as the growing incidence of chronic illnesses, augmented funding from both private and government sectors for pharmaceutical manufacturing, and heightened research and development efforts in formulating these drugs. Inhalation anesthesia, including Sevoflurane and Desflurane, and intravenous general anesthetic drugs like Propofol, Etomidate, and Ketamine, administered in conjunction with other medications, contribute to the expansion of the market.

A significant catalyst for market growth is the emphasis on cardiovascular health, with the World Health Organization's 2022 report underscoring cardiovascular diseases as a leading global cause of mortality. Patients with conditions such as coronary heart disease, heart failure, and atrial fibrillation, who often undergo open-heart surgery, further propel the demand for general anesthesia drugs. In essence, a confluence of these factors collectively propels the global market for general anesthesia drugs towards significant expansion.

Request for SAMPLE copy of report: https://www.persistencemarketresearch.com/samples/33865

Market Scope:

Report Coverage  Details
Market Revenue 2023 US$5.10 billion
Estimated Revenue 2030 US$6.44 billion
Growth Rate - CAGR  3.4%
Forecast Period  2023-2030
No. of Pages  210 Pages
Market Segmentation
  • Drug Class
  • Route of Administration
  • End-User
  • Region
Regions Covered
  • North America
  • Europe
  • Latin America
  • East Asia
  • The Middle East & Africa
  • South Asia & Pacific
Key Companies Profiled
  • Baxter International Inc.
  • AstraZeneca
  • AbbVie Inc.
  • B. Braun Melsungen AG
  • Fresenius SE & Co. KgaA
  • Pfizer
  • Hospira Inc.
  • Aspen Pharmacare Holdings Limited
  • Hikama Pharmaceuticals plc
  • Abbott Laboratories
  • Avet Pharmaceuticals, Inc
  • Piramal Enterprises Limited
  • Par Pharmaceutical
  • Teva Pharmaceuticals
  • Viatris/Mylan
  • Novartis AG
  • GlaxoSmithKline plc
  • Gilead Sciences, Inc.
  • Sanofi
  • Akorn
  • Apotex

In a nutshell, the Persistence Market Research report is a must-read for start-ups, industry players, investors, researchers, consultants, business strategists, and all those who are looking to understand this industry. Get a glance at the report at: https://www.persistencemarketresearch.com/market-research/general-anesthesia-drugs-market.asp

Market Growth Drivers:

Increasing Prevalence of Chronic Diseases: The global market for general anesthesia drugs is driven by the rising incidence of chronic diseases such as cancer, cardiovascular diseases, and osteoarthritis. As these conditions often necessitate surgical interventions, the demand for general anesthesia drugs is expected to grow in tandem with the prevalence of these health issues.

Growing Demand for Inhalation Anesthesia: The surge in demand for inhalation anesthesia drugs, including Sevoflurane and Desflurane, contributes significantly to market expansion. These drugs are administered through inhalation routes and are integral in maintaining unconsciousness during various medical procedures.

Funding Support from Private and Government Organizations: Increased funding from both private and government organizations for the development of pharmaceutical manufacturing segments is a crucial driver. This financial support facilitates research, innovation, and the production of high-quality general anesthesia drugs, contributing to market growth.

Research and Development Activities: The emphasis on research and development activities aimed at formulating advanced general anesthesia drugs plays a pivotal role in market expansion. Ongoing efforts to enhance the efficacy, safety, and delivery mechanisms of these drugs contribute to their broader application and adoption in medical procedures.

Global Cardiovascular Health Concerns: The World Health Organization's recognition of cardiovascular diseases as a predominant cause of global mortality acts as a catalyst for market growth. Patients with cardiovascular conditions, who often require surgical interventions, drive the demand for general anesthesia drugs, especially in procedures like open-heart surgery.

Market Restraints:

Stringent Regulatory Requirements: The general anesthesia drugs market faces challenges due to stringent regulatory requirements imposed by health authorities worldwide. Compliance with complex regulatory frameworks can increase development costs and timelines, acting as a restraint on market growth.

Side Effects and Safety Concerns: The use of general anesthesia drugs is associated with potential side effects and safety concerns. Adverse reactions, complications, and post-operative issues may limit the widespread adoption of these drugs, as both healthcare providers and patients prioritize safety in medical procedures.

Limited Accessibility in Developing Regions: Access to advanced healthcare, including specialized anesthesia drugs, is often limited in developing regions. Infrastructure constraints, economic challenges, and insufficient healthcare facilities hinder the widespread availability and usage of general anesthesia drugs, affecting market growth.

Alternatives such as Regional Anesthesia: The availability and adoption of alternative anesthesia methods, such as regional anesthesia, may act as a restraint. Some patients and healthcare providers prefer regional anesthesia techniques, limiting the market share of general anesthesia drugs in specific medical procedures.

High Cost of Anesthesia Drugs: The cost associated with general anesthesia drugs, including both manufacturing and administration, can be high. This may pose a barrier to adoption, particularly in healthcare systems with budget constraints or in regions where affordability is a significant concern.

Opportunities:

Rising Geriatric Population: The increasing global aging population presents a significant opportunity for the general anesthesia drugs market. Elderly individuals often require surgical interventions for age-related health issues, leading to a higher demand for anesthesia drugs in this demographic segment.

Technological Advancements: Ongoing technological advancements in drug formulations, delivery methods, and monitoring tools present opportunities for innovation within the general anesthesia drugs market. The development of more precise and targeted anesthesia solutions can enhance safety and efficacy, driving market growth.

Expansion in Emerging Markets: Emerging markets with growing healthcare infrastructure and increasing healthcare expenditure provide a substantial growth opportunity. Expanding market presence in regions where accessibility to healthcare is improving can open up new avenues for the adoption of general anesthesia drugs.

Telemedicine and Remote Anesthesia Monitoring: The integration of telemedicine and remote monitoring technologies creates opportunities for the remote administration and monitoring of anesthesia. This can improve healthcare delivery in underserved areas and facilitate the management of anesthesia in non-hospital settings.

Collaborations and Partnerships: Collaborations between pharmaceutical companies, research institutions, and healthcare providers can foster innovation and accelerate the development of new anesthesia drugs. Strategic partnerships may lead to the creation of novel formulations and expanded applications, enhancing market opportunities.

Market Segmentation

Which Drug Class Are Expected to Benefit the Most from Revenue Generation?

Propofol, a widely used general anesthetic, holds significance in surgical and critical care settings, including COVID-19 patients. The FDA's approval of Fresenius Propoven 2% for sedation in COVID-19 cases emphasizes its crucial role. Key manufacturers like Neon Laboratories Limited, Bharat Serums and Vaccines Limited, and Fresenius Kabi play pivotal roles in the production and distribution of propofol injections, shaping the dynamic landscape of the pharmaceutical industry in anesthesia and critical care sectors.

What Route of Administration Will Be Targeted the Most?

Sensors play a dominant role in the Anesthesia Drugs market, holding the highest percent share. This is attributed to their accuracy, lower rates of postoperative nausea and vomiting, and a reduced risk of blood clots. Intravenous Drugs lead the market due to advantages such as precise dose delivery, enhanced patient safety, and lower incidence rates of complications, including rare side effects like malignant hyperthermia. The use of intravenous drugs is associated with diminished risks, solidifying their preference in the anesthesia pharmaceutical sector. These advantages align with the market's focus on precision, safety, and minimizing postoperative complications.

Top Regional Markets

Why is Europe Emerging as a Dominating Region?

The United States faced significant shortages of crucial anesthesia drugs, including dexmedetomidine, midazolam, propofol, and neuromuscular blocking agents, during the emergence of COVID-19. In response, companies like Hikma Pharmaceutical introduced new products to meet heightened demand, exemplified by the "Propofol Injectable Emulsion" in May 2020. The anesthesia drugs market's momentum is further propelled by factors such as increasing surgical procedures, a rising aging population with more chronic conditions, and advancements in anesthesia technologies. The surge in cosmetic procedures, as highlighted by the American Society of Plastic Surgeons, underscores the growing demand for anesthesia drugs, particularly in general surgeries.

What Opportunities Lie in Asia Pacific for Manufacturers?

In China, there's been a significant rise in cosmetic procedures like facelifts and lip augmentations, particularly among individuals under 28 years old, accounting for around 12 million out of 22 million procedures in 2018. Teenagers comprised 8% of the total procedures. Concurrently, there's a steady increase in cardiovascular diseases (CVD) in China, with more than 2 in 5 fatalities attributed to CVD, surpassing mortality rates from cancer or other diseases, as reported in a 2018 study.

Key Recent Developments:

Technology Advancements: The anesthesia field has seen advancements in drug delivery systems and monitoring technologies. These innovations aim to enhance the precision and safety of administering anesthesia.

New Drug Approvals: Pharmaceutical companies continue to develop and seek approval for new general anesthesia drugs. Keep an eye on regulatory announcements for any new drugs entering the market.

Focus on Patient Safety: Patient safety is a crucial aspect of anesthesia administration. Recent developments may include the introduction of drugs or techniques that minimize side effects and improve recovery times.

Regional Anesthesia Growth: There has been a growing interest in regional anesthesia techniques, which involve numbing a specific part of the body rather than inducing general anesthesia. This trend may influence the demand for certain types of anesthesia drugs.

COVID-19 Impact: The COVID-19 pandemic has had widespread effects on healthcare systems. It's essential to consider how the pandemic has influenced the demand for general anesthesia drugs, as well as any changes in manufacturing or supply chain dynamics.

Market Consolidation: Mergers and acquisitions within the pharmaceutical and healthcare industry can impact the landscape of the general anesthesia drugs market. Companies combining resources may lead to new product developments or changes in market strategies.

Some of the market players:

  • Baxter International Inc.: Baxter is a global healthcare company that focuses on products related to hospital care, renal and critical care, and medical products. They provide a range of pharmaceuticals and medical devices.
  • AstraZeneca: AstraZeneca is a multinational pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of prescription drugs. They have a broad portfolio spanning various therapeutic areas.
  • AbbVie Inc.: AbbVie is a pharmaceutical company known for its focus on research and development in areas such as immunology, oncology, neuroscience, and virology. They are recognized for drugs like Humira.
  • B. Braun Melsungen AG: B. Braun is a German medical and pharmaceutical company specializing in the production of medical supplies, devices, and pharmaceutical products. They have a diverse range of healthcare solutions.
  • Fresenius SE & Co. KgaA: Fresenius is a global healthcare group with core competencies in dialysis, infusion, and transfusion therapy. They operate in various healthcare segments, including pharmaceuticals and medical devices.
  • Pfizer: Pfizer is one of the world's largest pharmaceutical companies, engaged in the discovery, development, and manufacturing of prescription medicines and vaccines.
  • Hospira Inc.: Hospira, now a subsidiary of Pfizer, was a global provider of injectable drugs and infusion technologies. It focused on products for hospitals and clinics.
  • Aspen Pharmacare Holdings Limited: Aspen is a South African-based multinational pharmaceutical company. It is known for manufacturing and supplying a broad range of pharmaceutical products.
  • Hikma Pharmaceuticals plc: Hikma is a multinational pharmaceutical company with a focus on developing, manufacturing, and marketing a wide range of generic and in-licensed pharmaceutical products.

General Anesthesia Drugs Market Research Segmentation

By Drug Class:

Propofol

Sevoflurane

Dexmedetomidine

Desflurane

Remifentanil

Midazolam

By Route of Administration:

Intravenous Anesthesia

Inhaled Anesthesia

By End-User:

Hospitals

Ambulatory Surgical Centers

Specialty Clinics

By Region:

North America

Europe

East Asia

South Asia & Oceania

Latin America

Middle East & Africa

About Persistence Market Research:

Business intelligence is the foundation of every business model employed by Persistence Market Research. Multi-dimensional sources are being put to work, which include big data, customer experience analytics, and real-time data collection. Thus, working on “micros” by Persistence Market Research helps companies overcome their “macro” business challenges.

Persistence Market Research is always way ahead of its time. In other words, it tables market solutions by stepping into the companies’/clients’ shoes much before they themselves have a sneak pick into the market. The pro-active approach followed by experts at Persistence Market Research helps companies/clients lay their hands on techno-commercial insights beforehand, so that the subsequent course of action could be simplified on their part.

Contact

Persistence Market Research

Teerth Technospace, Unit B-704

Survey Number - 103, Baner

Mumbai Bangalore Highway

Pune 411045 India

Email: sales@persistencemarketresearch.com

Web: https://www.persistencemarketresearch.com

This report aims to provide a comprehensive overview of the scope of medication shortages between 2021 and 2024, the reasons behind them, and how healthcare systems have coped.

Title:

Content: My channel
* Drag categories can be customized sorting
Recover Default OK
Setup
Alert
A 30-hour flight is expensive and hard to buy.
An elderly woman walking her dog near a pond in Florida was attacked and killed by a 3-meter crocodile that crawled out of the water.
Health insurance drug prices plan to slash local pharmaceutical companies, the first to expand the crisis of shortage of drugs
Amoxicillin, a first-line antibiotic, has been out of stock for a long time. Recently, even the back-line antibiotic Ciprofloxacin injection form is also out of stock. The shortage crisis continues to expand. Even less willing to produce low-priced drugs, the shortage of drugs is becoming more and more serious.
In this regard, the Director of Health Insurance, Shi Chongliang, said that after a survey of drug price differences, this year's health insurance drug price is expected to be reduced by more than 6,000 drugs, a total amount of 8.18 billion yuan, not an external transfer of 15 billion yuan; in order to avoid affecting the willingness of pharmaceutical companies to supply drugs, three principles have been formulated, lower than the basic price is not adjusted. Drugs that have been reported to the Food and Drug Administration and have been evaluated and confirmed to be in shortage will not be adjusted.
The same principle applies to indicated medicines accepted by Health Insurance.
The impact of the epidemic, has not adjusted drug prices for two years, Shi Chongliang said that the price of new drugs will be on the road on April 1, this Friday will first announce the results of drug price adjustment, if manufacturers feel that the price of drugs is not enough to cover the cost, affordable costs and other information, apply to increase the price of health insurance payment.
Huang Jinshun responded last night that the pharmaceutical industry is aware of the Health Insurance Department's 15 billion yuan price reduction target, and firmly opposed, he can understand the government's intention to deny 15 billion yuan, this is a good start, I believe that Shi Chongliang's communication skills can make drug price adjustments to achieve a mutually acceptable balance point, drug dealers bottom line 7 billion.
"To deal with the long-term shortage of drugs, the government should face up to the problem of health insurance cutting drug prices year by year."
"Huang Jinshun said, the National Health Insurance Administration this year is expected to cut 15 billion yuan health insurance drug budget, of which 4 billion yuan to Western drug manufacturers, local drug manufacturers will bear a major impact, for the drug price difference is large or low price drugs may not be willing to produce, the problem of lack of drugs will be more difficult to solve; it is recommended that the government and all drug manufacturers should properly discuss to avoid the impact on production.
Shih Chong-liang promised to review the price of health insurance prescriptions, and if necessary, will set a "floor price" against prescription drugs to increase manufacturers' production willingness.
In this regard, Huang Jinshun pointed out that even if the health insurance sets the "floor price" of the medicine, but the international drug raw materials are floating, plus the cost of drug packaging, transportation and other miscellaneous expenses is likely to be higher, the "floor price" is also virtual, and cannot solve the long-term drug shortage problem.
According to the latest information of the Drug Deficiency Platform of the Food and Drug Department, two back-line antibiotics, such as Ciprofloxacin injection type and Moxifloxacin injection type, are also in a state of shortage of drugs, and if they do not improve, it may affect the treatment effect of patients with bacterial infection.
Huang Chin-shun suggested that the government convene an emergency meeting to bring together the medical, pharmaceutical, and public health sectors to discuss ways to solve the problem, and list all the "essential" drugs for the national defense, so as to prevent Taiwan from running out of medicines.
Health Insurance Budget Epidemic
The last one.
Egg shortage leads to public resentment Guo Tai-ming acid Tsai Government: Is today's "leftover eggs" happy?
The next one.
Interfering with Lin Shu-ho, the cheerleader, twisting the waist and patting the hips.
Extended reading
Super-popular
More >

Title:

Content: Posted Today, 09: 47
Published Today, 09: 47
Modified Today, 09: 49
Updated Today, 09: 49
Serbia faces shortage of 34 drugs
19 June 2023, 09: 47
Serbian Minister of Health Danica Grujicic reported a shortage of 34 drugs in the country, writes Pravda.Ru.
She stressed that although this problem can be partially solved by using analogues, there are cases when replacement is not possible.
In particular, Grujicic noted that they received information about the termination of supplies of the drug “Madopara ”, which is necessary for the treatment of Parkinson ’ s disease.
The Minister stressed that the solution to this problem can be found through cooperation with the Russian Federation.
They are considering purchasing medicines from Russia, where they are available at a lower cost.

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
Report: Lack of Obesity Drugs and Weight Loss Causes Inconvenience
Patients who are prescribed highly effective anti-obesity drugs are concerned about the increasing difficulty in obtaining them amid the long-term shortage caused by the high demand for drugs, according to a report published recently by the American website Axios.
Ethan Lazarus, a Denver-based certified bariatric physician, said: “They ’ ve been out of stock everywhere for about a month, and it ’ s gone from being easy to locate to being very difficult.
Lazarus and other doctors who spoke with Axios said almost all of their patients in recent weeks had difficulty finding their prescribed dose.
Patients are increasingly contacting pharmacies to keep track of their prescriptions and, in many cases, have to switch doses or medications altogether.
For some patients, one of the most disturbing aspects is how quickly persistent thoughts about food return.
Christine Rehn Fielding, director of the New York University Langone Weight Management Program, said that “food noise ” disappears in people who eat GLP products,“ and feel very free. ”
At the same time, doctors said some patients are also having more difficulty convincing insurers to re-allow coverage of their prescriptions after several tighter rules at the beginning of the year to curb spending on expensive drugs.
Experts say that stopping taking medications, even for a week or two, can be annoying.
Patients begin with lower doses before gradually increasing them to higher doses, a process that usually takes months.
- Ah!

Title:

Content: Advertisement
NEWS
The Ministry of health included iodine, aspirin and paracetamol in the list of potentially deficient drugs
Today at 19: 58
The Interdepartmental Commission of the Ministry of Health included 97 items in the list of drugs that could potentially become scarce in the Russian market.
This is reported by “Kommersant ”.
The list includes iodine, ibuprofen, acetylsalicylic acid (aspirin), lidocaine, paracetamol, fentanyl, phenobarbital (the main component of valocordine and corvalol) and other drugs.
With regard to these drugs, the Government will take measures to ensure that they are available to consumers.
According to the “Pharmaceutical Bulletin ”, the Ministry of Health issued 44 permits to accelerate the registration of drugs.
Another 80 permits for amendments under the shortened procedure, 11 permits for the circulation of drugs in foreign packaging and 7 permits for the temporary circulation of unregistered medicines in the country.
Earlier, Izvestia reported a deficiency of Tamoxifen, used in many oncological diseases, in particular breast cancer.
In turn, the Ministry of Health reported more than 470 thousand packages of the drug in civil circulation.
That ’ s about six months, they said.
Read also
Events of the week on afisha.ru
We recommend you

Title:

Content: Go to main content
Live broadcast
The expert commented on the possibility of a shortage of drugs in Russia
0
Photo: Izvestia / Zurab Javakhadze
Voice-over text
Highlight the main
INCLUDING
off
In Russia there is no shortage of drugs, including imported, said in an interview with “Izvestia ” Vice-President of the Russian Union of Industrialists and Entrepreneurs (RSPP) Viktor Cherepov.
“We currently have no shortage of medicines in any of the groups, because all sanctions are applied with a reservation after the comma: there is not much, except for medicines, medical products and agricultural products.
None of the drugs fall under sanctions, all foreign companies continue to supply within the framework of concluded contracts, ” he said.
Supply disruptions were due solely to logistical problems.
“Container transportation was disrupted, trucks could not pass through the customs of Belarus, Lithuania and Finland in a timely manner.
Now drugs and substances are coming in, ” the vice-president of the RSPP emphasized.
According to the expert, in theory, Russia may lack innovative drugs that require additional registration in the country.
However, there are ways to solve this problem.
Among them, Cherepov called the government decree on the accelerated registration of such drugs, point permits for the purchase of unregistered drugs, parallel imports and the so-called compulsory licensing.
Read more in an exclusive interview with Izvestia:
“No medicine has been sanctioned, supplies continue ”
Read also
Live broadcast

Title:

Content: Alert
Ku Kwang-min, a veteran of the pro-independence movement, has died, and the Green Camp mourns Tsai Ing-wen, a slow half-beat, a reverie.
Continuous renewal / 228 consecutive holidays 3rd day National Highway northbound traffic tide significantly increased snow tunnel blocked 3 km
Cai Tianfeng 's corpse cooking case / The ex-husband' s family of four were remanded for questioning in May after questioning this morning
Health insurance cuts drug prices fear to expand drug shortage The health insurance director proposed 3 stages, 5 as a response
Health insurance drug prices have not been cut in two years, and Health Insurance Commissioner Shi Chongliang previously said that the price is expected to be cut by 8.18 billion yuan this year.
However, experts speculate that large-scale original pharmaceutical products will withdraw from the Taiwan health insurance market in the future, triggering a greater shortage crisis.
The Ministry of Health and Welfare held a press conference today, Shi Chongliang said that the drug price adjustment is adjusted annually according to law, but in recent years, affected by the epidemic and the Russian-Ukrainian war, the drug price policy will be comprehensively reviewed.
Shih Chung-liang said that the price adjustment is in accordance with the provisions of Article 46 and 62 of the Health Insurance Law, since the year 2012, annual adjustment, according to the market research price and the price difference of health insurance, as well as the total amount of drug expenditure in the previous year, the next year adjustment, according to the law is the first month of the second quarter of the implementation of new drug price, is a long-term practice.
"In recent years, the COVID-19 epidemic, the Russian-Ukrainian war, the global environment and other factors have affected.
"Shi Chongliang said that this year for the reduction of pharmaceutical products and the entire quota to make adjustments, a total of 14,000 health care drugs, is expected to affect about 6,000, but the global problem plus domestic manufacturing problems, there are three exclusions," recent shortage of drugs "," has been lower than the floor price or after adjustment will be lower than the floor price of drug guaranteed floor price "," new drug manufacturers can provide information Re-approved. ”
Shih Chung-liang said that the softening agent discussed recently is less than NT $1, so this year will reconsider the need for price protection based on the indication of the drug, and if the company still believes that the new drug price is not enough, it can submit cost analysis data within two weeks to re-verify the new drug price.
According to Shih Chong-liang, the Department of Health and Welfare will launch five major actions for drug shortage. The “Single Processing Window ” and the Food and Drug Administration jointly grasp the information of drug shortage. The“ NHI System Notice ” will notify medical institutions of alternative drugs by VPN. Paid.
At present, there is no price guarantee for the indication drugs in the short to medium and long term, Shi Chongliang said, and will reopen discussions with the clinical side, if the indication drugs are necessary and irreplaceable, the price can be protected.
The cost of raw materials has been considered, and it can be raised after the new drug price is released, and the new price will be reviewed as soon as possible.
Medium-term measures are drug expenditure target adjustment, Shi Chongliang said, since the implementation of 102 years more than 10 years, will do a new review, including adjustment methods to adjust items, etc., focusing on the current market oligopoly supply of clinically necessary drugs, will carry out risk control to give appropriate price protection mechanism.
At the same time, the small amount of drugs used by children will affect the willingness of manufacturers to supply, and will also discuss the trial of a national unified procurement if necessary.
Long-term measures include a comprehensive review of the drug price policy.
Health Insurance Shi Chongliang Epidemic
Extended reading
The annual budget of health insurance new drugs can not be completely approved by Shi Chongliang: strive to 100% this year
Medical industry to raise a number of drugs to obtain difficult health insurance drug price adjustment to March 1 announcement
Float prices will be reviewed in due course
To address the shortage of drugs, health insurance plans to unify the procurement of children 's drugs first implementation
Related News
When will my medicine be available?
The Ministry of Health and Welfare first explained the causes and progress of 15 types of drug deficiencies.
This morning, Vice Minister of Health and Welfare Wang Pisheng led the Director of Food and Drug Administration Wu Hsiu-mei and the Director of Health Insurance Shih Chung-liang to explain the situation.
For the first time, the Minister of Health and Welfare has explained in detail...
Wang Bisheng: To organize the “Drug Deficiency Prevention Center ” with 4 major aspects
The shortage of drugs has not yet been solved, and the new drug price of health insurance will be on the road on April 1 according to law.
This year, there is no shortage of drugs in the house. ”
Wang Bisheng Solves Drug Deficiency Problem Short-term Adjustment of Drug Expenditure System and Establishment of Drug Deficiency Center in the Medium Term
The problem of drug shortage is serious, and Wang Bi-sheng, political undersecretary of the Ministry of Health and Welfare, said at a press conference this morning that the problem of drug shortage is complex, and it is impossible to deal with all of the more than 14,000 medicines of the National Health Insurance in a single way.
Film / National shortage of drugs extended fever Wang Bisheng opened a press conference to explain the strategy
The national shortage of drugs has expanded from primary pharmacies and clinics to hospitals. Wang Bi-sheng, Vice-Minister of Health and Welfare, Wu Hsiu-mei, Director of Food and Drug Administration, and Shi Chung-liang, Director of Health and Welfare, held a press conference this morning to explain the short-, medium- and long-term...
Health insurance cuts drug prices fear to expand drug shortage The health insurance director proposed 3 stages, 5 as a response
Health insurance drug prices have not been cut in two years, and Health Insurance Commissioner Shi Chongliang previously said that the price is expected to be cut by 8.18 billion yuan this year.
However, experts speculate that large-scale original pharmaceutical products will withdraw from the Taiwan health insurance market in the future.
u Story / 120-second emergency ambulance service facing shortage of manpower and unequal protection
"In fact, at present, 80% of the fire work is emergency care, and the rescue is relatively small, because we do a good job of prevention."
"New Taipei City Fire Department Freshwater Detachment Senior Ambulance Officer Su Weizheng handled a wealth of rescue cases, often putting the needs of the people in the first place.
Ko Ting-ju, a representative of the Firefighters Association, is also a first-line ambulance. He hopes that all people who have been rescued after their cardiopulmonary function has stopped can “go back to their daily lives and live their lives well. ”
udn Forum
Product recommendation

Title:

Content: Israel faced an acute shortage of various drugs: the Association of pharmacists announced the details
Pharmacists said that the problem is not properly solved by state bodies, in particular the Ministry of Health.
The Association of Pharmacists has warned of an acute shortage of drugs, including Ritalin, drugs used to treat heart and blood vessel problems, and drugs to treat skin diseases.
Pharmacists wrote about it in a letter sent to Health Minister Nietzan Horowitz and his office ’ s CEO, Nachman Ashe, on Monday.
There is a shortage of medicines in Israel.
In the past two years, and in particular in the last few months, the phenomenon of shortages has intensified, ” said David Pepo, chairman of the Association of Pharmacists.
“The shortage is understandable for a number of reasons: COVID-19, the war in Ukraine, the global employment crisis and the economic crisis, ” Pepo explained.
“To this should be added the serious disruptions taking place in the distribution systems of medicines in Israel, which are due to staff shortages, malfunctions, high distribution costs and many other explanations of all sorts, ” Pepo said.
Earlier, Cursor wrote that in supermarkets in the coming days, a shortage of chicken and turkey is expected.
Recall that scientists have named a substance that reduces the risk of suicide.
In addition, the Minister of culture Healy Tropper said whether to cooperate with Netanyahu.
Read the latest news from Israel and the world on the Kursor channel in Telegram.
Author of the material:
TAGS:

Title:

Content: Lack of medicines in the Gaza Strip increases the suffering of Palestinians
The Palestinian Ministry of Health warned this week of a “shortage of medicines and medical consumables and a shortage of primary care items amounting to more than 60% of the basic list of primary care medicines. ”
An empty pharmacy in the Gaza Strip (Getty)
In Rafah pharmacies in the southern Gaza Strip, Mohammed Khader is searching for medicines for his father and sister, but he is facing extreme difficulty in finding them amid a severe shortage in the Strip due to the Israeli aggression for months, for which Israel is being tried before the International Court of Justice on charges of genocide, which has so far claimed the lives of some 30,000 martyrs, mostly children and women.
“This is the fifth pharmacy I am looking at, ” says the young man who fled to Rafah from Jabalia in the northern Gaza Strip, explaining,“ I found only one of three types (medicines) prescribed by the doctor, my father has a hole in the eardrum due to the shelling and he suffers all the time. ”
“My sister has chronic SLE and she needs four types of treatment, only one of which is available.
“Her health is deteriorating very badly, she is in great pain and we can ’ t do anything. ”
This week, the Palestinian Ministry of Health warned of a “shortage of medicines and medical consumables and a shortage of primary care items amounting to more than 60% of the basic list of primary care medicines. ”
The ministry said there were 350,000 people with chronic diseases without medication and warned of "serious health complications for patients".
In his pharmacy in Rafah, pharmacist Mohammed Sehwail says that what is happening is a “catastrophic period, ” explaining that“ not all types of drugs are available, especially for chronic diseases such as heart disease, stress, diabetes and cancer. ”
There is a shortage of children ’ s medicines, antibiotics and even painkillers. ”
"Even alternative medicines that may help in some cases have run out for months."
In another pharmacy, pharmacist Abdulhadi Dheer apologizes to a man who asks him about several types of medicines for Parkinson ’ s disease, while a woman leaves frustrated that no medicine has been found.
"The need for medicine has reached its peak, especially with the spread of diseases and epidemics due to overcrowding, malnutrition and living conditions," he said.
He points out that many come and “suffer from the symptoms of hepatitis, which is serious, but we feel helpless, there are no drugs, we cannot intervene without the guidance of doctors, even the alternatives to drugs have run out. ”
Some 1.4 million Palestinians, more than half of Gaza ’ s population, are crammed into Rafah amid desperate humanitarian and living conditions and a high risk of disease, according to the United Nations.
The Gaza Strip has been under an Israeli blockade since 2007, and this blockade has been tightened since the beginning of the Israeli aggression on the Gaza Strip, which receives little aid.
The Palestinian Ministry of Health warned that the accumulation of displaced people in the cold "has increased the spread of respiratory, skin and other infectious diseases," including hepatitis A.
In October, Israel launched a concentrated bombing campaign, followed by a massive ground offensive in the Strip, killing 28,663 people in the Gaza Strip, the majority of them women and children, according to the Palestinian Ministry of Health.
In the west of Rafah, more than 200 people stand in line in front of the pharmacy of the Kuwaiti hospital, waiting for their turn, carrying prescriptions and hoping to obtain the required medicines.
Jihan al-Quqa, displaced from Khan Younis, who has come since early morning, complains: “We stand for hours to get a pill.
They give us a pill. There are no antibiotics, no treatments.
The children are sick and the elderly. ”
“My husband has diabetes and his leg is swollen but we can ’ t get medicine for him.
Doctors say he has clogged veins because he doesn ’ t take medication. ”
Abdallah al-Haj, who had his leg amputated, sits in a wheelchair and laments, “There is no pharmacy in Rafah that has pain relief for me to sleep at night. ”
Months after the war broke out in October, Gaza ’ s health system appears to have collapsed.
According to the UN, there are no fully operational hospitals in Gaza, and only 13 of the 36 medical facilities across the Strip are operating at limited capacity.
On Wednesday, the health agency warned that hospitals in Gaza lacked “adequate supplies. ”
Doctors are forced to perform amputations due to a lack of means to treat patients and save their limbs, according to the World Health Organization ’ s local representative, Dr. Rick Peppercorn, from Gaza.
Nabil al-Othmani, 60, comes every day to ask about the medication he needs for epilepsy, but to no avail.
Trying to hold back his tears, he explains, “they tell me he ’ s not available at all. ”
Mohammad Yaghi, displaced from Gaza City, said: “We are slowly dying.
Because of the lack of medicines and treatments inside the city of Rafah. ”

Title:

Content: Experts have recorded a shortage of antibiotics in the world due to the increase in the number of infectious diseases.
On December 21, writes the Financial Times with reference to the head of the group of the World Health Organization (WHO) for the supply of medicines and ensuring access to them Lisa Hedman, reports Day.Az.
Twenty-eight of the 35 countries for which WHO collects data are deficient in penicillin-type drugs.
In the United States and Canada complained about the lack of amoxicillin.
Less is known about the situation in poor or small countries, according to Hedman.
It is noted that in addition to the difficulties experienced by pharmaceutical manufacturers in the pandemic, the current situation is complicated by high energy prices, and this leads to a decrease in profits of companies.
In addition, countries, according to Hedman, did not expect that in the first year without masks, respiratory infections would hit the population so hard.
In addition to antibiotics, pharmacists also complain about the lack of painkillers, drugs for tuberculosis and drugs for skin infections.

Title:

Content: Lack of medicines in MOH hospitals and accumulation of indebtedness Repercussions / solutions
3 hours ago
Dr. Naeem Malkawi
The problem of shortage of medicines in Jordanian hospitals requires quick and effective attention and intervention, as providing medicines to patients is one of the foundations of quality health care and one of the most important strategies of the Ministry of Health, however, the shortage of medicines in many hospitals leads to health, economic and social challenges that threaten the quality of health care and patient safety.
The budget of the Ministry of Health of medicines, vaccines, vaccines and medical consumables for this year 2023 was estimated at 103.75 million dinars, where the actual for the past year 2022 was 93.8 million dinars.
The question is, how did the Ministry of Health accumulate such a large indebtedness in the item of medicines to reach 300 million dinars for pharmaceutical companies?
And why last week was the debt of 2019 cleared and deducted estimated at 50% of the debt for that year?
This means that there is still a delay in the payment of dues for companies for the years 2020, 2021 and 2022 in addition to eight months of the current year 2023, and this brings us to a range of reasons and challenges:
1.
The aim of the Ministry of Health was to reduce the bureaucracy of procedures and overcome the complexity of procurement references in hospitals and health directorates in the governorates and not to obtain price and discount preferences, but the results indicate a defect in the management and mechanism of dealing with the strategy of unified and central procurement, despite the margin for hospital administrations to use the power of direct purchase in cases of necessity.
2.
Preparation of sub-budgets for hospitals: Evidence shows that there is a problem in the preparation of sub-budgets for hospitals and the main budget of the Ministry of Health with regard to the item of medicines, which is due to the lack of accurate and sufficient data on the number of patients and hospital needs of medicines, and the lack of accurate forecasting of future needs.
3.
Delays in the review of financial claims and invoices between the Ministry of Health and the hospitals on the one hand and the pharmaceutical companies on the other hand, is one of the most important reasons behind the accumulation of indebtedness, and this negatively affects the liquidity of the pharmaceutical companies and hinders them from providing a sustainable service in adhering to the procedures of supplying medicines according to schedule.
4.
Lack of coordination and communication: There may be a lack of coordination and communication between hospitals, the Ministry of Health and pharmaceutical companies, which complicates the supply and distribution of medicines and increases the chances of delays and the depletion of medicines from hospitals in the absence of an effective policy for stock management and the time required for stock adequacy.
5.
Focusing on the trade names of certain drugs from specific production sources and not adopting the protocol of writing the scientific name for the prescriptions of patients.
6.
One of the reasons that may be major and important at the same time is the funding aspect and the lack of the necessary allocations or use them in other aspects other than medicines to fill a deficit or emergency during the use of budget items due to the scarcity of available liquidity. Medication.
Lack of medication can lead to:
1.
Threat to patient safety: Lack of medication puts sick people at risk, as this can lead to delays in receiving necessary treatment or the unavailability of vital drugs, putting their lives at risk.
2.
Economic Implications: The lack of medicines entails additional economic costs for the health system and patients.
Medical cases may be referred to other medical centers or private hospitals, increasing pressure on other MOH budget items.
3.
Pressure on health care workers: Health care workers are under pressure as a result of dealing with patients affected by drug shortages and repeatedly facing their inquiries and complaints.
4.
Social repercussions:
Increased anxiety and stress: A lack of medication can lead to an increase in anxiety and stress among patients and their families, as they live in uncertainty about the availability of the necessary treatment.
Lack of medication can affect the level of trust in the health system among citizens, who may feel that the system is unable to provide them with adequate health care.
Increased costs and social burdens: Some patients may have to incur additional costs to obtain drugs from other sources outside hospitals, affecting their financial and economic status.
After all this narrative there must be ways to overcome these dilemmas:
1.
Preparation of budgets scientifically and professionally: Hospitals should develop more accurate standards for the preparation of sub-budgets for medicines, through the analysis of previous data, estimation of future needs and other scientific and methodological foundations in the preparation of budgets and commitment to apply them accurately.
2.
Improve coordination and communication between parties: Coordination between the Ministry of Health, hospitals and pharmaceutical companies should be strengthened through the establishment of structured mechanisms for information exchange, review of invoices, and completion of claims, and not delay them.
3.
Implementation of fiscal reforms: The Government and the Ministry of Health should implement fiscal reforms that provide funding to cover this important item and pay dues in a timely manner, reduce bureaucracy in the financial audit process, and proceed with payment procedures within the timetable mechanism agreed in the tender terms.
4.
Achieving social responsibility: The government and pharmaceutical companies should adopt a social responsibility towards patients by providing these drugs and reducing their prices in the market to make them more accessible to patients while relieving part of the pressure and burden on hospitals.
Addressing the problem of drug shortages in government hospitals requires comprehensive cooperation between all concerned parties from government, Ministry of Health, hospitals, drug suppliers and patients.
To provide medicines on a permanent basis and to ensure the provision of high quality health care to the Jordanian patient.

Title:

Content: Saudi News
There are 50 urgent reports every hour about the shortage of medicines in Saudi Arabia.
The Ministry of Health revealed that it received 107,246 reports during the first quarter of this year 2021 regarding the lack of medicines and vaccines in hospitals and health centers affiliated to the Ministry, with 1,191 reports daily and 50 reports every hour.
According to official data issued by the Ministry, during the first quarter of this year, the health received 67,065 reports related to the lack of medicines, in addition to 40,181 reports on the lack of vaccinations in health centers.
In order to solve the problem of shortage of medicines and vaccines, the ministry said that it has established an operations room to follow up reports of shortage of medicines to identify the challenges facing health facilities in providing medicines to beneficiaries, which reduced the number of weekly reports.
Statistics of communications

Lack of medicines in the hospitals of the Ministry of Health.
Description of the communication
Reports received from some beneficiaries related to the lack of availability of the medicine disbursed to them by the establishment.
Number of complaints closed
 98.95%
Number of communications
 67065
Source of the communication
Call Center « 937 » - « Twitter »
Service Evaluation
 85.81%

Lack of vaccinations in health centers
Description of the communication
Notifications received from some beneficiaries who did not receive vaccinations service.
Number of complaints closed
 99  34%
Number of communications
 40181
Source of the communication
Call Center (937) - Twitter
Service Evaluation
 88.82%
Report Period
 Q1 - 2021
Report Period
 Q1 - 2021
Decision for improvement
An operations room has been established to follow up reports of lack of medicines to identify the challenges facing health facilities in providing medicines to beneficiaries, thus reducing the number of weekly reports.
Decision for improvement
A weekly report containing the most important challenges leading to the lack of vaccinations was directed to be prepared and presented to leaders on a regular basis, which led to a reduction in the number of reports related to this classification.
These were the details of urgent news | 50 reports every hour on the shortage of medicines in Saudi Arabia for today we hope that we have succeeded by giving you the details and full information and to follow all our news you can subscribe to the system alerts or in one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available on Al-Watan Online has been verified by the editorial team in Gulf 365 and may have been modified and may have been transferred in full or quoted from it and you can read and follow up on the news from its main source.
You may also read.

Title:

Content: MEDICINES ARE STILL LACKING AT THE HOSPITAL, DENOUNCES JPP

5 months this has now been going on, this 3rd world health care needs to come to an end, as well as waiting years for consultations and operations. There is no proper health care unless you are willing to pay.

Below From Jornal Madeira

“Once again, and contrary to what has been stated by the Regional Health Service, several users have complained about the lack of medicines in the hospital pharmacy”, denounces the JPP.

“Just this week there were complaints that are confirmed by health professionals: if one day a type of medicine is missing, another day there is something else missing and, since October, the failure of medicines in the hospital pharmacy is persistent.

This situation is incomprehensible and unacceptable in what is the provision of a public health service, a service that embodies a constitutional right of citizens: the right to Health. The JPP regrets that, although all the complaints already made and the attempts of the users themselves to make themselves heard, via user support office, the situation remains unresolved. It becomes worse when the regional health service is not held accountable in the face of this further limitation of safeguarding the rights of users”, says Paulo Alves.

Faced with this situation, which could trigger more serious situations, the JPP calls on SESARAM and the authorities to resolve this situation once and for all, fulfilling its mission.

To users, the JPP leaves the alert: “make a complaint in writing at the user support office, expose your situation and enforce what is your right: the right to complain so that your own right to health is assured “.

%d bloggers like this:

Title:

Content: Urgent.
Member of the government monitoring and response teams Dr. Ramzi Abu Sitta: – The availability of medicines does not make a difference
News source / Libya Channel 24
Member of the government monitoring and response teams Dr. Ramzi Abu Sitta:
The availability of medicines does not substitute for the provision of health personnel and the support of health centers.
– The severe shortage of medical staff is caused by the migration of doctors in the public sector and their orientation to work in the private sector because of the great neglect suffered by government hospitals
Among the reasons for the migration of medical personnel to the government sector is the lack of security, especially as armed groups are imposing themselves in health centers under the pretext of guarding, in addition to the administrations of those centers, which leads to restrictions on the profession of doctor.
- Government hospitals in remote areas, especially in the south, most of them work in light of a large shortage of medical staff, and often have a general doctor accompanied by a number of trained doctors.
2022-12-09 13: 00: 02
1670590802.
About News Source
Libya Channel 24

Title:

Content: HI, {{username}}
Manage account
Change password
HEADLINES
{{headlineCount}} new {{headlineCount = = 1?
'update': 'updates'}}
+ MORE HEADLINES
World Health Organization warns of antibiotic crisis
Here are her details.
17
MARCH
2023.
A
+
A
- Ah!
Print
Email
Email
A
+
A
- Ah!
A new health analysis has revealed an acute shortage of antibiotics under development, particularly those needed to target potentially dangerous diseases.
A WHO review shows that only 12 new types of antibiotics entered the drug market over the five years from 2017 to 2021, and that 27 types of antibiotics are currently under development in clinical trials against pathogens deemed “critical, ” numbers that the WHO considers too few.
The update for the new antibiotics was published on Wednesday ahead of the European Conference on Microbiology and Infectious Diseases in Copenhagen, which will take place from April 15 to 18.
Of the 27 antibiotics under development, only six are considered "innovative" enough to be able to overcome previously popular antibiotic resistance, and two of the six target high forms of that resistance.
Valeria Gigante, who leads the WHO ’ s antimicrobial resistance department in Geneva, said in a statement: “In the five years covered by this report, we have only obtained 12 approved antibiotics, with only one of them capable of targeting all pathogens that the WHO considers critical. ”
"It is difficult to predict whether and when these drugs will be licensed because failure is still a possibility in the later stages of trials."
Pharmaceutical companies are often not enthusiastic about developing antibiotics because these treatments are usually short term and less profitable, the WHO report said, noting that they make up a small fraction of the revenue for companies compared to treatments for diseases such as cancer and heart problems.
“The increase in microbial resistance to popular antibiotics around the world is extremely worrying, and without immediate action we risk a return to the pre-antibiotic era, where infections spread and become deadly. ”
“Through increased investment and collaboration, we can make progress in the fight against antimicrobial resistance and ensure that patients have equitable access globally to effective treatments for infections, ” she said.
Venkatasupramanian Ramasupramanian, president of the Society of Clinical Infectious Diseases of India, said: “The world is already living in a post-antibiotic era. ”
“We lack a sustainable economic model for antibiotic innovation.
The current products under evaluation mainly meet the requirements of developed countries, resulting in an imbalance relative to those that must be made available to developing countries. ”
Skynews
MORE ABOUT
ADVERTISE HERE
JUST IN
TRENDING
HEADLINES
{{headlineCount}} new {{headlineCount = = 1?
'update': 'updates'}}
+ MORE HEADLINES
TRENDING

Title:

Content: Egyptian News
Mohsen Hassan for DMC: Solving the Drug Shortage Crisis in the Next Few Weeks
Ahmed Wael Omar - Cairo on Tuesday, April 30, 2024 12: 36 AM - Dr. Mohsen Hassan, director of the commercial sector in one of the pharmaceutical companies in Egypt, said that in 2019 the Egyptian Drug Authority was established, a historic leap in the Egyptian pharmaceutical industry, pointing out that there are procedures to ensure the quality, effectiveness and safety of the drug starting from the raw material where it is analyzed more than once.
Mohsen Hassan added during an interview with the program "evening dmc", on the channel dmc, that the production processes of the drug are analyzed more than analysis, and the random withdrawal of the can inside the pharmacy, and change the raw material takes the same steps as the previous one again, and the matter has a large control percentage.
Mohsen Hassan stressed that after the state provided the dollar, it is now available to buy any raw materials, and the shortage of medicine is on the way to solve in the next few weeks, pointing out that the guarantee of the quality of the Egyptian product as a medicine is compared to the "brand".
He pointed out that the pharmaceutical companies are committed to any legislation or decisions of the medical authorities, which is an important part of the medical system and we have a great role in providing high quality treatment and a suitable price for the Egyptian patient, stressing that the Egyptian medicine during the recent period is comparable to foreign medicines, and 90% of the cans sold in the Egyptian market are produced by Egyptian companies.
Advertisements
You may also read.

Title:

Content: -- -- -- / -- -- --
Site Management
Central Pharmacy announces receipt of 62 drugs to treat cancer patients
The Director General of the Central Pharmacy of the Hospitals, Samir Farhat, revealed that 62 drugs were received for the treatment of cancer patients.
Farhat said on Sunday in a statement to the third radio channel that within the framework of the program of the central pharmacy, the central pharmacy received a large amount of drugs intended for the treatment of cancer patients.
“From November 1, 2022 to January 1, 2023, we received 62 cancer drugs, ” he said.
"The central pharmacy has met all the needs of hospital pharmacies across different states."
He added that the central pharmacy has all the material means to take care of all hospital requests in a timely manner.
The director of the central pharmacy pointed out that the problem of drug shortage is a global problem, due to the Asian manufacturers of the drug as well as problems related to supply, in addition to the closure witnessed by China during the COVID-19 crisis.
Add your comment
All fields are required, and your email will not be published.
Please adhere to the site policy in the comments.
Your comment has been sent for review, it will be published after approval!
COMMENTS
0.
Excuse me! Excuse me!
There is no content to show!

Title:

Content: 09: 33, 03 September 2021
In Russia, there was a shortage of a vital medicine for childhood epilepsy
In Russia, there was a shortage of a vital medicine for childhood epilepsy, – writes the newspaper RBC.
Two charitable foundations have drawn attention to the problem.
In addition, parents complain about the lack of a number of drugs, including those that do not have registration in the country.
At the same time, doctors warn that replacing one drug with any analogue or suspending its intake threatens to worsen the condition of the child.
The Ministry of Industry assured that now they are taking the necessary measures for the prompt import of the drug.
They explained the interruptions in the delay in the re-registration of this funds.
Uploading comments...
The most discussed
Popular for the week
On the air today

Additionally, it will address specific concerns regarding the potential impact on your parent's medications and suggest alternative solutions.

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
Report: Lack of Obesity Drugs and Weight Loss Causes Inconvenience
Patients who are prescribed highly effective anti-obesity drugs are concerned about the increasing difficulty in obtaining them amid the long-term shortage caused by the high demand for drugs, according to a report published recently by the American website Axios.
Ethan Lazarus, a Denver-based certified bariatric physician, said: “They ’ ve been out of stock everywhere for about a month, and it ’ s gone from being easy to locate to being very difficult.
Lazarus and other doctors who spoke with Axios said almost all of their patients in recent weeks had difficulty finding their prescribed dose.
Patients are increasingly contacting pharmacies to keep track of their prescriptions and, in many cases, have to switch doses or medications altogether.
For some patients, one of the most disturbing aspects is how quickly persistent thoughts about food return.
Christine Rehn Fielding, director of the New York University Langone Weight Management Program, said that “food noise ” disappears in people who eat GLP products,“ and feel very free. ”
At the same time, doctors said some patients are also having more difficulty convincing insurers to re-allow coverage of their prescriptions after several tighter rules at the beginning of the year to curb spending on expensive drugs.
Experts say that stopping taking medications, even for a week or two, can be annoying.
Patients begin with lower doses before gradually increasing them to higher doses, a process that usually takes months.
- Ah!

Title:

Content: Politics Economy Society Culture Incident
Pills for greed
Are drugs disappearing from Pskov pharmacies?
February 18, 2022, 16: 54
0
Social networks are full of reports of the disappearance from the sale of drugs, dietary supplements and vitamins.
The opinion is expressed that this may be due to the fact that a number of popular drugs have not been re-registered in the territory of the Russian Federation.
"Pskovskaya Pravda" found out whether this is true, and what kind of medicine is missing in Pskov pharmacies.
“Due to a significant increase in demand ”
Information about the shortage or disappearance from the windows of Russian pharmacies of certain drugs appears quite regularly.
So, in April 2021, several large pharmaceutical associations said that due to the change in the rules of public procurement of strategically important drugs (their list includes 215 items) in Russia, there may be a shortage of drugs, and some players will leave the market altogether.
Photo by Andrey Stepanov
In December 2021, the All-Russian Union of Patients reported that in Russia there is a shortage of 42 drugs, including vital for the treatment of patients with cystic fibrosis, multiple sclerosis, cancer.
The public organization suggested that there was an increased demand for these drugs, since they were recommended for the treatment of coronavirus.
On February 10, 2022, it became known that the pharmaceutical company Bausch Health notified Russian distributors about the shortage of the drug "Convulex".
The manufacturer explained this by a decrease in supplies in connection with the reduction of the Ministry of Health and the Federal Antimonopoly Service of the marginal price of the drug.
Finally, on February 16, in response to numerous media publications about the shortage of the popular antidepressant Zoloft, Roszdravnadzor reported that the drug will appear in Russian pharmacies only in the second quarter of 2022.
According to the agency, “there are now temporary delays in its supply due to a significant increase in demand for the drug in other countries. ”
“Sometimes there are interruptions. ”
“Ordinary ” pharmacists and pharmacists do not see the problem.
“As a rule, there are interruptions in the supply of drugs for pressure and antiviral, but this is rather caused by the high demand for these drugs at certain times of the year.
Sometimes there are interruptions due to the fact that reregistration of drugs is carried out, this happens annually.
Or maybe the thing is that they did not conclude a supply agreement on time, ” Natalia Fedorovskaya, a pharmacist at one of the Pskov pharmacies, told Pskov Pravda.
The leaders of pharmacy chains confirm these conclusions.
Svetlana Zhonina, director of Pharma pharmacy chain, which has 29 points in the Pskov region, says that there is “always something, but there is no ” on the shelves.
The reasons may be different: high demand, a decrease in the volume of production of the drug, a decrease in the volume of purchases associated with the tightening of legislation, as a result of which the pharmacy network no longer has conditions for storing a particular drug.
Photo by Andrey Stepanov
However, emphasizes Svetlana Zhonina, “the market is saturated with generics and analogues, if you try, you can always offer something: this doctor must do, but our workers can.
There are so many names, there is always an alternative. ”
The problem, she said, is that “buyers want imports – that ’ s all. ”
Or they refuse to accept alternatives.
Although for the same "Zoloft", assures the director of "Farmia", "there are a whole bunch of analogues, including imported ones.
The same drug, only a different manufacturer. ”
“They sit on their phones and beg. ”
Natalia Ivanova, director of SUE Pharmacy, agrees with her colleague: “This happens regularly – something disappears, then it appears. ”
Usually, the disappearance of the drug from circulation is associated with problems with raw materials or with government prices unfavorable for suppliers.
However, it happens that the deficit arises due to increased demand.
"A year ago, because of the hype associated with the pandemic, antibiotics, blood-thinning, antiviral drugs disappeared, - said Natalia Ivanova. - It happens that due to demand, the drug is" washed out "from suppliers throughout Russia.
Then our purchasing managers sit on their phones and beg for at least some packages. ”
The disappearance of “Convulex ” is now in everyone ’ s ears.
“Zoloft ” too, but it is not so actively involved in commercial sales.
This is not the drug that every second prescribes.
Natalia Ivanova, Director of SUE Pharmacy
According to the director of Pharmacy, now in its network of 12 pharmacies, mainly located in the districts of the Pskov region, there are no "Phenazepam," Finlepsin ", eye drops" Lecrolin ", antibiotic" Flemoxin "," Pulmicort "in a dosage of 0.5 milligrams," ACC "200 micrograms, syrups from allergies" Loratadin "and" Clarice. "
“This is one of the known drugs, ” explains Natalia Ivanova. – There are more rare ones.
The disappearance of “Convulex ” is now in everyone ’ s ears.
“Zoloft ” too, but it is not so actively involved in commercial sales.
This is not the drug that every second prescribes. ”
“Empirically determined. ”
The mechanism of disappearance of drugs that have not passed state re-registration, “Pskov Truth ” explained Tatiana Kuzmina, Director of the state public health institution of the Pskov region“ Pharmacy Management ” (his tasks include the purchase of preferential drugs and providing them to citizens, as well as monitoring the circulation of medicines and medical devices in the region).
“Until the end of the year, manufacturers had to re-register medicines.
Those who have not passed this procedure are excluded from the state register and, accordingly, can no longer have circulation on the territory of the Russian Federation, ” she said.
There is no list of drugs that have not been re-registered.
Each time we empirically determine which drug has disappeared from the registry.
And no one will say why: did not pass re-registration or the manufacturer has some difficulties
Tatyana Kuzmina, Director of the Pharmacy Department of the Pskov Region
However, she added that “if the drug has already been imported into the territory of the Russian Federation, then it is sold before the expiration date. ”
Accordingly, it is quite difficult to predict exactly what and when will disappear from the shelves of pharmacies.
“There is no list of drugs that have not been re-registered, ” explained Tatyana Kuzmina. – Each time we empirically determine which medicine has disappeared from the registry.
And no one will say why: it has not passed re-registration or the manufacturer has some difficulties. ”
You can check the drugs “manually ” on the website of the Federal Service of Roszdravnadzor: there is a section“ Entering into civil circulation of medicines ”.
It is possible to find information on each specific medicine.
And if the shelf life of the drug is 2 years, and it was imported 3 years ago, then we can conclude that at the moment it is not in Russia.
"We understand, we contact manufacturers, - the director of the Pharmacy Department told" PP ". - So far it is reliably known that" Convulex "has disappeared.
We received the answer that at least in 2022 it will not be. ”
Follow us in social networks
Comments
Authorization
No comments
• Quarantine for rabies was introduced in the Ostrovsky district
• Pskovichki will take part in the “Comedy Battle ” on the TV channel“ TNT ” on February 18
• Arkady Gokhman leaves the post of chief doctor of the Pskov Children 's Regional Hospital
• On February 19, the scheme of bus traffic on Rizhsky Prospekt in Pskov will change
• Pskov plant "Titan-Polymer" creates conditions for career growth
• More than 50 protocols were on the Pskov “governors ” due to poor snow removal
• More than 7 million rubles will be allocated for patching roads in Pskov
• Public toilets with magnetic locks will be installed in the center of Pskov
Boris Yelkin explained why there will be no temporary pedestrian bridge instead of Troitsky
Boris Yelkin told what will be the repaired Trinity bridge in Pskov
• Nearly 1,000 people fell ill with coronavirus in Pskov region on February 17
• Part of Alexander Nevsky Street in Pskov will be closed from February 21 to March 14
• The people of Great Britain tried to illegally carry almost 100 kilograms of hashish
• 345 million rubles will be received by municipalities of the Pskov region to increase salaries in the public sector
• The first component of Sputnik V will be used for revaccination of Pskov residents
• Beds fund for covid-patients expanded in the Pskov region
• Up to + 5 degrees will warm the air in the Pskov region on February 18
• Construction of a new school on Yubileinaya Street in Pskov is ahead of schedule
• February 17
• Scientific and practical conference in honor of the 350th anniversary of Peter the Great will be held in Pskov on February 18
• Up to 2 degrees of frost will cool in the Pskov region on the night of February 18
Julia Zaitseva: It ’ s nice that the girls skaters took gold and silver
• Preparation for the road season began in Pskov and Pskov region
• Since the beginning of the week, about 200 people have applied to the Pskov emergency room with street injuries
• Pskov athlete won first place at the Junior Russian Athletics Championships
• In the Pskov region will be implemented measures to increase labor productivity
Almost 45 thousand packs of counterfeit cigarettes found by customs officers in the south of the Pskov region
• Rosselkhozbank told about the trends in the housing market
• 952 new cases were added to the covidstatistics of the Pskov region on February 16
• The refectory is offered to be opened in the belfry of the Pechora monastery
• Self-employed owners of private farms can now receive subsidies. Who? How? For what?
We deal with Rosselkhozbank
• Revision February 16 12: 50
How will the routes of Pskov buses change from March 1?

Title:

Content:

3 Undervalued Pharma Stocks Worth Buying

IPSEY – With the growing prevalence of chronic diseases, the adoption of advanced digital technologies, and new drug discoveries, the pharmaceutical industry is set to witness significant growth this year and beyond. Thus, it could be wise to invest in quality pharma stocks Ipsen (IPSEY), Supernus (SUPN), and Kamada (KMDA), which are currently trading at a discount. Continue reading….

The pharmaceutical industry is well-positioned to experience substantial growth in the foreseeable years, thanks to the escalating incidence of chronic diseases, widespread adoption of new technologies, and relentless R&D in the space.

Given the industry tailwinds, it seems wise to invest in fundamentally sound pharma stocks Ipsen S.A. (IPSEY), Supernus Pharmaceuticals, Inc. (SUPN), and Kamada Ltd. (KMDA), currently trading at discounted valuations, for potential gains.

With its swift vaccine development, life-saving treatments, and unwavering commitment to research and development (R&D), the pharma industry has an irreplaceable role in fortifying global health.

Over the past two decades, the pharmaceutical industry has grown remarkably, with global revenues reaching $1.48 trillion in 2022. The increasing prevalence of chronic diseases such as cancer, diabetes, and heart disease globally has also substantially heightened the need for innovative and advanced pharmaceuticals and treatments.

Furthermore, the industry is experiencing a rapid transformation with the widespread adoption of advanced digital platforms, big data analytics, and Artificial Intelligence (AI). These digital technologies are revolutionizing critical and labor-intensive processes within the industry, allowing for greater efficiency and streamlining of operations.

Such technologies are also extensively employed for drug discovery and development, drug production, smart process automation, and predictive maintenance optimization. According to a report by Polaris Market Research, the global e-pharmacy market size is projected to reach $371.25 billion, growing at a 19.4% CAGR.

Given the industry’s promising growth prospects, it could be wise to scoop up shares of discounted and quality pharma stocks IPSEY, SUPN, and KMDA that have the potential to yield significant returns.

Let’s delve into the fundamentals of the featured stocks.

Ipsen S.A. (IPSEY)

Based in Boulogne-Billancourt, France, IPSEY is a biopharmaceutical company specializing in oncology, neuroscience, and rare diseases. It operates through two segments, Specialty Care and Consumer Healthcare. The company also excels in neurotoxin research.

On March 3, IPSEY completed the acquisition of Albireo Pharma, Inc., a leading innovator in bile-acid modulators that treat rare liver conditions. The acquisition is anticipated to strengthen IPSEY’s Rare Disease portfolio, offering promising therapeutics for pediatric and adult rare cholestatic-liver diseases and enhancing the company’s scientific and commercial capabilities.

On February 15, IPSEY, Université de Montréal, and IRICoR announced that IPSEY had exercised its option to exclusively acquire rights to a pre-clinical stage program with potential oncology applications. The company would now take on all global development activities and commercialization of the drug candidate.

IPSEY, Université de Montréal, and IRICoR also announced plans to expand their strategic partnership by entering into a new multi-year collaboration and option agreement for two discovery-stage programs in oncology. Such expansion initiatives are expected to enhance IPSEY’s position in the oncology sector.

In terms of forward EV/Sales, IPSEY is trading at 2.74x, 28.1% lower than the industry average of 3.81x. Its forward EV/EBITDA multiple of 8.00 is 38.7% lower than the industry average of 13.04. In addition, IPSEY’s forward Price/Sales of 2.87x is 34.9% lower than the industry average of 4.40x.

On April 27, IPSEY presented its sales performance for the first quarter of fiscal 2023 that ended March 31, 2023. The company’s total sales increased 7.8% year-over-year to €741.90 million ($792.50 million) for the quarter.

IPSEY’s sales during the fiscal year that ended December 31, 2022, increased 14.4% year-over-year to €3.03 billion ($3.23 billion). Its core operating income rose 13.5% from the year-ago value to €1.12 billion ($1.19 million).

The company’s core consolidated net profit grew 17.9% year-over-year to €872.40 million ($931.90 million), and its core EPS was €10.51, up 18.4% year-over-year.

The consensus revenue estimate of $3.48 billion for the fiscal year (ending December 2023) reflects a 7% year-over-year improvement. Likewise, the consensus revenue estimate of $3.65 billion for the next fiscal year (ending December 2024) indicates a 5.1% rise year-over-year. Moreover, the company topped the consensus revenue estimates in all four trailing quarters, which is impressive.

Shares of IPSEY have gained 20.1% over the past year to close the last trading session at $29.72.

IPSEY’s solid fundamentals are apparent in its POWR Ratings. The stock has an overall rating of B, equating to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.

IPSEY has an A grade for Value and Stability and a B for Quality. It is ranked #20 in the 168-stock Medical – Pharmaceuticals industry.

In addition to the POWR Ratings I’ve just highlighted, you can see IPSEY’s ratings for Growth, Momentum, and Sentiment here.

Supernus Pharmaceuticals, Inc. (SUPN)

SUPN is a biopharmaceutical company that develops and markets products for Central Nervous System (CNS) diseases. Its diverse neuroscience portfolio includes treatments for epilepsy, migraine, Attention Deficit Hyperactivity Disorder (ADHD), and hypomobility in Parkinson’s Disease (PD), among others.

On February 14, SUPN announced its agreement with UBS Bank (UBS) USA for a credit line, granting the company an uncommitted demand-secured line of credit of up to $150 million. This additional capital would empower SUPN to enhance its financial strength and support its growth objectives.

Jack Khattar, SUPN’s President and CEO, said, “We are pleased to further enhance the strength and flexibility of our balance sheet with this line of credit.”

In terms of forward non-GAAP EV/Sales, SUPN is trading at 3.49x, 8.6% lower than the industry average of 3.81x. Likewise, the stock’s forward Price/Sales multiple of 3.09 is 29.7% lower than the industry average of 4.40.

For the first quarter that ended March 31, 2023, SUPN’s revenues marginally increased year-over-year to $153.76 million. Its non-GAAP operating earnings rose 8.9% year-over-year to $30.50 million. Also, as of March 31, 2023, the company’s current assets stood at $883.34 million, compared to $734.15 million as of December 31, 2022.

Analysts expect SUPN’s revenue for the fiscal year ending (December 2024) to increase  9.7% year-over-year to $668.75 million. The consensus EPS estimate of $2.08 for the same period reflects a 58.1% growth year-over-year. Also, the company surpassed the consensus revenue and EPS estimates in three of the trailing four quarters.

The stock has gained 23.7% over the past year to close the last trading session at $34.59.

SUPN’s positive outlook is reflected in its POWR Ratings. The stock has an overall rating of B, translating to Buy in our proprietary rating system.

SUPN has an A grade for Value and a B for Momentum and Quality. It is ranked #22 out of 168 stocks within the Medical – Pharmaceuticals industry.

Click here to access additional SUPN ratings (Stability, Growth, and Sentiment).

Kamada Ltd. (KMDA)

Based in Rehovot, Israel, KMDA supplies plasma-derived protein therapeutics. Its segments include Proprietary Products and Distribution. The company’s portfolio encompasses treatments for immune thrombocytopenic purpura, hepatitis B prevention in transplants, varicella post-exposure, intravenous AATD, and more.

On May 16, KMDA announced Swissmedic’s marketing authorization for Glassia® in Switzerland to treat adults with clinically evident emphysema resulting from severe hereditary Alpha-1 antitrypsin deficiency. These advancements would broaden KMDA’s market presence and offer crucial treatment alternatives to patients in Switzerland.

KMDA’s CEO, Amir London, said, “Switzerland is the first European country to approve Glassia for AATD, representing a significant milestone for Kamada, in a market which is currently estimated to be over $15 million annually.”

Furthermore, on May 3, the company announced FDA approval for its application to manufacture CYTOGAM®, marking it as the third product authorized for production at its Israeli facility. By leveraging its portfolio of four FDA-approved IgGs, KMDA anticipates ongoing expansion from these crucial products in 2023 and beyond.

In terms of forward EV/Sales, KMDA is trading at 1.59x, 58.3% lower than the industry average of 3.81x. Also, the stock’s forward Price/Sales of 1.62x is 63.1% lower than the industry average of 4.40x.

For the fiscal first quarter that ended March 31, 2023, KMDA’s revenues increased 9.3% year-over-year to $30.71 million, and its gross profit grew 4.8% year-over-year to $11.84 million. In addition, the company’s operating income rose 17.5% from the prior year’s period to $289 million. Its adjusted EBITDA grew 16.5% year-over-year to $3.83 million.

Analysts expect KMDA’s revenue to increase 9% year-over-year to $154.14 million for the fiscal year ending December 2024. The company’s EPS for the same year is expected to grow 38.5% from the prior year to $0.18. The stock has gained 25.1% year-to-date to close the last trading session at $5.19.

KMDA’s robust outlook is apparent in its POWR Ratings. The stock has an overall rating of B, which translates to Buy in our proprietary rating system.

KMDA has an A grade for Growth, Value, and Sentiment. It has ranked #14 within the same industry.

Click here to access additional KMDA ratings for Stability, Quality, and Momentum.

What To Do Next?

Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today’s volatile markets:

3 Stocks to DOUBLE This Year >

IPSEY shares were trading at $29.72 per share on Wednesday afternoon, up $0.05 (+0.17%). Year-to-date, IPSEY has gained 13.53%, versus a 12.07% rise in the benchmark S&P 500 index during the same period.

About the Author: Aanchal Sugandh

Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program. She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns. More...

More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
IPSEYGet RatingGet RatingGet Rating
SUPNGet RatingGet RatingGet Rating
KMDAGet RatingGet RatingGet Rating
UBSGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com

Investor Alert: How to Trade Key 6/14 Event?

Are you impressed by the recent rally for the S&P 500 (SPY)? Steve Reitmeister points out why this may yet be another sucker’s rally before the next leg lower. This is especially true as we come into the next Fed meeting on Wednesday 6/14. Get Steve’s updated market outlook, trading plan and top picks below...

3 Value Stocks to Add to Your Portfolio

The stock market will likely remain under pressure with rising concerns about an economic slump and high-interest rates. Therefore, investors could look to add fundamentally strong stocks Novo Nordisk (NVO), Novartis (NVS), and NetScout Systems (NTCT) to their portfolios, which are trading at discounts. Keep reading…

To Buy or Not to Buy These 2 Airline Stocks?

Macroeconomic issues might hamper the airline industry’s near-term performance. Therefore, I think it is best to wait for a better entry point in Delta Air Lines (DAL) and United Airlines Holdings (UAL). Keep reading...

Buy, Sell, or Hold: Nike (NKE)

Footwear giant NIKE (NKE) reported a 14% increase in revenues during the third quarter, but it still holds high inventory levels. With the company optimistic about its fiscal 2024 prospects, is the stock a buy, sell, or hold? Read on to learn my view…

To Buy or Not to Buy These 2 Airline Stocks?

Macroeconomic issues might hamper the airline industry’s near-term performance. Therefore, I think it is best to wait for a better entry point in Delta Air Lines (DAL) and United Airlines Holdings (UAL). Keep reading...

Read More Stories

More Ipsen S.A. (IPSEY) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All IPSEY News

Title:

Content: Semiengineering: The global "core shortage" begins to end, and overcapacity gradually appears
2021 / 11 / 24 15: 59: 11 Source: ijiwei Author: Jenny Editor: Lonely City
The current wave of semiconductor and IC package shortages is expected to continue through 2022, but there are also signs that supply may eventually catch up with demand.
The same is true for capacity, materials and equipment in semiconductors and packaging.
After a period of shortages across all segments, the current view is that while some product shortages, such as automotive chips, are likely to persist in 2022, most of the chip supply is likely to return to relative normality by mid-2022.
But it depends on several economic factors, so all of this could change overnight.
The semiconductor industry has experienced a period of disruption. At the beginning of 2020, the business looked bright, but the market fell after the COVID-19 outbreak.
Throughout 2020, countries took various measures to mitigate the outbreak, such as home orders and business closures.
Economic turmoil soon followed.
By mid-2020, the IC market rebounded as the home economy drove demand for computers, televisions and other consumer electronics.
There is a shortage of consumer chips and advanced IC packages.
Then, in the first half of 2021, demand for cars, smartphones and other products surged, leading to a shortage of chips in these areas.
Today, many types of chips are in tight supply and have long lead times, while others are more readily available.
It depends on the chip and the supplier.
Global chip manufacturing capacity is also tight, especially 8-inch fabs with more mature processes.
For some time, 8-inch fab capacity has been sold out, and this is not expected to change anytime soon.
And now, many foundry customers are preparing for a new round of comprehensive price increases.
At the same time, in terms of packaging, some packaging types will continue to be in short supply, and capacity in many areas is tight.
Delivery times for advanced equipment are long.
The shortage of semiconductors is not all pessimistic.
"With the exception of some products, the supply and demand situation is expected to be resolved mainly in the first half of 2022 or the second half of 2022," IBS CEO Handel Jones said in a new report. "Many factors contributed to the strong demand for semiconductors.
However, some of the factors driving past demand growth are weakening due to market saturation.
Consumers' purchasing power will weaken as a result of reduced stimulus and high inflation. "
There are also some bad signs on the supplier side.
According to IBS, overcapacity is likely to occur in the second half of 2022 or sometime in 2023, depending on the different products.
It is impossible to explain the situation of each semiconductor product or package, and each product has its own supply and demand background.
But there are several key products that can provide some insight into the situation.
These include application processors, MCUs, PMIC and WiFi chips, as well as various packaging technologies.
fab
Over the years, the integrated circuit industry has experienced ups and downs.
The current recovery is one of the biggest on record in recent times.
According to IBS data, overall, the semiconductor market is expected to reach $542.55 billion in 2021, an increase of 21.62% over 2020. IBS forecasts that the market is expected to grow by 7.13% in 2022.
According to TEL, the wafer manufacturing equipment (WFE) market is expected to grow by 40% in 2021. “The WFE market is expected to expand significantly due to the sharp rise in demand for leading-edge logic chips and memory, ” TEL President and CEO Toshiki Kawai said in a speech.
Nevertheless, the semiconductor industry designs and manufactures a large number of different chips, such as analog chips, GPUs, MCUs, memory, microprocessors, and power semiconductors.
GPUs, processors, and other advanced logic chips are produced in 12-inch fabs, using a variety of process technologies from 16nm / 14nm to 5nm nodes.
From 16nm / 14nm to 5nm, chipmakers rely on finFETs. “Compared to previous planar transistors, the fin contacts the gate on three sides, giving better control over the channels formed within the fin, ” said Nerissa Draeger, program director at Lam Research University.
12-inch fabs also produce chips for mature process nodes from 65nm to 28nm.
Meanwhile, other chips are manufactured in older 8-inch fabs using a 350nm to 90nm process.
Many chips are also produced in smaller wafer sizes in fabs, such as 6-inch, 4-inch, and so on.
Currently, mature process nodes in 8-inch and 12-inch fabs are tight even if they are not sold out. “Over the past few years, there has been a surge in demand for various chips manufactured on 8-inch and mature CMOS technology nodes ≥ 28nm, whether in traditional CMOS, bipolar CMOS DMOS or RF-SOI-based process platforms.
These devices include MCUs, PMICs, digital display driver ICs (DDICs), RF ICs, and image signal processing (ISP) wafers required to manufacture backlit CMOS image sensors.
This demand is also underpinned by technology trends across multiple segments, ” said David Haynes, Managing Director of Strategic Marketing at Lam Research.
“The supply problem of automotive semiconductors is well documented, but at the same time, demand for consumer products, new 5G-enabled devices, and display applications is increasing, ” Haynes said.“ The situation is further complicated by the fact that many IDMs and foundries that manufacture these chips produce not one product but multiple products. ”
Historically, they have been able to rebalance fab capacity to meet growing demand for a certain product type, but when demand for so many products has surged at the same time, it is difficult or impossible to adjust production in this way.
While there has been an increase in global capacity for some device types, such as display drives, recent reports indicate that the industry as a whole has yet to reach a balance between supply and demand. ”
All in all, OEM production capacity is tight.
“Looking ahead to the fourth quarter, we expect wafer shipments and ASP trends to remain strong. Capacity utilization at 8-inch and 12-inch facilities will continue to remain at full capacity, ” said Jason Wang, co-president of UMC.
Whether it is a mature process node or a frontier node, fab capacity is expected to be tight in the foreseeable future.
It depends on the production process and the supplier.
“While we do not rule out the possibility of inventory adjustments, we expect TSMC ’ s production capacity to remain very tight in 2021 and throughout 2022, ” TSMC CEO Wei Zhejia said in a recent conference call.
Summing up the situation, Gartner analyst Samuel Wang said: “Foundry plants are mostly booked for capacity in the first half of 2022, and some have long-term agreements with fabless customers for 3-4 years. Gartner ’ s assumption is that chip inventory will reach normal in the second quarter of 2022. ”
Shortages of various components from small suppliers are likely to last longer, "he said.
Application processor issues
At the same time, according to IBS, wireless is the largest segment in the semiconductor field, accounting for 40% of the total business.
In the wireless space, 5G smartphones and related infrastructure are the main drivers of many chips.
Overall, shipments of 5G smartphones are expected to reach 578 million units in 2021, up from 225 million units in 2020, IBS said.
Although 5G is growing in many regions, the smartphone market in China is slowing.
5G smartphones consist of a variety of chips such as application processors, CMOS image sensors, memory, PMIC and RF.
Application processors are cutting-edge devices that integrate CPU, graphics, and AI capabilities on the same chip.
Application processor complexity continues to increase, Source: Semiconductor Engineering
Apple's new iPhone 13 uses the A15 application processor, which is based on TSMC's 5nm process of 15 billion transistor design.
Many other phones use Qualcomm ’ s Snapdragon 888, which is a 5nm SoC.
These chips are manufactured by foundries.
Today, TSMC and Samsung are the only foundries capable of manufacturing 7nm and 5nm chips, and are both developing 3nm.
Intel, which recently re-entered the foundry business, is increasing production efforts at 10nm and 7nm, and developing 4nm.
Demand for 5G-based leading-edge application processors and chipsets has been strong for some time.
But the capacity of foundries for these chips seems to be slightly inadequate.
“Wafer capacity shortages are likely to continue into the fourth quarter of 2021 or the first quarter of 2022, ” said Jones of IBS.
How long the capacity shortage will last depends on several factors. “Newly designed technologies such as the Apple A15 and Qualcomm Snapdragon 888 are 5nm and are planning to migrate to 3nm in 2022, ” Jones said.“ If 3nm smartphone chipsets are launched in the second half of 2022, 5nm and 7nm capacity could be in excess in the third quarter of 2022 or the fourth quarter of 2022. ”
Things could change.
Analysts said that the Apple iPhone 14, scheduled to be launched in 2022, should have used TSMC ’ s 3nm process as an application processor.
However, now the iPhone 14 is expected to use 4nm.
Analysts say the iPhone 15, which Apple will launch in 2023, will use a 3nm application processor.
In other words, TSMC ’ s 3nm revenue growth has been delayed until 2023.
All in all, 3nm production uptake by all parties is a constantly changing goal.
“There are indications that both TSMC and Samsung are delaying increasing production of 3nm wafers, ” Jones said.
That ’ s not the only problem for Apple and other smartphone vendors.
In the latest fiscal quarter, Apple's sales fell by $6 billion due to a shortage of chips and manufacturing capacity.
The problem is not the lack of access to cutting-edge nodes, but the shortage of mature process chips.
According to KeyBanc, Apple ’ s sales have been affected by shortages in several areas, including OLED touch screen controllers.
The touch screen controller used to control the display is manufactured by a mature process.
Other mature node chips are also in short supply, including Wi-Fi 6 chips. The production process of Wi-Fi and some RF chips is 28nm, 22nm and 16nm.
According to IBS, the shortage of Wi-Fi and other RF chips is likely to continue into the second quarter of 2022, and possibly even the third quarter of 2022.
PMICs for smartphones and other products have also been in short supply. PMICs are used to control the flow and direction of electricity and are manufactured in a process from 180 nm to 40 nm.
According to IBS, the PMIC shortage is expected to continue into the second quarter of 2022 or the third quarter of 2022.
Related articles
Key word: Semiconductor
Soft media 's website: IT home hot products - Value shopping guide, coupons most buy - rebate coupons iPhone home Win7 home Win10 home Win11 home
Soft media software: Magic cube swordfish browser (speed kernel) cloud calendar cool point desktop Win7 optimization master Win10 optimization master soft media mobile APP application

#### Scope of Medication Shortages (2021–2024)
Medication shortages have been reported globally, affecting various therapeutic areas including oncology, neurology, cardiology, and infectious diseases.

Title:

Content: Patients complained to Putin about the shortage of 42 rare drugs
21 December 2020, 08: 02
Photo: 1Mediainvest.ru
The All-Russian Union of Patients sent an appeal to the President of the Russian Federation Vladimir Putin on behalf of 20 patient associations.
It lists 42 rare drugs intended for the treatment of chronic diseases.
The reason for the shortage is that they were included in the recommendations for the treatment of patients with coronavirus.
In this regard, there is an increased demand for them, write “New news ”.
According to Izvestia, the organization is confident that funding should be increased, production increased, and the mechanism for regulating the marginal cost of drugs from the list of vital and important drugs (VED) should be changed.
The co-chairman of the GSP, Yuliy Zhulev, said that in a number of cases the organization did not receive answers from relevant NGOs, or they indicated that there was no problem.
In the list of scarce drugs are vital, intended for the treatment of oncology and cystic fibrosis, for patients with multiple sclerosis, rheumatic diseases, primary immunodeficiency and others.
The GSP noted that problems with the availability of drugs have worsened since September 2020.
Zhulev said that this is due to the fact that the distribution of drugs is also carried out on those who are sick with coronavirus.
First of all, it concerns antibiotics.

Title:

Content: Posted Today, 09: 47
Published Today, 09: 47
Modified Today, 09: 49
Updated Today, 09: 49
Serbia faces shortage of 34 drugs
19 June 2023, 09: 47
Serbian Minister of Health Danica Grujicic reported a shortage of 34 drugs in the country, writes Pravda.Ru.
She stressed that although this problem can be partially solved by using analogues, there are cases when replacement is not possible.
In particular, Grujicic noted that they received information about the termination of supplies of the drug “Madopara ”, which is necessary for the treatment of Parkinson ’ s disease.
The Minister stressed that the solution to this problem can be found through cooperation with the Russian Federation.
They are considering purchasing medicines from Russia, where they are available at a lower cost.

Title:

Content: General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
General Supervision
Elham Aboul Fath
Editor-in-Chief
Thank you for your patience.
Report: Lack of Obesity Drugs and Weight Loss Causes Inconvenience
Patients who are prescribed highly effective anti-obesity drugs are concerned about the increasing difficulty in obtaining them amid the long-term shortage caused by the high demand for drugs, according to a report published recently by the American website Axios.
Ethan Lazarus, a Denver-based certified bariatric physician, said: “They ’ ve been out of stock everywhere for about a month, and it ’ s gone from being easy to locate to being very difficult.
Lazarus and other doctors who spoke with Axios said almost all of their patients in recent weeks had difficulty finding their prescribed dose.
Patients are increasingly contacting pharmacies to keep track of their prescriptions and, in many cases, have to switch doses or medications altogether.
For some patients, one of the most disturbing aspects is how quickly persistent thoughts about food return.
Christine Rehn Fielding, director of the New York University Langone Weight Management Program, said that “food noise ” disappears in people who eat GLP products,“ and feel very free. ”
At the same time, doctors said some patients are also having more difficulty convincing insurers to re-allow coverage of their prescriptions after several tighter rules at the beginning of the year to curb spending on expensive drugs.
Experts say that stopping taking medications, even for a week or two, can be annoying.
Patients begin with lower doses before gradually increasing them to higher doses, a process that usually takes months.
- Ah!

Title:

Content: Advertisement
NEWS
The Ministry of health included iodine, aspirin and paracetamol in the list of potentially deficient drugs
Today at 19: 58
The Interdepartmental Commission of the Ministry of Health included 97 items in the list of drugs that could potentially become scarce in the Russian market.
This is reported by “Kommersant ”.
The list includes iodine, ibuprofen, acetylsalicylic acid (aspirin), lidocaine, paracetamol, fentanyl, phenobarbital (the main component of valocordine and corvalol) and other drugs.
With regard to these drugs, the Government will take measures to ensure that they are available to consumers.
According to the “Pharmaceutical Bulletin ”, the Ministry of Health issued 44 permits to accelerate the registration of drugs.
Another 80 permits for amendments under the shortened procedure, 11 permits for the circulation of drugs in foreign packaging and 7 permits for the temporary circulation of unregistered medicines in the country.
Earlier, Izvestia reported a deficiency of Tamoxifen, used in many oncological diseases, in particular breast cancer.
In turn, the Ministry of Health reported more than 470 thousand packages of the drug in civil circulation.
That ’ s about six months, they said.
Read also
Events of the week on afisha.ru
We recommend you

Title:

Content: Thursday, 14 Jumada I 1444 Hijri, corresponding to 08 December 2022 AD
A medical crisis in Kuwait.
Urgent parliamentary action
Contact – Editorial Team:
Two deputies in the Kuwaiti National Assembly submitted two requests to the Parliamentary Health Affairs Committee to study the causes of the shortage of medicines, which has become a crisis threatening the health of Kuwaitis, according to media reports.
Medications are not available for dispensing
MP Dr. Jenan Bushehri sent a letter to the National Assembly, in which she confirmed that “despite the assurances of officials in the Ministry of Health of sufficient pharmaceutical stock for the community, many medicines are not available for disposal, which makes the general health situation on the verge of collapse, ” according to“ Al-Qabas ”.
Boushehri asked the Health Affairs Committee to study the causes of the shortage of medicines in private and private health institutions and centers, and to submit its report in the next session, including the causes, results, recommendations and those responsible for the crisis.
The MP stressed that all constitutional options are available in the event of any complacency or inaction in the development of permanent solutions that preserve the health of the population of the State of Kuwait.
Also read:
18 "homosexuals" arrested in a massage and massage center in Kuwait..
They committed adultery and lured teenagers.
200 drugs not available
MP Faisal al-Kandari asked Prime Minister Sheikh Ahmed Nawaf al-Ahmad al-Sabah to form an investigation committee on the lack of medicines and irregularities in the Ministry of Health, and said: "We will wait for the results before using constitutional tools."
Al-Kandari added: “I continue to extend a helping hand to the government for the benefit of Kuwait and its people, and I have gradually used constitutional tools, waiting for the procedures to address the issue of the unavailability of more than 200 types of medicines. ”

Title:

Content: Go to main content
Live broadcast
The expert commented on the possibility of a shortage of drugs in Russia
0
Photo: Izvestia / Zurab Javakhadze
Voice-over text
Highlight the main
INCLUDING
off
In Russia there is no shortage of drugs, including imported, said in an interview with “Izvestia ” Vice-President of the Russian Union of Industrialists and Entrepreneurs (RSPP) Viktor Cherepov.
“We currently have no shortage of medicines in any of the groups, because all sanctions are applied with a reservation after the comma: there is not much, except for medicines, medical products and agricultural products.
None of the drugs fall under sanctions, all foreign companies continue to supply within the framework of concluded contracts, ” he said.
Supply disruptions were due solely to logistical problems.
“Container transportation was disrupted, trucks could not pass through the customs of Belarus, Lithuania and Finland in a timely manner.
Now drugs and substances are coming in, ” the vice-president of the RSPP emphasized.
According to the expert, in theory, Russia may lack innovative drugs that require additional registration in the country.
However, there are ways to solve this problem.
Among them, Cherepov called the government decree on the accelerated registration of such drugs, point permits for the purchase of unregistered drugs, parallel imports and the so-called compulsory licensing.
Read more in an exclusive interview with Izvestia:
“No medicine has been sanctioned, supplies continue ”
Read also
Live broadcast

Title:

Content: Israel faced an acute shortage of various drugs: the Association of pharmacists announced the details
Pharmacists said that the problem is not properly solved by state bodies, in particular the Ministry of Health.
The Association of Pharmacists has warned of an acute shortage of drugs, including Ritalin, drugs used to treat heart and blood vessel problems, and drugs to treat skin diseases.
Pharmacists wrote about it in a letter sent to Health Minister Nietzan Horowitz and his office ’ s CEO, Nachman Ashe, on Monday.
There is a shortage of medicines in Israel.
In the past two years, and in particular in the last few months, the phenomenon of shortages has intensified, ” said David Pepo, chairman of the Association of Pharmacists.
“The shortage is understandable for a number of reasons: COVID-19, the war in Ukraine, the global employment crisis and the economic crisis, ” Pepo explained.
“To this should be added the serious disruptions taking place in the distribution systems of medicines in Israel, which are due to staff shortages, malfunctions, high distribution costs and many other explanations of all sorts, ” Pepo said.
Earlier, Cursor wrote that in supermarkets in the coming days, a shortage of chicken and turkey is expected.
Recall that scientists have named a substance that reduces the risk of suicide.
In addition, the Minister of culture Healy Tropper said whether to cooperate with Netanyahu.
Read the latest news from Israel and the world on the Kursor channel in Telegram.
Author of the material:
TAGS:

Title:

Content: Experts have recorded a shortage of antibiotics in the world due to the increase in the number of infectious diseases.
On December 21, writes the Financial Times with reference to the head of the group of the World Health Organization (WHO) for the supply of medicines and ensuring access to them Lisa Hedman, reports Day.Az.
Twenty-eight of the 35 countries for which WHO collects data are deficient in penicillin-type drugs.
In the United States and Canada complained about the lack of amoxicillin.
Less is known about the situation in poor or small countries, according to Hedman.
It is noted that in addition to the difficulties experienced by pharmaceutical manufacturers in the pandemic, the current situation is complicated by high energy prices, and this leads to a decrease in profits of companies.
In addition, countries, according to Hedman, did not expect that in the first year without masks, respiratory infections would hit the population so hard.
In addition to antibiotics, pharmacists also complain about the lack of painkillers, drugs for tuberculosis and drugs for skin infections.

Title:

Content: Healthcare companies moved higher as tech companies continue to enter the space.

Facebook parent Meta Platforms has created a tool to predict the structure of hundreds of millions of proteins using artificial intelligence. Researchers say it promises to deepen scientists' understanding of biology, and perhaps speed the discovery of new drugs.

Meanwhile, a drug used to extend the lives of people with advanced prostate cancer is in short supply and will be for months, leaving some patients with no treatment option as the manufacturer works to ramp up production. The Food and Drug Administration said last week the availability of Pluvicto is limited as manufacturer Novartis struggles to meet demand. The drugmaker said the shortage stems from manufacturing and delivery issues.

Write to Amy Pessetto at amy.pessetto@dowjones.com

(END) Dow Jones Newswires

03-16-23 1727ET

Title:

Content: Egyptian News
Mohsen Hassan for DMC: Solving the Drug Shortage Crisis in the Next Few Weeks
Ahmed Wael Omar - Cairo on Tuesday, April 30, 2024 12: 36 AM - Dr. Mohsen Hassan, director of the commercial sector in one of the pharmaceutical companies in Egypt, said that in 2019 the Egyptian Drug Authority was established, a historic leap in the Egyptian pharmaceutical industry, pointing out that there are procedures to ensure the quality, effectiveness and safety of the drug starting from the raw material where it is analyzed more than once.
Mohsen Hassan added during an interview with the program "evening dmc", on the channel dmc, that the production processes of the drug are analyzed more than analysis, and the random withdrawal of the can inside the pharmacy, and change the raw material takes the same steps as the previous one again, and the matter has a large control percentage.
Mohsen Hassan stressed that after the state provided the dollar, it is now available to buy any raw materials, and the shortage of medicine is on the way to solve in the next few weeks, pointing out that the guarantee of the quality of the Egyptian product as a medicine is compared to the "brand".
He pointed out that the pharmaceutical companies are committed to any legislation or decisions of the medical authorities, which is an important part of the medical system and we have a great role in providing high quality treatment and a suitable price for the Egyptian patient, stressing that the Egyptian medicine during the recent period is comparable to foreign medicines, and 90% of the cans sold in the Egyptian market are produced by Egyptian companies.
Advertisements
You may also read.

Title:

Content: 24 May 2022 - 13: 35
on the pharmacist strike.
The medicine crisis is over.
Only the patient pays the price.
Lebanon, news, lbci, pharmaceutical news, pharmacies, strike, the patient alone pays the price
Enjoy watching our videos online
More details about our online video streaming packages
SUBSCRIBE NOW
Sign in
This is, in short, the case of any patient, in a country whose officials have not yet reached a radical solution to a crisis as old as the dollar crisis.
The higher the exchange rate, the more humiliated they are at the doors of pharmacies in search of a cut medicine.
Advertisement
* For the protection of intellectual property rights, please do not copy more than 20% of the content of the news, mentioning the name of the website of the LBCI Lebanon News and attach it to the hyperlink of the news under penalty of legal prosecution.
Advertisement
Read also.

Title:

Content: “Russian pharmaceutical companies are intensively working on the creation of innovative drugs ”
Snezhana Chernogortseva, Deputy Director for Marketing and Sales, Valenta Pharm, about the company ’ s business development
In 2022, the production of medicines and materials used for medical purposes in Russia increased by more than 20% compared to the previous year.
Snezhana Chernogortseva, deputy general director of Valenta Pharm for marketing and sales, told about how the pharmaceutical industry during the period of sanctions and geopolitical crisis managed not only to maintain, but also to improve its performance, about the main trends in this market and new medicines.
— How would you characterize the current situation in the Russian pharmaceutical market and how the events taking place in the world affected it?
— Despite the fact that now our country may face some shortage in the field of unique drugs of foreign companies, the necessary drugs for basic nosologies are still available for patients, and many of them are produced by domestic manufacturers.
Among them are antiviral, antihistamines, painkillers, antimicrobial, antibacterial and many other drugs.
Among OTC drugs in our country, most of the needs are covered by Russian traditional original drugs or domestic analogues of Western manufacturers.
Moreover, now Russian pharmaceutical companies are intensively working on the creation of innovative drugs for the treatment of complex, including orphan, diseases.
Speaking specifically about Valenta Pharm, we continue to invest in the development of our portfolio and the development of innovative prescription and over-the-counter drugs.
This course the company took initially, and today it is more relevant than ever.
— Along with import substitution, what other trends in 2022 would you note?
One of the main trends of recent years in the field of pharmaceuticals is the development of e-commerce.
In the autumn of this year, an experiment on the Internet trade of prescription drugs was approved.
This was facilitated by the successful experience of the OTC drug trade, which market participants acquired during the coronavirus pandemic.
We, as a company interested in ensuring that the pharmaceutical market develops in accordance with modern trends, see great potential in this direction.
First, it allows to increase the speed of obtaining drugs by patients and reduce dependence on outside help, especially for those for whom a trip to the pharmacy is not always an easy task - these are first of all people with low mobility, elderly people, patients with orphan diseases, and in general we are with you when we are sick, and medicines are needed here and now.
Secondly, this qualitatively increases the availability of drugs, since there are not always around the clock pharmacies, and drugs in some cases may be needed urgently.
It is also worth noting that scaling this initiative to a large extent will reduce the severity of the issue of availability of drugs for rare diseases, which, as a rule, are not sold in pharmacies due to the lack of demand for them, including due to the emerging short-term logistical difficulties.
— One of the important components of successful import substitution is localization of production.
How are you doing with that?
“Valenta Pharm ” is one of the few pharmaceutical companies with its own modern research and production complex in the territory of the Russian Federation.
All this, of course, gives us an advantage in the current economic conditions.
The site in Shchelkovo near Moscow was put into operation in 2017.
It is one of the largest high-tech production facilities in Eastern Europe with an area of   19 thousand square meters, which produces about 100 million packages of drugs per year.
On the territory of our complex, in addition to production workshops, there is also a modern research center, on the basis of which innovative development of new medicines is carried out, as well as localization issues are solved if necessary.
We are sincerely proud of our production, since the quality, efficiency and safety of our products are at the heart of all processes and operations.
That's what defines our company's DNA.
We are actively working on the expansion of local production sites, in particular on the construction of a new high-tech workshop for liquid non-sterile forms.
This would not have been possible without the support of the state.
For example, we receive tax benefits from the Moscow region, subsidies for the development of engineering infrastructure, the purchase of new equipment, as well as preferential interest rates on lending.
What achievements of your company are you most proud of this year?
In 2022, there were many significant events for the company.
So, this year we resumed the production of phenotropil, we can say, brought the legend back to the market.
Phenotropil is a drug with a rich history and a wide range of prescriptions, including to increase concentration and improve brain activity among different age groups in conditions of high stress and stress, which is especially important today.
In addition, we brought to the market a truly innovative drug Aterixen – the first drug that can and should be used as a proactive anti-inflammatory therapy.
It helps reduce the factors that trigger a cytokine storm, including COVID-19.
Our drug Grammidin also showed great results: the increase in its sales for the year was 41%.
In the midst of seasonal and viral diseases, consumers preferred grammidine, since the drug helps to cope with the main symptom of diseases - a sore throat, which once again confirms its effectiveness.
No less significant event for our company was the inclusion of ingavirin in the 16th version of the Methodological recommendations of the Ministry of Health for the prevention, diagnosis and treatment of a new coronavirus infection.
Ingavirin has been on the market for a long time and has proven itself well in both the medical and patient communities, including during the 2009 swine flu pandemic.
Numerous clinical studies (over 15 years of presence of the drug on the market, 12 clinical studies have been conducted) have shown that ingavirin is able to effectively fight acute respiratory viral infections and influenza, including types A, B and swine A (H1N1), which is raging in our country at present.
All studies conducted, including double-blind, randomized, placebo-controlled clinical studies to assess efficacy and safety, comply with international standards of evidence-based medicine.
We did not stop there, and in the midst of the pandemic, in 2020, we began to test the ability of ingavirin to reduce the symptoms of COVID-19 and reduce the time until patients recover.
The results of two studies showed its effectiveness against new coronavirus infection in both outpatients and hospital patients.
According to the results of studies, ingavirin is included in the list of possible drugs for the treatment of COVID-19 Temporary Guidelines for the Prevention, Diagnosis and Treatment of New Coronavirus Infection.
— What plans does the company have for the next year, taking into account the prospects for the development of the pharmaceutical industry
As for forecasts in the Russian pharmaceutical industry, in my opinion, the main trends should be the development of own drugs, active investment in research, innovation, maximum localization of production.
In the current realities, it is critically important not to stand still – it is necessary to constantly improve and actively work on the creation and implementation of innovative practices.
Over the past few years, we have continued to invest both in the development of new drugs and in further research into the company ’ s existing products.
We continue to build an effective dialogue with both the scientific medical community and the state in order to be in the center of current problems and open issues and as quickly as possible, but at the same time effectively and safely for patients to cover the needs related to health and quality of life of people.
Another priority task was and remains the development of own production facilities, the expansion of the scientific and production complex and the active localization of the production of portfolio products.
Russian medical science and the pharmaceutical industry have developed intensively in recent decades, focusing on the best world practices, while both stand on a serious foundation of the Soviet school - this is a strong point of support and a guarantee of confidence for further qualitative growth.
Evgeny Kuznetsov
Download news...
Download news...
Download news...
Download news...
Download news...
Download news...
Download news...
Download news...
Download news...
Download news...
Download news...

Title:

Content: -- -- -- / -- -- --
Site Management
Central Pharmacy announces receipt of 62 drugs to treat cancer patients
The Director General of the Central Pharmacy of the Hospitals, Samir Farhat, revealed that 62 drugs were received for the treatment of cancer patients.
Farhat said on Sunday in a statement to the third radio channel that within the framework of the program of the central pharmacy, the central pharmacy received a large amount of drugs intended for the treatment of cancer patients.
“From November 1, 2022 to January 1, 2023, we received 62 cancer drugs, ” he said.
"The central pharmacy has met all the needs of hospital pharmacies across different states."
He added that the central pharmacy has all the material means to take care of all hospital requests in a timely manner.
The director of the central pharmacy pointed out that the problem of drug shortage is a global problem, due to the Asian manufacturers of the drug as well as problems related to supply, in addition to the closure witnessed by China during the COVID-19 crisis.
Add your comment
All fields are required, and your email will not be published.
Please adhere to the site policy in the comments.
Your comment has been sent for review, it will be published after approval!
COMMENTS
0.
Excuse me! Excuse me!
There is no content to show!

Title:

Content: 09: 33, 03 September 2021
In Russia, there was a shortage of a vital medicine for childhood epilepsy
In Russia, there was a shortage of a vital medicine for childhood epilepsy, – writes the newspaper RBC.
Two charitable foundations have drawn attention to the problem.
In addition, parents complain about the lack of a number of drugs, including those that do not have registration in the country.
At the same time, doctors warn that replacing one drug with any analogue or suspending its intake threatens to worsen the condition of the child.
The Ministry of Industry assured that now they are taking the necessary measures for the prompt import of the drug.
They explained the interruptions in the delay in the re-registration of this funds.
Uploading comments...
The most discussed
Popular for the week
On the air today

The shortages have impacted both generic and branded medications, with some of the most affected categories including:
- **Chemotherapy drugs** (e.

Title:

Content: NEWS
NEWS
Putin said about the shortage of some drugs in pharmacies
Photo: Moscow 24 / Nikita Simonov
As a result of inspections, there was a shortage of some drugs in pharmacies, as well as an increase in prices for certain drugs.
This was stated by Vladimir Putin during a meeting with the government.
However, the Russian leader stressed that there has been an increase in the production of pharmaceutical products in Russia.
“For three quarters of last year, it amounted to about 22%, and 60% in our market are already domestic medicines.
Nevertheless, the deficit was formed for some drugs, and prices have grown, ” Putin said.
Meanwhile, Roszdravnadzor did not confirm reports of a shortage of antibiotics in Russian pharmacies.
The department assured the residents of the state that the supply and release of drugs continues.
Before that, the press spread information that in Russia there are not enough antibiotics intended for the treatment of children.
Labeling operator says there is no shortage of antibiotics in Russia
More news - in the telegram channel "Moscow 24".
Subscribe!
close
Contact Us
Feedback form
Attach file
Send
close

Title:

Content: Advertisement
NEWS
The Ministry of health included iodine, aspirin and paracetamol in the list of potentially deficient drugs
Today at 19: 58
The Interdepartmental Commission of the Ministry of Health included 97 items in the list of drugs that could potentially become scarce in the Russian market.
This is reported by “Kommersant ”.
The list includes iodine, ibuprofen, acetylsalicylic acid (aspirin), lidocaine, paracetamol, fentanyl, phenobarbital (the main component of valocordine and corvalol) and other drugs.
With regard to these drugs, the Government will take measures to ensure that they are available to consumers.
According to the “Pharmaceutical Bulletin ”, the Ministry of Health issued 44 permits to accelerate the registration of drugs.
Another 80 permits for amendments under the shortened procedure, 11 permits for the circulation of drugs in foreign packaging and 7 permits for the temporary circulation of unregistered medicines in the country.
Earlier, Izvestia reported a deficiency of Tamoxifen, used in many oncological diseases, in particular breast cancer.
In turn, the Ministry of Health reported more than 470 thousand packages of the drug in civil circulation.
That ’ s about six months, they said.
Read also
Events of the week on afisha.ru
We recommend you

Title:

Content: Egyptian News
Mohsen Hassan for DMC: Solving the Drug Shortage Crisis in the Next Few Weeks
Ahmed Wael Omar - Cairo on Tuesday, April 30, 2024 12: 36 AM - Dr. Mohsen Hassan, director of the commercial sector in one of the pharmaceutical companies in Egypt, said that in 2019 the Egyptian Drug Authority was established, a historic leap in the Egyptian pharmaceutical industry, pointing out that there are procedures to ensure the quality, effectiveness and safety of the drug starting from the raw material where it is analyzed more than once.
Mohsen Hassan added during an interview with the program "evening dmc", on the channel dmc, that the production processes of the drug are analyzed more than analysis, and the random withdrawal of the can inside the pharmacy, and change the raw material takes the same steps as the previous one again, and the matter has a large control percentage.
Mohsen Hassan stressed that after the state provided the dollar, it is now available to buy any raw materials, and the shortage of medicine is on the way to solve in the next few weeks, pointing out that the guarantee of the quality of the Egyptian product as a medicine is compared to the "brand".
He pointed out that the pharmaceutical companies are committed to any legislation or decisions of the medical authorities, which is an important part of the medical system and we have a great role in providing high quality treatment and a suitable price for the Egyptian patient, stressing that the Egyptian medicine during the recent period is comparable to foreign medicines, and 90% of the cans sold in the Egyptian market are produced by Egyptian companies.
Advertisements
You may also read.

g.

Title:

Content: Therapeutic drug monitoring market size, share, growth opportunities, revenue insights and competitive analysis will record a significant growth of 8.4% by 2029
Data Bridge Market Research recently published a comprehensive industry research report on the “Global Therapeutic Drug Monitoring Market, ” which includes an analysis of the growth, regional marketing, challenges, opportunities and drivers analyzed in the report.
The market insights gained through this therapeutic drug monitoring market research analysis report contribute to a clearer understanding of the market landscape, issues that may be disrupted in the future, and excellent positioning to define the brand.
Through detailed competitive analysis in this report, companies can measure or analyze the strengths and weaknesses of their competitors to help them develop superior business strategies for their products.
In order to gain a deeper understanding of the market and competitive landscape,
During the forecast period from 2022 to 2029, the therapeutic drug monitoring market is expected to grow at a rate of 8.4%.
Data Bridge Market Research Report for Therapeutic Drug Monitoring Market provides analysis and information on various factors expected to be prevalent throughout the forecast period, while providing an impact on market growth.
The rise of the global healthcare industry is accelerating the growth of the therapeutic drug monitoring market.
Get an exclusive PDF sample copy of the Therapeutic Drug Monitoring Market Report for the complete research structure, including the complete TOC, tables and data @ https: / / www.databridgemarketresearch.com / request-a-sample /? dbmr = global-therapeutic-drug-monitoring-market
Market Overview:
The analysis covered in the Generic Therapeutic Drug Monitoring Market Analysis report assesses the various segments that have witnessed the fastest growth in a crude forecast framework.
Market research includes an analysis of market attractiveness, in which each segment is compared based on market size, growth rate and overall attractiveness.
All the information, facts, and statistics covered in the report lead to actionable insights, better decision-making, and better business strategy.
The Therapeutic Drug Monitoring Market Report contains historical data, current market trends, environment, technological innovations, future technologies and technological advancements in related industries.
An excellent therapeutic drug monitoring report provides excellent market insight in product trends, marketing strategies, future products, new geographic markets, upcoming events, sales strategies, customer behavior or behavior.
The report also measures market drivers, market constraints, challenges, opportunities and key developments in the market.
This market report is an accurate study of the therapeutic drug monitoring industry and provides an estimate of the new victories in the therapeutic drug monitoring market.
The large therapeutic drug monitoring business report showcases significant product development and tracking acquisitions,
Some of the major players in the therapeutic drug monitoring market report are
• Thermo Fisher Technology
• Illumination
• Kegan
• Scientific Continent
• Agilent Technologies
• Oxford Nanopore Technology.
• Hoffmann-LaRoche Co., Ltd.
• Bio-Rad Lab
• General Electric Beckerman Coulter
• Bio-Rad Lab
• Hoffmann-LaRoche Co., Ltd.
• Siemens Healthcare Pte Ltd
• Thermo Fisher Technology
• Abbot
• Bayer
• Bio-Mérieux
• Allaire
• Danaher
• Teraida
• Tecan Trading Company
• SQI Diagnosis
• Seizumi Medical Corporation
• QEST  Spectrum
There are countless genes
• Miraka Holdings
• Merck Corporation
• Internal Diagnosis
• Exagen Inc.
• European Diagnostic AB
• Diazorin Spa
• Adaptive biotechnology
• where .mpany
• Eppendorf
• Abbot
• Siemens
• PerkinElmer Company
• Acer Gene Inc.
• Genetic Star
• Cool
There are countless genes
• GATC Biotechnology
• Biomass
New England Biological Laboratory
Key TOC Highlights: Global Therapeutic Drug Monitoring Market
Chapter 1: Therapeutic Drug Monitoring Market Overview
Chapter 2: Impact of the Global Economy on the Therapeutic Drug Monitoring Market
Chapter 3: Global Market Scale Competition by Industry Producers
Chapter 4: Global Production, Income (Value), by Region
Chapter 5: Global Supply (Production), Consumption, Exports, Imports, Geography
Chapter 6: Global Production, Revenue (Value), Price Trends, Product Types
Chapter 7: Global Market Analysis, Based on Chapter 8
Market Industry Value Chain
Chapter 9: Market Chains, Purchasing Strategies, and Downstream Buyers
Chapter 10: Key Strategies and Policies for Distributors / Suppliers / Traders
Chapter 11: Key Economic Indicators by Market Suppliers
Chapter 12: Analysis of Market Influence Factors
Chapter 13: The Market Forecast Period
Chapter 14: The Future of the Market
Chapter 15: The Appendices
Explore the full TOC, tables and data: https: / / www.databridgemarketresearch.com / toc /? dbmr = global-therapeutic-drug-monitoring-market
The therapeutic drug monitoring market is segmented by product, technology, drug category, therapeutic area and end user.
Growth between these segments will help you analyze undergrowth segments in the industry and provide users with valuable market profiles and market insights to help them make strategic decisions to identify top market applications.
• On the basis of products, the therapeutic drug monitoring market is segmented into consumables and equipment.
The device is further subdivided into diagnostic devices and proteomics tools.
• On a technical basis, the therapeutic drug monitoring market is segmented into immunoassay and proteomics technologies.
The immunoassays were subdivided into cloning enzyme donor immunoassay, fluorescence polarization immunoassay, particle enhancement turbidity immunoassay and chemiluminescence immunoassay.
Proteomics techniques are further subdivided into liquid chromatography / mass spectrometry and gas chromatography / mass spectrometry.
• By drug category, the therapeutic drug monitoring market is segmented into psychotropic drugs, bronchodilators, immunosuppressants, antibiotics, anti-arrhythmia drugs and anti-tumor drugs.
• According to the therapeutic area, the therapeutic drug monitoring market is segmented into digestive tract and metabolism, blood and hematopoietic organs, cardiovascular diseases, skin diseases, urogenital diseases as well as sex hormones, hormone preparations, anti-infective drugs, anti-tumor drugs and immunomodulators., musculoskeletal diseases, neurological diseases, respiratory diseases and sensory diseases.
• Based on end users, the therapeutic drug monitoring market is segmented into hospital laboratories, laboratories, etc.
Key questions answered by this study
1) What makes the therapeutic drug monitoring market suitable for long-term investment?
2) Understand the value chain areas where participants can create value?
3) Areas where CAGR and YOY growth are likely to increase dramatically?
4) Which geographical region has a better demand for products / services?
5) What opportunities will the emerging field provide for new and mature entrants to the therapeutic drug monitoring market?
6) Risk analysis related to service providers?
7) What are the factors driving the need for therapeutic drug monitoring in the coming years?
8) What is the analysis of the impact of various factors on the growth of the global therapeutic drug monitoring market?
9) What strategies do big players use to help them gain market share in mature markets?
How can technology and customer-centric innovation make a big difference in the therapeutic drug monitoring market?
If you choose the global therapeutic drug monitoring market; then the following country analysis will be included:
• North America (USA, Canada and Mexico)
• Europe (Germany, France, UK, Netherlands, Italy, Nordic countries, Spain, Switzerland and the rest of Europe)
• Asia Pacific (China, Japan, Australia, New Zealand, Korea, India, Southeast Asia and the rest of Asia Pacific)
• South America (Brazil, Argentina, Chile, Colombia, other countries, etc.)
Middle East and Africa (Saudi Arabia, United Arab Emirates, Israel, Egypt, Turkey, Nigeria, South Africa, other MEA regions)
Visit the full report at https: / / www.databridgemarketresearch.com / reports / global-therapeutic-drug-monitoring-market
Why you need to buy this report:
• Detailed examination of the global therapeutic drug monitoring market
• Evaluate the production capacity of market participants and their manufacturing chains, each manufacturer.
• Presentation of key market participants.
• Understand the full size of the market and estimate forecasts
• Access information by region, company, type and application
Some of the key questions answered in this report:
• – Who are the major players in the therapeutic drug monitoring market space and how are your operations (capacity, production, sales, price, cost, gross and revenue)?
• What therapeutic drug monitoring market opportunities and threats are vendors in the global therapeutic drug monitoring industry facing?
• What applications / end-users or product types can you look for for incremental growth prospects?
What is the market share for each type and application?
What are the key approaches and limitations that are hindering the therapeutic drug monitoring market?
• What are the different sales, marketing and distribution channels in the global industry?
Explore trend reports:
Global Dental Digital X-Ray Market – Industry Trends and Forecasts 2029 https: / / www.databridgemarketresearch.com / reports / global-dental-digital-x-ray-market
Cancer Celiac Market – Industry Trends and Forecasts to 2028 https: / / www.databridgemarketresearch.com / reports / global-cancer-cachexia-market
Laparoscopy Market – Industry Trends and Forecasts to 2028 https: / / www.databridgemarketresearch.com / reports / global-laparoscopes-market
Enteroscopy Market – Industry Trends and Forecasts to 2028 https: / / www.databridgemarketresearch.com / reports / global-enteroscopes-market
About Data Bridge Market Research:
Data Bridge positions itself as an unconventional and novel market research and consulting firm with unparalleled resilience and integrated approach.
We are determined to tap the best market opportunities and provide effective information for your business to thrive in the market. Data Bridge strives to provide appropriate solutions to complex business challenges and initiate an easy decision-making process.
Contact us:
Data Bridge Market Research
United States: + 1 888 387 2818
United Kingdom: + 44 208 089 1725
Hong Kong: + 852 8192 7475
Email: Corporatesales @ databridgemarketresearch.com

, cisplatin, carb